

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/078922 A2

- (51) International Patent Classification⁷: C12N
- (21) International Application Number: PCT/US2004/005896
- (22) International Filing Date: 27 February 2004 (27.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/451,455 28 February 2003 (28.02.2003) US
60/490,230 25 July 2003 (25.07.2003) US
10/789,526 26 February 2004 (26.02.2004) US
- (71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **TACHAS, George** [AU/AU]; 44 Sackville Street, New Melbourne, VIC (AU). **DOBIE, Kenneth** [US/US]; 703 Stratford Ct. #4, Del Mar, CA 92014 (US).
- (74) Agents: **SHUSTER, Michael, J.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION

(57) Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

WO 2004/078922 A2

**MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION
AND INSULIN-LIKE GROWTH FACTOR EXPRESSION**

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/451,455, filed February 28, 2003, and U.S. Provisional Application No. 60/490,230, filed July 24, 2003, the entire disclosures of which are hereby incorporated by reference in their entirety for all purposes.

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of growth hormone receptor. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding growth hormone receptor. Such compounds are shown herein to modulate the expression of growth hormone receptor and also to modulate the expression of insulin-like growth factor 1 (IGF-I) to animal and human equivalent therapeutic levels which are relevant to the treatment of diseases including acromegaly, gigantism, age-related macular degeneration, diabetic retinopathy, diabetic nephropathy, diabetes, and growth hormone and IGF-I dependent tumors. The growth hormone receptor modulating effects are also relevant to the treatment of arthritis and other conditions involving growth hormone receptor and/or growth hormone/insulin-like growth factor-I axis. Similarly, antisense compounds directed to any one or more of the targets in the growth hormone/insulin-like growth factor-I axis, including growth hormone, growth

hormone receptor, IGF-I and IGF-I receptor, can be used in the treatment of the same conditions.

BACKGROUND OF THE INVENTION

5

Growth hormone, released by the pituitary, is a member of a cascade of hormones that regulate growth of the body and its organs. Secretion of growth hormone into the bloodstream is followed by binding to growth hormone receptor (GHR) on many cell and organ types. Growth hormone signaling is mediated by this interaction. Growth hormone signaling causes the production of another hormone, insulin-like growth factor-I (IGF-I or IGF-1), which is produced in the liver, adipose tissue and kidney and secreted into the bloodstream. About 75% of serum IGF-I is produced in the liver in response to growth hormone stimulation. Many disorders are caused by and/or associated with elevated growth hormone levels and/or elevated IGF-I levels in plasma and/or tissues including acromegaly, gigantism, retinopathy, macular degeneration, nephropathy, diabetes and cancers. This role of IGF-I in mediating many growth hormone effects is well recognized and the interrelationship is referred to as the growth hormone/insulin-like growth factor-I axis. In a normal feedback loop, IGF-I also causes the production of growth hormone by the pituitary to be reduced.

Growth hormone is produced and secreted by a set of specialized cells in the anterior pituitary. Growth hormone has direct and indirect effects on many tissues, such as stimulating bone and soft tissue growth and influencing carbohydrate, protein, and lipid metabolism. Direct biological activities of growth hormone include receptor binding, internalization of the hormone/receptor complex, and activation of proteins involved in signal transduction.

Protein and RNA transcripts for receptors of growth hormone (GHR) have been detected in many of the tissues influenced by the hormone. It was determined that a single molecule of growth hormone binds sequentially to two receptor molecules, forming an active complex. This complex, in turn, signals stimulation of other genes, including IGF-I. IGF-I, produced and secreted by the liver and other target tissues, mediates some of the indirect effects of growth hormone on growth and development. Other intracellular events occurring after the growth hormone/growth hormone receptor interaction include activation of tyrosine kinases such as Janus kinase 2 (Jak-2), which leads to phosphorylation and activation of other proteins including signal transducer and activator of transcription 5A and 5B (STAT 5A and 5B) and mitogen activated protein (MAP) kinase that, in turn, activate other proteins and genes.

The cDNA encoding the growth hormone receptor has been cloned from many species. The receptor consists of an extracellular hormone-binding region (exons 2-7), a single membrane spanning region (exon 8), and an intracellular region (exons 9-10). There are also multiple alternative 5' untranslated regions which are alternative first exons of the gene, in both the human and mouse transcripts. Growth hormone receptor has no intrinsic kinase domain, but the intracellular region plays a major role in the signal transduction process. A truncated form of the receptor, known as growth hormone binding protein (GHBP), lacks the transmembrane and intracellular regions of growth hormone receptor and is secreted into the serum. The truncated protein is produced by one of two different processes, depending on the animal species. In mice and rats, alternative splicing of growth hormone receptor precursor messenger RNA replaces the transmembrane and intracellular

regions with a very short hydrophilic tail (encoded by exon 8A; 15, 16). In humans, cows, and pigs (among others), no alternative RNA splicing is apparent but instead the GHBP is produced by proteolysis of the growth hormone receptor. The
5 function of the binding protein appears to be to modulate the level of circulating growth hormone.

Growth hormone receptor is expressed in many organs and tissues including liver, adipose tissue, muscle, cartilage, bone, tooth, kidney, eye, cardiovascular system, gut,
10 reproductive organs, skin, brain, endocrine system and immune system.

The three-dimensional structure of the extracellular domain of growth hormone receptor has been established. It consists of two modules, each of about 100 amino acids,
15 arranged as two sandwiches each with seven strands of beta-sheet. The secreted form of the extracellular domain of growth hormone receptor is the GHBP.

The growth hormone receptor is biologically responsive to growth hormone stimulation. JAK2 is the primary effector
20 molecule for growth hormone receptor signaling. JAK2 is activated post growth hormone receptor dimerisation. When the growth hormone dimerizes its receptors, the JAKs are brought close together, and with proper alignment transphosphorylate each other, leading to full activation. The intracellular
25 targets for the JAKs include tyrosine residues in the receptor cytoplasmic domain itself, which in turn activate SH2 domains (STATS, Shc and SHP2). These may go on to activate the MAP kinase pathway, which regulates cell proliferation. JAK2 also phosphorylates and activates other
30 signaling molecules, such as IRS-1 and -2 and phosphatidyl 3-inositol kinase, which are important parts of the insulin signaling mechanism and may account for the insulin-like actions of growth hormone. Activated JAK2 also phosphorylates

STAT5, and when activated, is involved in the transcription of a number of genes.

Growth hormone receptor activation leads to many actions in many organs including the following outcomes in the following organs:

Liver: Increased secretion of insulin-like growth factor-I, synthesis of plasma proteins, regulation of nitrogen balance enzymes, increased carbohydrate synthesis/storage, and increased fat breakdown; Adipose Tissue: Breakdown of fat stores; Muscle: Increased protein synthesis, decreased protein breakdown; Cartilage: Increased height by increasing proliferation and differentiation of chondrocytes in growth plate; Bone & Tooth: Increased turnover of tissue, both synthesis and breakdown; Kidney: Increased sodium, bicarbonate and water retention; Eye: increased retinal neovascularization; Cardiovascular: Hypertrophy, increased contractility, stroke volume, cardiac output; Gut: Hypertrophy, increased amino acid, sodium, calcium, phosphate and B12 uptake; Reproductive System: Increased sperm production and motility, increased accessory gland secretion in male, increased number of follicles and ovulation rate, increased follicular maturation rate, increased milk production; Skin: Increased skin thickness and strength, increased hair growth and thickness; Brain: Increased neuron proliferation and connectivity prenatally, increased myelin formation, improved long-term memory; Endocrine System: Increased insulin synthesis and secretion, increased adrenal steroidogenesis; Immune System: Increased immune cell proliferation, increased killing by monocytes, macrophages and NK cells, increased antibody production.

Downstream from growth hormone receptor in the growth hormone signaling pathway are IGF-I and IGF-I receptor. The insulin-like growth factors (IGFs) are important in

proliferation. In particular, IGF-I and IGF-2 are ubiquitous polypeptides each with potent mitogenic effects on a broad range of cells. Molecules of the insulin-like growth factor type are also known as "progression factors" promoting
5 "competent" cells through DNA synthesis. The insulin-like growth factors act through a common receptor known as the Type I receptor or IGF-IR, which is tyrosine kinase linked.

Particular proteins, referred to as insulin-like growth factor binding proteins (IGFBPs), appear to be involved in
10 autocrine/ paracrine regulation of tissue insulin-like growth factor availability (Rechler and Brown, *Growth Regulation*, 1992, 2, 55-68). Six IGFBPs have so far been identified. The exact effects of the IGFBPs are not clear and observed effects *in vitro* have been inhibitory or stimulatory
15 depending on the experimental method employed (Clemmons, *Growth Regn.* 1992, 2, 80,). There is some evidence, however, that certain IGFBPs are involved in targeting insulin-like growth factor-I to its cell surface receptor. Also expression of IGFBP-3 is regulated by growth hormone (Karen et
20 al, *supra*).

The IGF-IR is a tyrosine kinase linked cell surface receptor (Ullrich et al., *EMBO J.* 1986, 5, 2503-2512,) that regulates cell division, transformation and apoptosis in many cell types (LeRoith et al., *Endocr. Rev.*, 1995, 16, 143-163;
25 Rubin and Baserga, *Laboratory Investigation*, 1995, 73, 311-331).

If feedback regulation of growth hormone production is lost and the pituitary continues to release aberrant amounts of growth hormone, the level of insulin-like growth factor-I
30 continues to rise, leading to bone growth and organ enlargement. The excess growth hormone also causes changes in sugar and lipid metabolism, which may lead to diabetes. Defects in the growth hormone signalling pathway often lead

to abnormalities of stature and body and/or organ size. Mutations in the growth hormone receptor gene result in extreme short stature (Laron's syndrome). Excessive production of growth hormone can lead to acromegaly or
5 gigantism.

Acromegaly and gigantism are related growth disorders wherein growth hormone excess, sometimes caused by pituitary tumor, causes progressive cosmetic disfigurement and systemic organ manifestations. It affects 40-50 per million people
10 worldwide with about 15,000 sufferers in each of the US and Europe and an annual incidence of about 4-5 per million. It is initially characterized by abnormal growth of the hands and feet and bony changes in the facial features. Patients have reduced quality of life with overgrowth of the jaw,
15 enlargement of hands and feet, deepening of the voice, thickening of skin, offensive body odor, articular cartilage problems, hyperphosphatemia, peripheral neuropathies, higher blood pressure, diabetes, heart disease, and cancer, and have a reduced life expectancy if untreated. The mortality rate is
20 about twice that of the normal population due to cardiorespiratory and cardiovascular diseases, diabetes and neoplasia, particularly colon cancer. The goal of current treatment is to reverse the effects of the hypersecretion of growth hormone and normalize production of IGF-I which is
25 elevated by about 50% in these patients. When effective, treatment moderates disease symptoms and disease-associated mortality.

Gigantism, the disease of excess growth hormone in children, is a rare disorder. In gigantism, excessive linear
30 growth occurs whilst epiphyseal growth plates are open during childhood with growth hormone excess caused via a benign pituitary tumor. In both gigantism and acromegaly, all growth parameters are affected, although not necessarily

symmetrically. Many of the growth related outcomes are mediated by elevated levels of serum IGF-I. Serum blood levels of IGF-I are elevated by about 50% in patients and reduction of serum IGF-I is used to monitor treatment success.

5
10
15
20
Treatments for acromegaly and gigantism involve the ability to lower the elevated IGF-I in plasma. This may be achieved by surgical removal and radiation therapy of the benign pituitary tumor but this is effective in only 50% of patients. Dopamine agonists such as bromocriptine mesylate or cabergoline may be dosed orally which is convenient but they only reduce growth hormone production and associated IGF-I sufficiently in 10% of cases. They also produce significant gastrointestinal and central side effects in 20-30% of patients. Also used in treatment of acromegaly are the somatostatin analogues such as Sandostatin or octreotide, which inhibit the release of growth hormone releasing hormone (GHRH) from the hypothalamus, and/or pituitary and thereby reducing production of growth hormone in the pituitary. This compound is effective in 60-65% patients with acromegaly but it must be injected under the skin every 8 hours or intramuscularly for effective treatment.

25
30
Recently a growth hormone receptor antagonist, Trovert, also known as Somavert, Pegvisomant and B2036-PEG, was shown in clinical trials to be effective in 90-95% of patients. Clinical trial experience to date shows a 10% drop-out rate and adverse effects such as liver dysfunction. Trovert is a growth hormone molecule with a 9 amino acid substitution with 4-5 pegylations to increase half life. Like all modified proteins it is immunogenic, with antibodies being made to Trovert within 1 month of dosing. This can impact Trovert's short and long term utility and makes dosing difficult to predict. Trovert was initially dosed once per month by

subcutaneous (sc) administration, but current clinical practice suggests dosing will need to be once/day sc. Trovert interferes with growth hormone binding to its receptor but not the Growth Hormone Binding Protein (GHBP) fragment of the growth hormone receptor. GHBP binds growth hormone prolonging its action, which can be disadvantageous in conditions involving excess growth hormone and/or excess IGF-I. Pegylation may also impact on Trovert's long term safety profile.

10 Diabetes and its life threatening complications such as diabetic retinopathy and nephropathy are also disorders associated with growth hormone and/or IGF-I levels. First line treatment of these conditions involves controlling hyperglycemia. Drugs that control diabetes reduce the incidence of nephropathy by 60% and also reduce the incidence of retinopathy. However, about half of all diabetics are unaware of disease and therefore remain untreated, so diabetic nephropathy and retinopathy are likely to remain a major condition requiring other treatments. In retinopathy surgical ablative treatments such as laser pan-retinal photocoagulation are used but these remain incompletely effective and destroy retinal tissue, causing partial vision field loss. In type I diabetics ACE and AII inhibitors decrease albuminuria excretion by acting on the kidney and in 20 Type II diabetics the same inhibitors act locally on kidney and also decrease blood pressure to reduce the risk of death from kidney failure by another 50%. However, 20-30% of patients remain resistant to treatment with current glycemic control drugs and ACE drugs. There is thus a need for better 25 treatments.

The underlying cause of diabetes, diabetic retinopathy and diabetic nephropathy may be insulin related hyperglycemia, but growth hormone and/or insulin-like growth

factor-I excess is also important. Octreotide inhibitors of GHRH that decrease production of pituitary growth hormone, reducing systemic levels of growth hormone and IGF-I, and/or modulating local tissue levels show potential in the clinic.

5 A study with octreotide by Grant et al., *Diabetes Care*, **2000**, 2, 504-9) reducing sIGF-1 by 51% at maximally tolerated doses of octreotide 5000 µg/day sc reduced the need for laser surgery in retinopathy patients to 1 patient out of 22 rather than 9/22 in placebo in a 15 month study. Also ocular
10 disease was reduced to 27% vs placebo of 42% bordering on significance (P 0.06). Three human studies using octreotide at levels that reduced sIGF1 45%, about 20% and about 10% respectively were at least partly effective in clinical trials of nephropathy. The outcome reported by Serin et al.
15 (*JAMA*, **1991**, 265, 888-92) with 11 patients used high doses of octreotide in a 12 week study that reduced serum IGF-I by 45%. At the time it was stated to be the best effect observed on reducing glomerular filtration rate with a 22-33% reduction relative to placebo. This dose, however, was near
20 maximally tolerated doses of octreotide.

Animal pathology model studies with octreotide and Trovert also support the view that agents that modulate the growth hormone/insulin-like growth factor-I axis are beneficial in the treatment of these diabetic conditions.

25 Growth hormone and its receptor are implicated in the induction of glomerular hypertrophy and sclerosis in partial nephrectomy and diabetic nephropathy with somatostatin inhibitors octreotide and PTR-3173 (Groenbaek et al., *J. Endocrinol.*, **2002**, 172, 637-643 and Landau et al., *Kidney International*, **2001**, 60, 505-512) and growth hormone receptor antagonist, G120K-PEG, a weaker version of Trovert,
30 preventing complications in type I and Type II diabetic mice (Chen et al., *Endocrinology*, **1996**, 137, 11, 5136-5165;

Flyvbjerg et al., *Diabetes*, **1999**, *40*,377-382, and Segev et al., *J. Am. Soc. Nephrol.* **1999**, *10*,2374-81). Growth hormone and its receptor are implicated in the induction of retinal neovascularization through IGF-I with somatostatin inhibitors octreotide and growth hormone receptor antagonist MK678, inhibiting retinal neovascularization in mice. MK678 reduction of neovascularization correlated with low serum IGF-I (Smith et al, *Science*, **1997**, *276*, 1706-9). Oxygen induced retinopathy in the mouse was also responsive to octreotide as reported by Higgins et al., *Exp. Eye Res*, **2002**, *74*,553-9.

Macular degeneration is also associated with elevated growth hormone and/or IGF-I levels. Age-related macular degeneration (AMD) is caused by deterioration of the central part of the retina, the macula, resulting in loss of detailed vision. Wet AMD, the less common form, is caused by leakage from new blood vessels growing behind the retina. The growth hormone/ IGF-I axis is involved in formation of new blood vessels relevant to this condition and to diabetic retinopathy.

Various cancers are also associated with aberrant growth hormone and/or IGF-I levels. Reduction of serum IGF-I by 20-50% using Trovert decreased tumor volume in breast cancer in animal models and helped in colon cancer, liver metastasis, and meningiomas (Friend et al., *Proceedings 11th NCI EORTC. AACR Symposium* and Friend, *Growth Horm. IGF Res.*, **2001**, Jun: 11 Suppl A: S121-3). The incidence of breast, colon, prostate, and lung cancer is increased in individuals in the high normal range of serum IGF-I. There have been no clinical studies with Trovert in cancers. However, octreotide is indicated for gastro-pancreatic cancers.

Other conditions that may be associated with elevated growth hormone and/or IGF-I levels include rheumatoid

arthritis. A pilot clinical study showed octreotide was useful for the treatment of active refractory rheumatoid arthritis in a subset of patients (Paran et al., *Ann. Rheum. Dis.*, **2001**, *60*, 888-91. with comments and authors' reply in *Ann. Rheum. Dis.*, **2002**, *61*, 1117).

Longevity may also be improved with modulation of growth hormone receptor (Coschigano et al., *Endocrinology*, **2000**, *141*, 2608-2613). There was a significant increase in lifespan of nearly a year in double knockout animals with low levels of IGF-I and high levels of growth hormone.

Another application to modifying levels of growth hormone and/or IGF-I via the growth hormone receptor may enable stem cell differentiation towards neural cell production as growth hormone inhibits neuronal differentiation of neural progenitor cells (Turnley et al., *Nature Neuroscience*, 7 October **2002**, published online). Other applications will be known to those skilled in the art.

Although the underlying roles in various disease or conditions may be different, the above conditions arise at least in part from incorrect levels of expression of local and/or systemic growth factors growth hormone and IGF-I and/or their receptors growth hormone receptor and IGF-IR. In these situations, dopamine agonists, somatostatin antagonists, and growth hormone receptor antagonists targeting the proteins have been used and/or shown potential.

While a range of treatments have been developed for agents that modify the growth hormone-insulin-like growth factor axis, and growth hormone receptor and IGF-IR, none is completely effective and/or free of adverse side effects. Moreover, there is potential disadvantages in the routes and/or frequencies of administration that can affect compliance.

It is therefore an object of the present invention to

provide novel products and compositions wherein one or more of the above problems and limitations are ameliorated.

In the last decade, there have been reports of the use of antisense oligonucleotides to explore gene function and several reports in the development of nucleic acid based
5 drugs. Antisense oligonucleotides inhibit mRNA translation via a number of alternative ways including destruction of the target mRNA through RNase H recruitment, or interference with RNA processing, nuclear export, folding or ribosome scanning.

10 Pellegrini et al. attempted to block growth hormone receptor synthesis in the central nervous system by infusing intracerebroventricularly an antisense 18-mer oligonucleotide complementary to a portion of the coding sequence of the rat growth hormone receptor mRNA overlapping the translation
15 initiation codon. *J. Neurosci.* 1996, 16, 8140-8148.

The current invention as exemplified herein for the first time, demonstrates that an antisense oligonucleotide targeted specifically to the growth hormone receptor reduces a clinical parameter of growth hormone activity, namely serum
20 insulin-like growth factor-I. Importantly, our antisense studies teach the ability to use antisense to growth hormone receptor to reduce serum insulin-like growth factor-I by similar degrees required for the clinical treatment of gigantism or acromegaly. Serum insulin-like growth factor-I
25 levels are elevated in acromegaly patients and reduced at human therapeutic Trovert doses by 50% in both 12 week studies (Trainer et al, *The New England J of Med* April 20, 2000) which show a decrease by 1.3 to 2 fold, and in long term greater than 1 year studies as reported by van der Lely
30 et al., *Lancet* 2001, Nov 24: 358 (9295) 1754-1759.

Similar levels of reduction of serum insulin-like growth factor-I are also reported with octreotide in 15 month clinical trials of diabetic retinopathy (Grant et al, *Supra*)

and in clinical trials in diabetic nephropathy (Serri et al, *supra*). Similar levels of reduction of 20-50% is also sufficient to prevent the growth of certain cancer in animal models (Friend, *supra*).

5

The present invention teaches for the first time that growth hormone receptor antisense can achieve human and animal equivalent therapeutic outcomes. It teaches that antisense to the mRNA of one component of the growth
10 hormone/insulin-like growth factor-I axis, namely growth hormone receptor, can affect another parameter in the axis, e.g., IGF-I. Importantly, it teaches that antisense targeting any other target in the growth hormone/insulin-like growth factor-I axis is potentially capable of achieving
15 therapeutic levels in conditions dependent on excess growth hormone or insulin-like growth factor-I levels.

SUMMARY OF THE INVENTION

The present invention is directed to compounds,
20 especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding growth hormone receptor, and which modulate growth hormone signaling or the growth hormone/insulin-like growth factor-I axis, particularly the expression of growth hormone receptor and/or
25 insulin-like growth factor-I. Further provided are methods of screening for modulators of growth hormone receptor and/or insulin-like growth factor-I and methods of modulating the expression of growth hormone receptor and/or insulin-like growth factor-I in cells, tissues or animals comprising
30 contacting said cells, tissues or animals with one or more of the compounds or compositions of the invention. Diagnostic methods and kits are also provided. Methods of treating an animal, particularly a human, suspected of having or being

prone to a disease or condition associated with growth hormone signaling or the growth hormone/insulin-like growth factor-I axis, particularly the expression of growth hormone receptor and/or insulin-like growth factor-I, are also set forth herein.

DETAILED DESCRIPTION OF THE INVENTION

A. Overview of the Invention

The present invention employs compounds, preferably oligonucleotides and similar species for use in modulating the function or effect of nucleic acid molecules encoding growth hormone receptor. This is accomplished by providing oligonucleotides which specifically hybridize with one or more nucleic acid molecules encoding growth hormone receptor. As used herein, the terms "target nucleic acid" and "nucleic acid molecule encoding growth hormone receptor" have been used for convenience to encompass DNA encoding growth hormone receptor, RNA (including pre-mRNA and mRNA or portions thereof (including both coding and noncoding regions), transcribed from such DNA, and also cDNA derived from such RNA. The hybridization of a compound of this invention with its target nucleic acid is generally referred to as "antisense". Consequently, the preferred mechanism believed to be included in the practice of some preferred embodiments of the invention is referred to herein as "antisense inhibition." Such antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved, degraded, or otherwise rendered inoperable. In this regard, it is presently preferred to target specific nucleic acid molecules and their functions for such antisense inhibition.

The functions of DNA to be interfered with can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise. The functions of RNA to be interfered with can include functions such as translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. One preferred result of such interference with target nucleic acid function is modulation of the expression of growth hormone receptor. In the context of the present invention, "modulation" and "modulation of expression" mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often the preferred form of modulation of expression and mRNA is often a preferred target nucleic acid.

In the context of this invention, "hybridization" means the pairing of complementary strands of oligomeric compounds. In the present invention, the preferred mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes

with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under
5 conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, and under conditions in which assays are performed in the case of *in vitro* assays.

In the present invention the phrase "stringent
10 hybridization conditions" or "stringent conditions" refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances and in the
15 context of this invention, "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated.

"Complementary," as used herein, refers to the capacity
20 for precise pairing between two nucleobases of an oligomeric compound. For example, if a nucleobase at a certain position of an oligonucleotide (an oligomeric compound), is capable of hydrogen bonding with a nucleobase at a certain position of a
25 target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligonucleotide and the further DNA, RNA, or
30 oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, "specifically hybridizable" and

"complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid.

It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). It is preferred that the antisense compounds of the present invention comprise at least 70% sequence complementarity to a target region within the target nucleic acid, more preferably that they comprise 90% sequence complementarity and even more preferably comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local

alignment search tools) and PowerBLAST programs known in the art (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403-410; Zhang and Madden, *Genome Res.*, 1997, 7, 649-656).

5 B. Compounds of the Invention

According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric
10 compounds which hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once
15 introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid. One non-limiting example of such an enzyme is RNase H, a cellular endonuclease which cleaves the RNA strand of an
20 RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNase H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression.
25 Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species
30 the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This

phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing.

The first evidence that dsRNA could lead to gene silencing in animals came in 1995 from work in the nematode, *Caenorhabditis elegans* (Guo and Kempheus, *Cell*, 1995, 81, 611-620). Montgomery et al. have shown that the primary interference effects of dsRNA are posttranscriptional (Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 1998, 95, 15502-15507). The posttranscriptional antisense mechanism defined in *Caenorhabditis elegans* resulting from exposure to double-stranded RNA (dsRNA) has since been designated RNA interference (RNAi). This term has been generalized to mean antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of endogenous targeted mRNA levels (Fire et al., *Nature*, 1998, 391, 806-811). Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the dsRNAs which are the potent inducers of RNAi (Tijsterman et al., *Science*, 2002, 295, 694-697).

In the context of this invention, the term "oligomeric compound" refers to a polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for

a target nucleic acid and increased stability in the presence of nucleases.

While oligonucleotides are a preferred form of the compounds of this invention, the present invention
5 comprehends other families of compounds as well, including but not limited to oligonucleotide analogs and mimetics such as those described herein.

The compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases
10 (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,
15 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.

In one preferred embodiment, the compounds of the invention are 12 to 50 nucleobases in length. One having
20 ordinary skill in the art will appreciate that this embodies compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases in length.

25 In another preferred embodiment, the compounds of the invention are 15 to 30 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length.

30 Particularly preferred compounds are oligonucleotides from about 12 to about 50 nucleobases, even more preferably those comprising from about 15 to about 30 nucleobases.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). One having skill in the art armed with the preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

C. Targets of the Invention

"Targeting" an antisense compound to a particular nucleic acid molecule, in the context of this invention, can be a multistep process. The process usually begins with the identification of a target nucleic acid whose function is to

be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target nucleic acid encodes growth hormone receptor.

The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present invention, the term "region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. "Segments" are defined as smaller or sub-portions of regions within a target nucleic acid. "Sites," as used in the present invention, are defined as positions within a target nucleic acid.

Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in

a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA transcribed from a gene encoding growth hormone receptor, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).

The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions which may be targeted effectively with the antisense compounds of the present invention.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, a preferred region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

Other target regions include the 5' untranslated region

(5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding 5 nucleotides on the gene), and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding 10 nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides 15 adjacent to the cap site. It is also preferred to target the 5' cap region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is 20 translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. Targeting splice sites, i.e., intron-exon junctions or exon-intron junctions, may also be particularly useful in situations where aberrant splicing is 25 implicated in disease, or where an overproduction of a particular splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred target sites. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different 30 gene sources are known as "fusion transcripts". It is also known that introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

In mouse, rat and monkey, growth hormone binding protein, which is the soluble shortened form of growth hormone receptor, is produced by alternative splicing of the growth hormone receptor primary transcript. In some embodiments it may be preferred to target regions of the transcript which are present in both the growth hormone receptor transcript and in the shorter growth hormone binding protein transcript. In other embodiments it may be preferable to target regions of the mRNA which are only present in the longer growth hormone receptor transcript. In humans, cows, and pigs (among others), no alternative RNA splicing is apparent but instead the shorter growth hormone binding protein is produced by proteolysis of the growth hormone receptor. It will be understood that in the context of this invention, "nucleic acid encoding growth hormone receptor"

thus includes nucleic acid encoding growth hormone binding protein."

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the invention, the types of variants described herein are also preferred target nucleic acids.

The growth hormone receptor mRNA has alternative 5' untranslated regions and one or more of these may be preferred for targeting.

The locations on the target nucleic acid to which the preferred antisense compounds hybridize are hereinbelow referred to as "preferred target segments." As used herein the term "preferred target segment" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target segments represent portions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of certain preferred target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present

invention. Additional preferred target segments may be identified by one having ordinary skill.

Target segments 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases
5 selected from within the illustrative preferred target segments are considered to be suitable for targeting as well.

Target segments can include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target segments
10 (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred target segments are represented by DNA or RNA
15 sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred target segments (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target
20 segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art armed with the preferred target segments illustrated herein will be able, without undue experimentation, to identify further preferred target segments.

25 Once one or more target regions, segments or sites have been identified, antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

30

D. Screening and Target Validation

In a further embodiment, the "preferred target segments" identified herein may be employed in a screen for

additional compounds that modulate the expression of growth hormone receptor. "Modulators" are those compounds that decrease or increase the expression of a nucleic acid molecule encoding growth hormone receptor and which comprise at least an 8-nucleobase portion which is complementary to a preferred target segment. The screening method comprises the steps of contacting a preferred target segment of a nucleic acid molecule encoding growth hormone receptor with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding growth hormone receptor. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding growth hormone receptor, the modulator may then be employed in further investigative studies of the function of growth hormone receptor, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.

The preferred target segments of the present invention may be also be combined with their respective complementary antisense compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides.

Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications (Fire et al., *Nature*, 1998, 391, 806-811; Timmons and Fire, *Nature* 1998, 395, 854; Timmons et al., *Gene*, 2001, 263, 103-112; Tabara et al., *Science*, 1998, 282, 430-431; Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 1998, 95, 15502-15507; Tuschl et al., *Genes Dev.*, 1999, 13, 3191-3197; Elbashir et al., *Nature*, 2001,

411, 494-498; Elbashir et al., *Genes Dev.* **2001**, *15*, 188-200). For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the target, thereby
5 triggering enzymatic degradation of the target (Tijsterman et al., *Science*, **2002**, *295*, 694-697).

The compounds of the present invention can also be applied in the areas of drug discovery and target validation. The present invention comprehends the use of the compounds
10 and preferred target segments identified herein in drug discovery efforts to elucidate relationships that exist between growth hormone receptor and a disease state, phenotype, or condition. These methods include detecting or modulating growth hormone receptor comprising contacting a
15 sample, tissue, cell, or organism with the compounds of the present invention, measuring the nucleic acid or protein level of growth hormone receptor and/or a related phenotypic or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated
20 sample or sample treated with a further compound of the invention. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene
25 product as a target for treatment or prevention of a particular disease, condition, or phenotype.

E. Kits, Research Reagents, Diagnostics, and Therapeutics

The compounds of the present invention can be utilized
30 for diagnostics, therapeutics, prophylaxis and as research reagents and kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to

elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

For use in kits and diagnostics, the compounds of the present invention, either alone or in combination with other
5 compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

As one nonlimiting example, expression patterns within
10 cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway,
15 cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

20 Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, 2000, 480, 17-24; Celis, et al., *FEBS Lett.*, 2000, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, 2000, 5, 415-
25 425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*,
30 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA

fingerprinting (SuRF) (Fuchs, *et al.*, *Anal. Biochem.*, 2000, 286, 91-98; Larson, *et al.*, *Cytometry*, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-21),
5 comparative genomic hybridization (Carulli, *et al.*, *J. Cell Biochem. Suppl.*, 1998, 31, 286-96), FISH (fluorescent *in situ* hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

10 The compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding growth hormone receptor. For example, oligonucleotides that are shown to hybridize with such efficiency and under such conditions as disclosed herein as
15 to be effective growth hormone receptor inhibitors will also be effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding growth hormone receptor
20 and in the amplification of said nucleic acid molecules for detection or for use in further studies of growth hormone receptor. Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid encoding growth hormone receptor can be detected
25 by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of growth hormone receptor in a sample may also be prepared.

30 The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals,

including humans. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful
5 therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals.

The compounds of the present invention have been shown to reduce expression of growth hormone receptor and to reduce
10 levels of IGF-I. These compounds are therefore believed to be useful for prevention, delay or treatment of conditions associated with growth hormone receptor or with the growth hormone/insulin-like growth factor-I axis, including acromegaly, gigantism, age-related macular degeneration,
15 diabetic retinopathy, diabetic nephropathy, diabetes, arthritis and growth hormone and IGF-I dependent tumors.

For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of growth hormone
20 receptor is treated by administering antisense compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a growth hormone receptor
25 inhibitor. The growth hormone receptor inhibitors of the present invention effectively inhibit the activity of the growth hormone receptor protein or inhibit the expression of the growth hormone receptor protein. In one embodiment, the activity or expression of growth hormone receptor in an
30 animal is inhibited by about 10%. Preferably, the activity or expression of growth hormone receptor in an animal is inhibited by about 30%. More preferably, the activity or

expression of growth hormone receptor in an animal is inhibited by 45% or more.

For example, the reduction of the expression of growth hormone receptor may be measured in serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding growth hormone receptor protein and/or the growth hormone receptor protein itself.

The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.

F. Modifications

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally preferred. In addition, linear compounds may have internal nucleobase complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound.

Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

5

Modified Internucleoside Linkages (Backbones)

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages.

10 As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art,
15 modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones containing a phosphorus atom therein include, for example,
20 phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-
25 amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or
30 more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside

residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;

5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and
5 5,677,439, certain of which are commonly owned with this
application, and each of which is herein incorporated by
reference.

Modified sugar and internucleoside linkages-Mimetics

10 In other preferred oligonucleotide mimetics, both the
sugar and the internucleoside linkage (i.e. the backbone), of
the nucleotide units are replaced with novel groups. The
nucleobase units are maintained for hybridization with an
appropriate target nucleic acid. One such compound, an
15 oligonucleotide mimetic that has been shown to have excellent
hybridization properties, is referred to as a peptide nucleic
acid (PNA). In PNA compounds, the sugar-backbone of an
oligonucleotide is replaced with an amide containing
backbone, in particular an aminoethylglycine backbone. The
20 nucleobases are retained and are bound directly or indirectly
to aza nitrogen atoms of the amide portion of the backbone.
Representative United States patents that teach the
preparation of PNA compounds include, but are not limited to,
U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is
25 herein incorporated by reference. Further teaching of PNA
compounds can be found in Nielsen *et al.*, *Science*, 1991, 254,
1497-1500.

Preferred embodiments of the invention are
oligonucleotides with phosphorothioate backbones and
30 oligonucleosides with heteroatom backbones, and in particular
-CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene
(methyylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-
N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native

phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified sugars

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also

known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

5 Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is
10 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics
15 such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785;
20 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

25 A further preferred modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH₂-)_n group bridging the 2' oxygen atom and the
30 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Natural and Modified Nucleobases

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine

and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, 5 those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are 10 particularly useful for increasing the binding affinity of the compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine 15 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the 20 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 25 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 30 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Conjugates

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992, and U.S. Patent 6,287,860, the entire disclosure of which are incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a

polyamine or a polyethylene glycol chain, or adamantane
acetic acid, a palmityl moiety, or an octadecylamine or
hexylamino-carbonyl-oxysterol moiety. Oligonucleotides
of the invention may also be conjugated to active drug
5 substances, for example, aspirin, warfarin, phenylbutazone,
ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-
pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic
acid, flufenamic acid, folinic acid, a benzothiadiazide,
chlorothiazide, a diazepam, indomethacin, a barbiturate, a
10 cephalosporin, a sulfa drug, an antidiabetic, an
antibacterial or an antibiotic. Oligonucleotide-drug
conjugates and their preparation are described in United
States Patent Application 09/334,130 (filed June 15, 1999)
which is incorporated herein by reference in its entirety.

15 Representative United States patents that teach the
preparation of such oligonucleotide conjugates include, but
are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105;
5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717,
5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;
20 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718;
5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;
4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;
4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;
25 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,
5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667;
5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;
5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and
5,688,941, certain of which are commonly owned with the
30 instant application, and each of which is herein incorporated
by reference.

Chimeric compounds

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNaseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more

oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

G. Formulations

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite

or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

5 Sodium is a suitable pharmaceutical salt, particularly for oligonucleotide compounds.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the
10 action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin *et al.*,
15 published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach *et al.*

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the
20 desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its
25 entirety.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of
30 ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by

inhalation or insufflation of powders or aerosols, including
by nebulizer; intratracheal, intranasal, epidermal and
transdermal), oral or parenteral. Parenteral administration
includes intravenous, intraarterial, subcutaneous,
5 intraperitoneal or intramuscular injection or infusion; or
intracranial, e.g., intrathecal or intraventricular,
administration. Oligonucleotides with at least one 2'-O-
methoxyethyl modification are believed to be particularly
useful for oral administration. Pharmaceutical compositions
10 and formulations for topical administration may include
transdermal patches, ointments, lotions, creams, gels, drops,
suppositories, sprays, liquids and powders. Conventional
pharmaceutical carriers, aqueous, powder or oily bases,
thickeners and the like may be necessary or desirable.
15 Coated condoms, gloves and the like may also be useful.

The pharmaceutical formulations of the present
invention, which may conveniently be presented in unit dosage
form, may be prepared according to conventional techniques
well known in the pharmaceutical industry. Such techniques
20 include the step of bringing into association the active
ingredients with the pharmaceutical carrier(s) or
excipient(s). In general, the formulations are prepared by
uniformly and intimately bringing into association the active
ingredients with liquid carriers or finely divided solid
25 carriers or both, and then, if necessary, shaping the
product.

The compositions of the present invention may be
formulated into any of many possible dosage forms such as,
but not limited to, tablets, capsules, gel capsules, liquid
30 syrups, soft gels, suppositories, and enemas. The
compositions of the present invention may also be formulated
as suspensions in aqueous, non-aqueous or mixed media.
Aqueous suspensions may further contain substances which

increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

Formulations of the present invention include liposomal formulations. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes which are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

The pharmaceutical formulations and compositions of the present invention may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Penetration enhancers and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

One of skill in the art will recognize that formulations are routinely designed according to their intended use, *i.e.* route of administration.

Also preferred antisense compounds are those capable of oral administration such as the 2'MOE antisense compounds and morpholino phosphorodiamidates. This provides further convenience for users relative to growth hormone receptor compounds in the prior art. Preferred compounds in the treatment of some conditions will be those that distribute broadly and thus capable of both local and/or systemic effects via the liver. It will be understood however, that in other conditions distribution to fewer organs may be preferred.

Preferred formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

For topical or other administration, oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999, which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts and fatty acids and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 09/108,673 (filed July 1, 1998), 09/315,298 (filed May 20, 1999) and 10/071,822, filed February 8, 2002, each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents

and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine,

acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially. Particularly preferred combinations comprise Octreotide, Trovert and/or other inhibitor(s) or antagonists of growth hormone, insulin-like growth factor-I, IGFBP-3, growth hormone receptor or insulin-like growth factor1 receptor.

Compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Alternatively, compositions of the invention may contain two or more antisense compounds targeted to different regions of the same nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

H. Dosing

The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual

oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, 5 monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have 10 the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

15 Preferred antisense oligonucleotides are made with chemistries capable of low frequency of dosing, i.e., once a day, once a week or less often. Particularly preferred antisense chemistries are those used herein which may be dosed once every second day and able to be dosed at least 20 once per week sc, if not less frequently at once per month, based on the observations of antisense of the same class. This is less frequently than Trovert in same animal model, which was dosed every day, and less frequently than current clinical experience with Trovert. This provides enormous 25 convenience for treatment of this chronic condition which may potentially improve compliance.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate 30 the invention and are not intended to limit the same.

EXAMPLES**Example 1****5 Synthesis of Nucleoside Phosphoramidites**

The following compounds, including amidites and their intermediates were prepared as described in US Patent 6,426,220 and published PCT WO 02/36743; 5'-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine
10 intermediate for 5-methyl-dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-N⁴-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-
15 3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite), 2'-Fluorodeoxyadenosine, 2'-Fluorodeoxyguanosine, 2'-Fluorouridine, 2'-Fluorodeoxycytidine, 2'-O-(2-Methoxyethyl) modified amidites, 2'-O-(2-methoxyethyl)-5-methyluridine intermediate, 5'-O-DMT-
20 2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite), 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine
25 intermediate, 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methyl-cytidine penultimate intermediate, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite), [5'-O-(4,4'-
30 Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyladenoin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite), [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-

isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite), 2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylamino-oxyethyl) nucleoside amidites, 2'-(Dimethylaminooxyethoxy) nucleoside amidites, 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine, 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine, 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine, 5'-O-tert-butyl-diphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine, 5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N dimethylaminooxyethyl]-5-methyluridine, 2'-O-(dimethylaminooxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2'-(Aminooxyethoxy) nucleoside amidites, N²-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites, 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine, 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]]-5-methyl uridine and 5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite.

Example 2

Oligonucleotide and oligonucleoside synthesis

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other

means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

5

Oligonucleotides: Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

10

Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

15

20

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

25

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

30

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as

described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

5 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

10 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Oligonucleosides: Methylenemethylimino linked
15 oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked
20 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,
25 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

30 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 3**RNA Synthesis**

In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5'-hydroxyl in combination with an acid-labile orthoester protecting group on the 2'-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.

Following this procedure for the sequential protection of the 5'-hydroxyl in combination with protection of the 2'-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5'- direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5'-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5'-silyl group is cleaved

with fluoride. The cycle is repeated for each subsequent nucleotide.

Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-
5 2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S_2Na_2) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55 °C. This releases the RNA oligonucleotides into solution,
10 deprotects the exocyclic amines, and modifies the 2'- groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

The 2'-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester
15 protecting group developed by Dharmacon Research, Inc. (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis.
20 However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron
25 withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient
30 stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous

conditions compatible with the final RNA oligonucleotide product.

Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of
5 Colorado, 1996; Scaringe, S. A., et al., *J. Am. Chem. Soc.*,
1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H.
J. Am. Chem. Soc., 1981, 103, 3185-3191; Beaucage, S. L. and
Caruthers, M. H. *Tetrahedron Lett.*, 1981, 22, 1859-1862;
Dahl, B. J., et al., *Acta Chem. Scand.*, 1990, 44, 639-641;
10 Reddy, M. P., et al., *Tetrahedron Lett.*, 1994, 25, 4311-4314;
Wincott, F. et al., *Nucleic Acids Res.*, 1995, 23, 2677-2684;
Griffin, B. E., et al., *Tetrahedron*, 1967, 23, 2301-2313;
Griffin, B. E., et al., *Tetrahedron*, 1967, 23, 2315-2331).

RNA antisense compounds (RNA oligonucleotides) of the
15 present invention can be synthesized by the methods herein or
purchased from Dharmacon Research, Inc (Lafayette, CO). Once
synthesized, complementary RNA antisense compounds can then
be annealed by methods known in the art to form double
stranded (duplexed) antisense compounds. For example,
20 duplexes can be formed by combining 30 μ l of each of the
complementary strands of RNA oligonucleotides (50 μ M RNA
oligonucleotide solution) and 15 μ l of 5X annealing buffer
(100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM
magnesium acetate) followed by heating for 1 minute at 90°C,
25 then 1 hour at 37°C. The resulting duplexed antisense
compounds can be used in kits, assays, screens, or other
methods to investigate the role of a target nucleic acid.

Example 4

30 Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed
oligonucleotides/oligonucleosides of the invention can be of
several different types. These include a first type wherein

the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

10 **Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above.

15 Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating
20 coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an
25 appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

30 **[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-

(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

5

[2'-O-(2-Methoxyethyl)Phosphodiester] -- [2'-deoxy Phosphorothioate] -- [2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester] -- [2'-deoxy phosphorothioate] -- [2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

25

Example 5

Design and screening of duplexed antisense compounds targeting growth hormone receptor

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target growth hormone receptor. In one embodiment these nucleic acid duplexes are double-stranded RNA compounds


(small interfering RNAs or siRNAs). In general, active sites for RNase H-dependent antisense oligonucleotides predict active sites for siRNA (Vickers et al., 2003, *J. Biol Chem.* 278, 7108-7118). In one embodiment of the invention, the nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide sequence shown in Table 1. Alternatively, a new "gene walk" in which a series of dsRNAs targeted to growth hormone receptor are synthesized and tested may be used.

The ends of the dsRNA strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. The duplex may be a unimolecular or bimolecular duplex; i.e., the two strands may be connected to each other directly or by means of a linker, or may be separate molecules.

By way of example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:



In another embodiment, a duplex comprising an antisense strand having the same sequence CGAGAGGCGGACGGACCG may be prepared with blunt ends (no single stranded overhang) as shown:



gctctccgctgcctggc

Complement

5 RNA strands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, CO). Once synthesized, the complementary strands are annealed. The single strands are aliquoted and diluted to a concentration of 50 uM. Once diluted, 30 uL of each strand
10 is combined with 15uL of a 5X solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume is 75 uL. This solution is incubated for 1 minute at 90°C and then centrifuged for 15 seconds. The tube
15 is allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes are used in experimentation. The final concentration of the dsRNA duplex is 20 uM. This solution can be stored frozen (-20°C) and freeze-thawed up to 5 times.

Once prepared, the duplexed antisense compounds are
20 evaluated for their ability to modulate growth hormone receptor expression.

When cells reached 80% confluency, they are treated with duplexed antisense compounds of the invention. For cells grown in 96-well plates, wells are washed once with 200 µL
25 OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 µL of OPTI-MEM-1 containing 12 µg/mL LIPOFECTIN (Gibco BRL) and the desired duplex antisense compound at a final concentration of 200 nM. After 5 hours of treatment, the medium is replaced with fresh medium. Cells are
30 harvested 16 hours after treatment, at which time RNA is isolated and target reduction measured by RT-PCR.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH₄OAc with >3
5 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages
10 obtained in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu product (+/- 32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang *et al.*, *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified
15 material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

20 Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate
25 internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster
30 City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

10 Oligonucleotide Analysis - 96-Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

25 Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is

expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

5

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in
10 complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by
15 trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #353872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be
20 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

25 The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA),
30 penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

10 HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

MCF7:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

b.END cells:

The mouse brain endothelial cell line b.END was obtained from Dr. Werner Risau at the Max Plank Institute (Bad Nauheim, Germany). b.END cells were routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

15

Treatment with antisense compounds:

When cells reached 65-75% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. Cells are treated and data are obtained in triplicate. After 4-7 hours of treatment at 37°C, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

25

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920

30

(**TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (**GTGCGCGAGCCCGAAATC**, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-H-ras (for ISIS 13920), JNK2 (for ISIS 18078) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of c-H-ras, JNK2 or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 10

Analysis of oligonucleotide inhibition of growth hormone receptor expression

Antisense modulation of growth hormone receptor expression can be assayed in a variety of ways known in the art. For example, growth hormone receptor mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR).

Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in
5 other examples herein. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System, available from
10 PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of growth hormone receptor can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis
15 (immunoblotting), enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS). Antibodies directed to growth hormone receptor can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be
20 prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art.

Reduction in expression of growth hormone receptor may also be indirectly measured by measuring decreases in insulin-like growth factor-I in serum or other bodily fluid,
25 tissues or organs.

Example 11

Design of phenotypic assays and *in vivo* studies for the use of growth hormone receptor inhibitors

Phenotypic assays

30

Once growth hormone receptor inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each

having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition.

Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of growth hormone receptor in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, OR; PerkinElmer, Boston, MA), protein-based assays including enzymatic assays (Panvera, LLC, Madison, WI; BD Biosciences, Franklin Lakes, NJ; Oncogene Research Products, San Diego, CA), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, MI), triglyceride accumulation (Sigma-Aldrich, St. Louis, MO), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, CA; Amersham Biosciences, Piscataway, NJ).

In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with growth hormone receptor inhibitors identified from the *in vitro* studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular

status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

5 Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the growth hormone receptor inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured
10 in both treated and untreated cells.

In vivo studies

The individual subjects of the *in vivo* studies described herein are warm-blooded vertebrate animals, which includes
15 humans.

The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study. To account for the psychological effects of receiving
20 treatments, volunteers are randomly given placebo or growth hormone receptor inhibitor. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are administering is a growth hormone receptor inhibitor or a placebo. Using
25 this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

Volunteers receive either the growth hormone receptor inhibitor or placebo for eight week period with biological
30 parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study period.

Such measurements include the levels of nucleic acid molecules encoding growth hormone receptor or growth hormone receptor protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and growth hormone receptor inhibitor treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the growth hormone receptor inhibitor show positive trends in their disease state or condition index at the conclusion of the study.

Example 12

RNA Isolation

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are routine in the art. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS.

5 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

15 Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Total RNA Isolation

20 Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for

15 minutes and the vacuum was again applied for 1 minute. An additional 500 μ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY
5 96TM plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVACTM manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVACTM
10 manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 140 μ L of RNase free water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be
15 automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

20

Example 13

Real-time Quantitative PCR Analysis of growth hormone receptor mRNA Levels

Quantitation of growth hormone receptor mRNA levels was
25 accomplished by real-time quantitative PCR using the ABI PRISMTM 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-
30 throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is

completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification

reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer minus $MgCl_2$, 6.6 mM $MgCl_2$, 375 μ M each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM[®] Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 μ L total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM[®] Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen[™] (Molecular Probes, Inc. Eugene, OR). GAPDH

expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, OR). Methods of RNA
5 quantification by RiboGreen™ are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30
10 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485nm and emission at 530nm.

Probes and primers to human growth hormone receptor were designed to hybridize to a human growth hormone receptor
15 sequence, using published sequence information (GenBank accession number NM_000163.1, incorporated herein as SEQ ID NO:4). For human growth hormone receptor the PCR primers were:

forward primer: GATGTCCCAATGTGACATGCA (SEQ ID NO: 5)

20 reverse primer: AAGTAGGCATTGTCCATAAGGAAGTT (SEQ ID NO: 6) and the PCR probe was: FAM-CCGGAAATGGTCTCACTCTGCCAAGA-TAMRA

(SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)

25 reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO:9) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

Probes and primers to mouse growth hormone receptor were
30 designed to hybridize to a mouse growth hormone receptor sequence, using published sequence information (GenBank accession number NM_010284.1, incorporated herein as SEQ ID NO:11). For mouse growth hormone receptor the PCR primers

were:

forward primer: TTGACGAAATAGTGCAACCTGATC (SEQ ID NO:12)

reverse primer: CGAATCCCGGTCAAACCTAATG (SEQ ID NO: 13) and the
PCR probe was: FAM-CATTGGCCTCAACTGGACTTTACTAA-TAMRA

5 (SEQ ID NO: 14) where FAM is the fluorescent reporter dye and
TAMRA is the quencher dye. For mouse GAPDH the PCR primers
were:

forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO:15)

reverse primer: GGGTCTCGCTCCTGGAAGAT (SEQ ID NO:16) and the
10 PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTTCATC- TAMRA 3'
(SEQ ID NO: 17) where JOE is the fluorescent reporter dye and
TAMRA is the quencher dye.

Example 14

15 Northern blot analysis of growth hormone receptor mRNA levels

Eighteen hours after antisense treatment, cell
monolayers were washed twice with cold PBS and lysed in 1 mL
RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was
prepared following manufacturer's recommended protocols.

20 Twenty micrograms of total RNA was fractionated by
electrophoresis through 1.2% agarose gels containing 1.1%
formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon,
OH). RNA was transferred from the gel to HYBOND™-N+ nylon
membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by
25 overnight capillary transfer using a Northern/Southern
Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
RNA transfer was confirmed by UV visualization. Membranes
were fixed by UV cross-linking using a STRATALINKER™ UV
Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then
30 probed using QUICKHYB™ hybridization solution (Stratagene, La
Jolla, CA) using manufacturer's recommendations for stringent
conditions.

To detect human growth hormone receptor, a human growth

hormone receptor specific probe was prepared by PCR using the forward primer GATGTCCCAATGTGACATGCA (SEQ ID NO: 5) and the reverse primer AAGTAGGCATTGTCCATAAGGAAGTT (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency
5 membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse growth hormone receptor, a mouse growth hormone receptor specific probe was prepared by PCR using the
10 forward primer TTGACGAAATAGTGCAACCTGATC (SEQ ID NO: 12) and the reverse primer CGAATCCCGGTCAAATAATG (SEQ ID NO: 13). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto,
15 CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.
20

Example 15

**Antisense inhibition of human growth hormone receptor expression by chimeric phosphorothioate oligonucleotides
25 having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of antisense compounds were designed to target different regions of the human growth hormone receptor RNA, using published sequences (GenBank accession number NM_000163.1, incorporated
30 herein as SEQ ID NO: 4, and the complement of positions 468085 to 502183 of the sequence with GenBank accession number NT_006702.8, incorporated herein as SEQ ID NO: 18). The compounds are shown in Table 1. "Target site" indicates

the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human growth hormone receptor mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which MCF7 cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

20

Table 1

Inhibition of human growth hormone receptor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
227452	Coding	4	332	tcagggcattctttccattc	79	19	1
227453	Coding	4	337	cataatcagggcattctttc	52	20	1
227464	Coding	4	947	cctttaatctttggaactgg	58	21	1
227468	Coding	4	1079	tcatcaatatctagctcaat	62	22	1
227469	Coding	4	1124	cttagaagtctgtctgtgtc	63	23	1
227475	Coding	4	1514	cctgctggtgtaaatgtcgct	68	24	1
227480	Coding	4	1724	atgtaaagtctctcttggtt	66	25	1
227481	Coding	4	1729	tggtgatgtaaagtctctct	45	26	1
227482	Coding	4	1734	ttctgtggtgatgtaaagt	53	27	1
227483	Coding	4	1739	aggctttctgtggtgatgta	75	28	1
227484	Coding	4	1744	tggtaggctttctgtggtg	63	29	1
227488	Coding	4	1922	agttggtctgtgctcacata	86	30	1
227489	Coding	4	1927	tgttcagttggtctgtgctc	75	31	1

227490	Coding	4	1936	gcatgattttgttcagttgg	67	32	1
227499	3'UTR	4	2656	tataaaagggctttgtaaaa	14	33	1
227500	3'UTR	4	4043	catagcagcaaagtagcaga	69	34	1
227501	3'UTR	4	4183	gctatTTTTGGCTATAGAAA	64	35	1
227502	3'UTR	4	4197	gattgaggtatTTAGCTATT	56	36	1
272302	Start Codon	4	31	gatccatacctgtaggacct	60	37	1
272303	Start Codon	4	36	ccagagatccatacctgtag	55	38	1
272304	Coding	4	115	tgctaaggatagctgctgtg	48	39	1
272305	Coding	4	160	ttgtctttaggcctggatta	68	40	1
272306	Coding	4	170	ttagaagaatttTGTCTTTAG	13	41	1
272307	Coding	4	185	gtgaatttaggctccttaga	55	42	1
272308	Coding	4	274	gctgtatgggtcctaggttc	57	43	1
272309	Coding	4	362	taacagctgttttccccagc	85	44	1
272310	Coding	4	439	ttcatccactgtaccacca	76	45	1
272311	Coding	4	468	ttgactatTTTCATCAACAG	47	46	1
272312	Coding	4	480	gggtggatctgggtgacta	57	47	1
272313	Coding	4	564	attgctgggtgcttcccatc	77	48	1
272314	Coding	4	652	tagggTCCATCATTTCAT	56	49	1
272315	Coding	4	684	caatgagtacactggaactg	53	50	1
272316	Coding	4	752	aactcgccataatttccaga	64	51	1
272317	Coding	4	857	agcccaaatattccaaagat	65	52	1
272318	Coding	4	913	tcagcattTTTAATCCTTGC	55	53	1
272319	Coding	4	979	atTTTCCTTCCTTGAGGAGA	67	54	1
272320	Coding	4	1000	agattgtgttcacctcctct	70	55	1
272321	Coding	4	1053	aaccCaagagTcatcactgt	64	56	1
272322	Coding	4	1084	ctggctcatcaatatctagc	84	57	1
272323	Coding	4	1110	tgtgtctgattcctcagtct	67	58	1
272324	Coding	4	1236	tatgtcattggcattgaaat	53	59	1
272325	Coding	4	1302	aaggcataagagatctgctt	66	60	1
272326	Coding	4	1420	actcagctccttCAGTAGGA	77	61	1
272327	Coding	4	1560	ggacatccctgccttattct	60	62	1
272328	Coding	4	1623	ggcattgtccataaggaagt	85	63	1
272329	Coding	4	1651	actTTTTGGCATCTGCCTCA	63	64	1
272330	Coding	4	1656	gatgcactTTTTGGCATCTG	47	65	1
272331	Coding	4	1861	cagtcgattgagatgagg	67	66	1
272332	Coding	4	1884	ctctttgtcaggcaagggca	75	67	1
272333	Coding	4	1913	gtgctcacatagccacatga	72	68	1
272334	Stop Codon	4	1949	aagaaaggctaaggcatgat	61	69	1
272335	3'UTR	4	1973	aaatacgtagctcttgggaa	47	70	1
272336	3'UTR	4	2196	caatcactgctactaaacag	69	71	1
272337	3'UTR	4	2249	aaacatagccattcaatgct	39	72	1
272338	3'UTR	4	2337	gtgctatggtttgcaattcaa	78	73	1
272339	3'UTR	4	2454	gttttacatatccaaactat	72	74	1
272340	3'UTR	4	2853	catcaaccaagatttgggtga	69	75	1
272341	3'UTR	4	2988	gaggctatagatcttatctc	65	76	1
272342	3'UTR	4	3271	tagtgagaaagaaagtTTC	45	77	1
272343	3'UTR	4	3765	aatgctctcaagaatgatgt	48	78	1
272344	3'UTR	4	3980	acactcaattctagcttttc	60	79	1
272345	3'UTR	4	4011	catctattacaataacatg	24	80	1
272346	3'UTR	4	4057	ctcttgagagaaaccatagc	67	81	1
272347	3'UTR	4	4097	tctacactgatgatacttta	62	82	1
272348	3'UTR	4	4120	cacagctttgaattgaatta	57	83	1
272349	3'UTR	4	4133	agtcttccaaacacacagct	68	84	1
272350	3'UTR	4	4156	aggctgttgtgaaatagtaa	67	85	1

272351	3'UTR	4	4170	atagaaatggtgtcaggctg	57	86	1
272352	3'UTR	4	4218	ccaaaatgacattctgagac	77	87	1
272353	3'UTR	4	4245	ataatggcttatgtggccac	72	88	1
272354	intron	18	2571	agttatgtgaccctgattga	65	89	1
272355	intron: exon junction	18	6418	ttgagtgttcctaaaatgaa	24	90	1
272356	intron	18	8405	atggaggctggagggtcaaa	63	91	1
272357	intron: exon junction	18	22712	taggggccatctttcaagac	62	92	1
272358	intron	18	25543	tctccagatagaatctaaac	53	93	1
272359	intron	18	29755	tccaaatattctggtacttt	72	94	1
272360	exon: intron junction	18	29935	tattagttaccttgaggaga	0	95	1
272361	intron: exon junction	18	30267	atcttccttcttagaaaata	10	96	1

As shown in Table 1, SEQ ID NOs 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93 and 94 demonstrated at least 45% inhibition of human growth hormone receptor expression in this assay and are therefore preferred. More preferred are SEQ ID NOs 30, 44 and 57.

ISIS 272322 (SEQ ID NO: 57) is targeted to exon 10, a region which appears in all growth hormone receptor transcripts. Compounds targeted to exon 10 are therefore preferred embodiments of the invention. Exon 3, reported to be alternatively spliced in the human transcript(s), may also be a preferred target region.

The target regions to which the preferred antisense sequences of Table 2 are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 3. The

sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 3 is the species in which each of the preferred target segments was found.

Example 16

10 **Antisense inhibition of mouse growth hormone receptor expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.**

In accordance with the present invention, a second series of antisense compounds were designed to target different regions of the mouse growth hormone receptor RNA, using published sequences (GenBank accession number NM_010284.1, incorporated herein as SEQ ID NO: 11, a variant of GenBank accession number AF120480.2 with an alternative splice site from exon 1B:exon 2, incorporated herein as SEQ ID NO: 97, a variant of GenBank accession number AF120480.2 with an alternative splice site at from exon 1C:exon 2, incorporated herein as SEQ ID NO: 98, a variant of GenBank accession number AF120480.2 with an alternative splice site from exon 1D:exon 2, incorporated herein as SEQ ID NO: 99, and a sequence derived from GenBank accession numbers AF120480.2 and AC073753.1, representing a genomic sequence, incorporated herein as SEQ ID NO: 100). The compounds are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the compound binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and

3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse growth hormone receptor mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which b.END cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 2

Inhibition of mouse growth hormone receptor mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
227443	5'UTR	11	5	tgcttggcagctcgtgggtt	0	101	1
227444	5'UTR	11	16	atggctgcgctgcttggca	53	102	1
227445	Start Codon	11	221	tacctgagacctcggagttt	69	103	1
227446	Start Codon	11	232	acaagatccatacctgaga	87	104	1
227447	Coding	11	300	gctggtgtagcctcacttcc	77	105	1
227448	Coding	11	313	tttgccaagagtagctggtg	60	106	1
227449	Coding	11	391	acgacacttggatcgag	69	107	1
227450	Coding	11	495	tggctttcccttttagcata	71	108	1
227451	Coding	11	520	atgagcaattcttgcagctt	49	109	1
227454	Coding	11	590	agttgaagtaacagctgttt	69	110	1
227455	Coding	11	620	agtagggtatccaaatggag	43	111	1
227456	Coding	11	717	gtccagttgaggccaatggg	97	112	1
227457	Coding	11	812	gaattatccatcccttcaga	67	113	1
227458	Coding	11	832	gtactgaatttcatactcca	75	114	1
227459	Coding	11	975	ctgaactcgctgtacttttc	60	115	1
227460	Coding	11	1041	aactggatatcttcttcaca	43	116	1
227461	Coding	11	1084	tgctactccaaatattccaa	75	117	1
227462	Coding	11	1115	gctttgaaaataactaca	31	118	1
227463	Coding	11	1137	atcagcatcttaatcctttg	39	119	1

227465	Coding	11	1190	tgagaagatctggatcaatc	51	120	1
227466	Coding	11	1245	ttgtagttatcatgaatgcc	50	121	1
227467	Coding	11	1265	catcattgtagaagtcgggt	33	122	1
227470	Coding	11	1388	ctccaaggataccagctgat	82	123	1
227471	Coding	11	1530	aggcacaagagatcagcttc	52	124	1
227472	Coding	11	1579	agagccaaggaagcatcat	42	125	1
227473	Coding	11	1710	aagtcaatgtttgccagtga	71	126	1
227474	Coding	11	1730	tgtcgcttacttgggcataa	68	127	1
227476	Coding	11	1837	gtaattttcttggcagggcg	41	128	1
227477	Coding	11	1850	cactgttcatgctgtaattt	61	129	1
227478	Coding	11	1878	tttttggcatctgactcaca	68	130	1
227479	Coding	11	1947	atgtcctcttgggttaaagct	59	131	1
227485	Coding	11	2044	cgtggtgtagtctgggacag	45	132	1
227486	Coding	11	2054	cggtgtgaaccgtggtgtag	39	133	1
227487	Coding	11	2106	tcaggcaaaggcaaagcagt	44	134	1
227491	Stop Codon	11	2182	taggaaaggctactgcatga	65	135	1
227492	3'UTR	11	2239	taaaacatagtttggttta	7	136	1
227493	3'UTR	11	2253	tccaacacagatttaaac	51	137	1
227494	3'UTR	11	2517	caaaagccacctgattgttt	56	138	1
227495	3'UTR	11	2527	tcctgaactgcaaaagccac	47	139	1
227496	3'UTR	11	2537	gcattcaatttcctgaactg	51	140	1
227497	3'UTR	11	2637	taaagtgtttgcatatccaa	77	141	1
227498	3'UTR	11	2824	ttgtaaaaatctaacttggt	49	142	1
227503	exon: exon junction	97	197	tacctgagaccccagttcat	24	143	1
227504	exon: exon junction	98	23	tacctgagaccccgcgcagc	34	144	1
227505	exon: exon junction	99	61	tacctgagaccacaaagcgg	39	145	1
227506	exon: intron junction	100	4352	cctccagtacctcggagttt	69	146	1
227507	intron: exon junction	100	4865	gtccttgcctccaggtagca	89	147	1
227508	exon: intron junction	100	5071	ttccactcaccacagttcat	51	148	1
227509	intron: exon junction	100	5153	gcagttctatcagaacttg	82	149	1
227510	intron	100	5196	ctccagacgtgacccgactc	64	150	1
227511	exon: intron junction	100	5264	ccacgcaccacaaagcggat	71	151	1
227512	intron	100	6350	taacctatggtgactatgtc	36	152	1
227513	intron: exon junction	100	7123	tacctgagacctgcaagaca	40	153	1
227514	intron	100	9753	atgetcacgtcagctattgg	43	154	1
227515	exon: intron junction	100	13932	aaattcttacttgtccccag	37	155	1
227516	intron:	100	17200	ttggctttccctggaggttc	57	156	1

	exon junction						
227517	exon: intron junction	100	17224	cttcactaaccttgagctt	63	157	1
227518	exon: intron junction	100	24259	cacggcttacctatttcgtc	6	158	1
227519	exon: intron junction	100	37843	tcacacctacctttgctgct	44	159	1
227520	intron: exon junction	100	40862	catcttaatccttggaaca	42	160	1

As shown in Table 2, SEQ ID NOs 102, 103, 104, 105, 106,
 5 107, 108, 110, 112, 113, 114, 115, 117, 120, 121, 123, 124,
 126, 127, 129, 130, 131, 135, 137, 138, 140, 141, 146, 147,
 148, 149, 150, 151, 156 and 157 demonstrated at least 50%
 inhibition of mouse growth hormone receptor expression in
 this experiment and are therefore preferred. More preferred
 10 are SEQ ID NOs 104, 147, and 149.

ISIS 227446, 227507 and 227509 (SEQ ID NO: 104, 147 and
 149) were subjected to dose-response studies. All three
 compounds showed good dose responses with IC50s of
 approximately 25 nM, 12.5 nM and 12.5 nM, respectively.

15 The target regions to which the preferred antisense
 sequences of Table 2 are complementary are herein referred to
 as "preferred target segments" and are therefore preferred
 for targeting by compounds of the present invention. These
 preferred target segments are shown in Table 3. The
 20 sequences represent the reverse complement of the preferred
 antisense compounds shown in Table 2. "Target site"
 indicates the first (5'-most) nucleotide number on the
 particular target nucleic acid to which the oligonucleotide
 binds. Also shown in Table 3 is the species in which each of
 25 the preferred target segments was found.

Table 3
Sequence and position of preferred target segments identified
in growth hormone receptor.

5

SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
144070	4	332	gaatggaaagaatgccctga	19	<i>H. sapiens</i>	161
144071	4	337	gaaagaatgccctgattatg	20	<i>H. sapiens</i>	162
144082	4	947	ccagttccaaagattaaagg	21	<i>H. sapiens</i>	163
144086	4	1079	attgagctagatattgatga	22	<i>H. sapiens</i>	164
144087	4	1124	gacacagacagacttctaag	23	<i>H. sapiens</i>	165
144093	4	1514	agcgacattacaccagcagg	24	<i>H. sapiens</i>	166
144098	4	1724	aaccaagaggacatttacat	25	<i>H. sapiens</i>	167
144099	4	1729	agaggacatttacatcacca	26	<i>H. sapiens</i>	168
144100	4	1734	acatttacatcaccacagaa	27	<i>H. sapiens</i>	169
144101	4	1739	tacatcaccacagaaagcct	28	<i>H. sapiens</i>	170
144102	4	1744	caccacagaaagccttacca	29	<i>H. sapiens</i>	171
144106	4	1922	tatgtgagcacagaccaact	30	<i>H. sapiens</i>	172
144107	4	1927	gagcacagaccaactgaaca	31	<i>H. sapiens</i>	173
144108	4	1936	ccaactgaacaaaatcatgc	32	<i>H. sapiens</i>	174
144118	4	4043	tctgctactttgctgctatg	34	<i>H. sapiens</i>	175
144119	4	4183	tttctatagccaaaaatagc	35	<i>H. sapiens</i>	176
144120	4	4197	aatagctaaatacctcaatc	36	<i>H. sapiens</i>	177
188518	4	31	aggtcctacaggtatggatc	37	<i>H. sapiens</i>	178
188519	4	36	ctacaggtatggatctctgg	38	<i>H. sapiens</i>	179
188520	4	115	cacagcagctatccttagca	39	<i>H. sapiens</i>	180
188521	4	160	taatccaggcctaaagacaa	40	<i>H. sapiens</i>	181
188523	4	185	tctaaggagcctaaattcac	42	<i>H. sapiens</i>	182
188524	4	274	gaacctaggaccatacagc	43	<i>H. sapiens</i>	183
188525	4	362	gctggggaaaacagctgtta	44	<i>H. sapiens</i>	184
188526	4	439	tggtggtacagtgatgaaa	45	<i>H. sapiens</i>	185
188527	4	468	ctgttgatgaaatagtgcaa	46	<i>H. sapiens</i>	186
188528	4	480	tagtgcaaccagatccacc	47	<i>H. sapiens</i>	187
188529	4	564	gatgggaagcaccagcaat	48	<i>H. sapiens</i>	188
188530	4	652	atggaaaatgatggacccta	49	<i>H. sapiens</i>	189
188531	4	684	cagttccagtgtactcattg	50	<i>H. sapiens</i>	190
188532	4	752	tctggaaattatggcgagtt	51	<i>H. sapiens</i>	191
188533	4	857	atctttggaatatttgggct	52	<i>H. sapiens</i>	192
188534	4	913	gcaaaggattaaaatgctga	53	<i>H. sapiens</i>	193
188535	4	979	tctcctcaaggaaggaaaat	54	<i>H. sapiens</i>	194
188536	4	1000	agaggaggtgaacacaatct	55	<i>H. sapiens</i>	195
188537	4	1053	acagtgatgactcttggggt	56	<i>H. sapiens</i>	196
188538	4	1084	gctagatattgatgagccag	57	<i>H. sapiens</i>	197
188539	4	1110	agactgaggaatcagacaca	58	<i>H. sapiens</i>	198
188540	4	1236	atctcaatgccaatgacata	59	<i>H. sapiens</i>	199
188541	4	1302	aagcagatctcttatgcctt	60	<i>H. sapiens</i>	200
188542	4	1420	tcctactgaaggagctgagt	61	<i>H. sapiens</i>	201
188543	4	1560	agaataaggcagggatgtcc	62	<i>H. sapiens</i>	202
188544	4	1623	acttccttatggacaatgcc	63	<i>H. sapiens</i>	203
188545	4	1651	tgaggcagatgccccaaagt	64	<i>H. sapiens</i>	204

188546	4	1656	cagatgccaaaaagtgcac	65	<i>H. sapiens</i>	205
188547	4	1861	cctcactactcaatgcgactg	66	<i>H. sapiens</i>	206
188548	4	1884	tgcccttgccctgacaaagag	67	<i>H. sapiens</i>	207
188549	4	1913	tcatgtggctatgtgagcac	68	<i>H. sapiens</i>	208
188550	4	1949	atcatgccttagcctttctt	69	<i>H. sapiens</i>	209
188551	4	1973	ttcccaagagctacgtattt	70	<i>H. sapiens</i>	210
188552	4	2196	ctgtttagtagcagtgattg	71	<i>H. sapiens</i>	211
188554	4	2337	ttgaatgcaaaccatagcac	73	<i>H. sapiens</i>	212
188555	4	2454	atagtttggatattgtaaac	74	<i>H. sapiens</i>	213
188556	4	2853	tcaccaaactcttggttgatg	75	<i>H. sapiens</i>	214
188557	4	2988	gagataagatctatagcctc	76	<i>H. sapiens</i>	215
188558	4	3271	agaaactttctttctcacta	77	<i>H. sapiens</i>	216
188559	4	3765	acatcattcttgagagcatt	78	<i>H. sapiens</i>	217
188560	4	3980	gaaaagctagaattgagtg	79	<i>H. sapiens</i>	218
188562	4	4057	gctatggttttctccaagag	81	<i>H. sapiens</i>	219
188563	4	4097	taaagtatcatcagtgtaga	82	<i>H. sapiens</i>	220
188564	4	4120	taattcaattcaaagctgtg	83	<i>H. sapiens</i>	221
188565	4	4133	agctgtgtgtttggaagact	84	<i>H. sapiens</i>	222
188566	4	4156	ttactatttcacaacagcct	85	<i>H. sapiens</i>	223
188567	4	4170	cagcctgacaacatttctat	86	<i>H. sapiens</i>	224
188568	4	4218	gtctcagaatgtcattttgg	87	<i>H. sapiens</i>	225
188569	4	4245	gtggccacataagccattat	88	<i>H. sapiens</i>	226
188570	18	2571	tcaatcagggtcacataact	89	<i>H. sapiens</i>	227
188572	18	8405	tttgaacctccagcctccat	91	<i>H. sapiens</i>	228
188573	18	22712	gtcttgaaagatggacccta	92	<i>H. sapiens</i>	229
188574	18	25543	gttttagattctatctggaga	93	<i>H. sapiens</i>	230
188575	18	29755	aaagtaccagaatatttggga	94	<i>H. sapiens</i>	231
144062	11	16	tgccaagcaggcgcagccat	102	<i>M. musculus</i>	232
144063	11	221	aaactccgaggtctcaggta	103	<i>M. musculus</i>	233
144064	11	232	tctcaggtatggatctttgt	104	<i>M. musculus</i>	234
144065	11	300	ggaagtggagctacaccagc	105	<i>M. musculus</i>	235
144066	11	313	caccagctactcttggcaaa	106	<i>M. musculus</i>	236
144067	11	391	ctcgattcaccaagtgtcgt	107	<i>M. musculus</i>	237
144068	11	495	tatgctaaaagggaaagcca	108	<i>M. musculus</i>	238
144072	11	590	aaacagctgttacttcaact	110	<i>M. musculus</i>	239
144074	11	717	cccattggcctcaactggac	112	<i>M. musculus</i>	240
144075	11	812	tctgaagggatggataattc	113	<i>M. musculus</i>	241
144076	11	832	tgagatgaaattcagtac	114	<i>M. musculus</i>	242
144077	11	975	gaaaagtacagcgagttcag	115	<i>M. musculus</i>	243
144079	11	1084	ttggaatatttggagtagca	117	<i>M. musculus</i>	244
144083	11	1190	gattgatccagatcttctca	120	<i>M. musculus</i>	245
144084	11	1245	ggcattcatgataactaaa	121	<i>M. musculus</i>	246
144088	11	1388	atcagctggtatccttggag	123	<i>M. musculus</i>	247
144089	11	1530	gaagetgatctcttgtgcct	124	<i>M. musculus</i>	248
144091	11	1710	tcactggcaaacattgactt	126	<i>M. musculus</i>	249
144092	11	1730	ttatgcccagtaagegcaca	127	<i>M. musculus</i>	250
144095	11	1850	aaattacagcatgaacagtg	129	<i>M. musculus</i>	251
144096	11	1878	tgtgagtcagatgccccaaa	130	<i>M. musculus</i>	252
144097	11	1947	agctttaaccaagaggacat	131	<i>M. musculus</i>	253
144109	11	2182	tcatgcagtagcctttccta	135	<i>M. musculus</i>	254
144111	11	2253	gttttaaatctgtgtggga	137	<i>M. musculus</i>	255
144112	11	2517	aaacaatcaggtggcctttg	138	<i>M. musculus</i>	256
144114	11	2537	cagttcaggaaattgaatgc	140	<i>M. musculus</i>	257
144115	11	2637	ttgatattgcaaacattta	141	<i>M. musculus</i>	258
144124	100	4352	aaactccgaggtactggagg	146	<i>M. musculus</i>	259
144125	100	4865	tgctaacctggagcaaggac	147	<i>M. musculus</i>	260
144126	100	5071	atgaactggggtgagtgaa	148	<i>M. musculus</i>	261

144127	100	5153	caaagttctgatagaactgc	149	<i>M. musculus</i>	262
144128	100	5196	gagtcgggtcacgtctggag	150	<i>M. musculus</i>	263
144129	100	5264	atccgcttgtgggtgcgtgg	151	<i>M. musculus</i>	264
144134	100	17200	gaacctccagggaaagccaa	156	<i>M. musculus</i>	265
144135	100	17224	aagctgcaaggtagtgaag	157	<i>M. musculus</i>	266

As these "preferred target segments" have been found by
 5 experimentation to be open to, and accessible for,
 hybridization with the antisense compounds of the present
 invention, one of skill in the art will recognize or be able
 to ascertain, using no more than routine experimentation,
 further embodiments of the invention that encompass other
 10 compounds that specifically hybridize to these preferred
 target segments and consequently inhibit the expression of
 growth hormone receptor.

According to the present invention, antisense compounds
 include antisense oligomeric compounds, antisense
 15 oligonucleotides, ribozymes, external guide sequence (EGS)
 oligonucleotides, alternate splicers, primers, probes, and
 other short oligomeric compounds which hybridize to at least
 a portion of the target nucleic acid.

20

Example 17**Western blot analysis of growth hormone receptor protein levels**

Western blot analysis (immunoblot analysis) is carried
 25 out using standard methods. Cells are harvested 16-20 h
 after oligonucleotide treatment, washed once with PBS,
 suspended in Laemmli buffer (100 ul/well), boiled for 5
 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for
 1.5 hours at 150 V, and transferred to membrane for western
 30 blotting. Appropriate primary antibody directed to growth

hormone receptor is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

5

Example 18**Reduction of serum IGF-I in animals after treatment with antisense to growth hormone receptor- 1 week pilot study**

10 Forty male Balb/C(a) mice weighing 9 to 10g were placed into cages, 4 animals per cage, and allowed to assimilate into their environment with new littermates ~1 week prior (Day -7) to the commencement of 1 week study. Mice of this age would be at their maximum growth rate. Their body
15 weights were measured and recorded every second day during this period. When mice weighed 11g (day -2), a blood sample was collected under anesthesia as described below, and a serum IGF-I assay was performed to determine pre-treatment values and to aid in the assigning of mice to treatment
20 groups in order to reduce animal variability. To obtain the blood sample, the animals were anaesthetized with pentobarbital (50mg/kg i.p.) and non-fasting blood samples collected exactly 5 minutes later from the retrobulbar plexus through heparinized capillary tubes under light ether
25 anesthesia. The 40 animals were placed into five groups with each group having a similar weight average and similar IGF-I average concentration for the trial.

30 Animals (n=8/group) were designated to the following five treatment groups:

Control - saline (once every 2 days)

ASO (Antisense to growth hormone receptor)- ISIS 227446 (SEQ ID NO: 104) (3 and 30mg/kg once every 2 days)

Mismatch (negative control oligonucleotide)- ISIS 261303
(SEQ ID NO: 267, 8-base mismatch to ISIS 227446) (30mg/kg
once every 2 days)

Octreotide - (25µg/kg/twice per day)

5

Saline, antisense, mismatch control and octreotide
samples were prepared, and coded for blinding. Animals were
given a subcutaneous dose of saline every second day, and
mismatch control or antisense with administration on days 0,
10 2, 4, 6. Animals were given twice daily doses of 25µg
octreotide. Animals were housed 4 per cage, for the duration
of one week. They had access to a pre-determined quantity of
standard mouse food and water at all times throughout the
experiment. They were housed in a quiet, temperature- and
15 humidity-maintained environment for the entirety of the
study. At day 0 and before treatment on each day or second
day, the animals had their body weight and food intake
measured, enabling the correct dose of agent to be
administered. The animals were monitored closely for any
20 changes in fur, skin, eye, locomotion or other changes in
behavior. No problems were observed. Every second day from
day -7 to day 7 body weight and food intake were measured.

On day 7, one day after the last dose of antisense,
and/or after the last octreotide dose, the animals were
25 anaesthetized with pentobarbital (50mg/kg i.p.) and non-
fasting blood samples collected exactly 5 minutes later from
the retrobulbar plexus through heparinized capillary tubes
under light ether anesthesia (as on day -7 and 0).

At day -2 and day 7, serum IGF-I measurement was done by
30 radioimmunoassay. The results are shown in Table 4. Serum
IGF-I level is the most widely used measure of growth hormone
biological activity in human therapy. It is used to measure
the efficacy of growth hormone antagonist treatments like

Trovert, which block cells' responsiveness to excess growth hormone, and dopamine agonists and octreotide somatostatin antagonist drugs that block growth hormone secretion from the pituitary.

5

Table 4

Effect of antisense inhibitor of growth hormone receptor on serum insulin-like growth factor-I levels

	IGF-I (ng/ml) Day -2	IGF-I (ng/ml) Day 7	% IGF-I reduction*
Saline Control	217.09 + 42.61	102.64 + 31.64	0
Octreotide	199.72 + 44.47	114.34 + 41.36	-
ASO 3mg/kg	216.23 + 78.14	129.63 + 33.76	-
ASO 30 mg/kg	181.84 + 71.32	56.95 + 10.34	44.51
Mismatch 30mg/kg	184.87 + 55.6	81.1 + 19.16	20.98

*Percent reduction in serum IGF-I at day 7 compared to saline control at day 7.

10

As shown in Table 4, the growth hormone receptor antisense compound, ISIS 227446 (SEQ ID NO: 104, dosed subcutaneously at 30mg/kg every second day for one week, produced a statistically significant and specific reduction of serum IGF-I to 55% of the control (saline) group. By t-test the antisense 30 mg/kg was significantly different from the saline control ($p < 0.005$) and the mismatch control ($p < 0.01$). The mismatch control was not statistically different from the saline control ($p > 0.05$). There was no effect at 3mg/kg. The 45% reduction in serum IGF-I levels in our study using 30mg/kg antisense every second day is comparable to that achieved using 10mg/kg daily Trovert (Van Neck et al., *J. Endocrinol.*, 2000, 167, 295-303).

25

The negative control 8-nucleotide mismatch oligonucleotide ISIS 261303 (SEQ ID NO: 267), reduced serum IGF-I by 21% compared to the control saline group, however,

this reduction was not statistically significant (with $p > 0.05$). Octreotide, 2 doses per day at 25 μ g each had no effect on serum IGF-I levels at day 7. The non-effect obtained with octreotide is consistent with data reported by Groenbaek et al. (J. Endocrinol., 2002, 172, 637-643) using this dose and twice this dose at day 7 in diabetic animals. In diabetic animals two 50 μ g doses of octreotide per day for two weeks are required to reduce sIGF-I levels.

Thus an antisense inhibitor of growth hormone receptor has now been demonstrated to specifically reduce serum insulin-like growth factor-I levels by 45% compared to control. Reduction of serum insulin-like growth factor-I by similar levels using octreotide or Trovert, are clinically relevant in the treatment of diseases including acromegaly, gigantism, age-related macular degeneration, diabetic retinopathy, diabetic nephropathy, diabetes, and growth hormone and IGF-I-dependent tumors as outlined *supra*. Thus antisense therapy is believed to be therapeutically useful for treatment of conditions associated with the growth hormone/insulin-like growth factor-I axis.

The serum remaining following the insulin-like growth factor-1 assay was isolated and stored at -80°C. The whole liver was removed rapidly for weighing and snap-frozen in labelled aluminum parcels by submersion in liquid-nitrogen. Kidney and spleen were also snap frozen in liquid nitrogen and stored at -80°C in the freezer. The carcass was weighed and then placed into a sealable plastic bag, snap-frozen on dry ice and kept at -80°C.

The decline in serum insulin-like growth factor-I with 30mg/kg of antisense was not sufficient to influence body weight or organ weights over this period. This confirms published results of others. Van Neck et al., J Endocrinol.,

2000, 167, 295-303. Looking at the study overall, body length increase during the study was in the range 7.5 - 10 %. Tail length increases were in proportion to overall length increases. Food intake did not vary significantly between treatment groups. Growth (body length and weight) were unaffected by any treatment. Weight was measured in two ways: weight trend (live animal), and final carcass weight. Absolute liver weights were unchanged except for a slight increase in liver weight (g/total body weight) for the octreotide group. Weights of other organs were unaffected. These observations were similar to those reported by van Neck et al. with Trovert except that liver weight was unaffected by Trovert, as also observed with growth hormone receptor antisense.

Growth hormone receptor mRNA levels in tissue samples from our current study are assayed from liver and kidney to test for an RNase H-based antisense mechanism of action. Growth hormone receptor protein levels by Western or binding assays in tissue samples from our current study are assayed from liver and/or kidney to test for additional and/or alternative antisense mechanisms of action. Liver contributes to 75% of serum insulin-like growth factor-I levels as shown in growth hormone receptor knockout animals of Sjogren et al., *Proc. Natl. Acad. Sci. USA*, 1999, 96, 7088-7092. Sample analysis of the liver and kidney insulin-like growth factor-I by Western and Northern blot total RNA analysis or quantitative PCR is also done as would be understood by those skilled in the art.

30 Example 19

Reduction of growth hormone receptor activity in animals after treatment with antisense to growth hormone receptor

Specific binding assays were carried out with liver tissue using iodinated human growth hormone [¹²⁵I] hGH.

Microsomal membrane preparations were obtained as follows. 400 mg of tissue powder was homogenized in cold
5 homogenizing buffer (50mM Tris /HCl, 250mM sucrose, pH 7.4). This was centrifuged at 2000 rpm for 10 min at 3°C and the supernatant was saved. This was centrifuged again at 15,000 rpm for 20 min. Pellets were resuspended in 0.5 ml of RRA buffer with inhibitor (50mM Tris, 20mM MgCl₂, pH 7.4).
10 Microsomal preparation samples were stored at -80°C until the specific binding assay.

The [¹²⁵I] hGH specific binding assay was done as follows. Four glass tubes were set up for each sample, two for (-), two for (+). Different sample and solutions were added in
15 each tube as follows (i) 0.2ml RRA buffer (50mM Tris, 20mM MgCl₂, 0.1%BSA, pH 7.4); (ii) 0.1ml membrane (1/2 or 1/4 dilution); (iii) 0.1ml hGH (10 µg /ml) for the(+) tube or 0.1ml RRA buffer for the(-) tube; and (iv) 0.1ml [¹²⁵I]-hGH tracer.

20 Samples were incubated at 4°C with shaking overnight. The reaction was stopped with 2.5ml of cold RRA, and the sample centrifuged at 2800 rpm for 25 min at 4°C. Supernatant was aspirated and pellets counted using the γ-counter. The specific binding capacity was calculated as : CPM(-) - CPM(+).
25 Protein content of the microsomal samples was determined by the BCA protein assay.

Table 5

Effect of antisense inhibitor on growth hormone receptor
growth hormone binding activity

	Specific binding/mg protein (cpm) $\frac{1}{2}$ dilution	Specific binding/mg protein (cpm) $\frac{1}{4}$ dilution
Saline Control	5647 \pm 746	9071 \pm 2371
ASO 30 mg/kg	4205 \pm 534 (26% reduction compared to saline)	5546 \pm 789 (39% reduction compared to saline)
Mismatch 30mg/kg	7090 \pm 1877	8431 \pm 2663

5 As shown in Table 5, the growth hormone receptor
antisense compound, ISIS 227446 (SEQ ID NO: 104, dosed
subcutaneously at 30mg/kg every second day for one week,
produced a statistically significant ($p < 0.05$) and specific
reduction of growth hormone receptor levels (measured by
10 growth hormone binding activity) to 61% of control (saline)
group. The negative control 8-nucleotide mismatch
oligonucleotide ISIS 261303 (SEQ ID NO: 267) had no effect
compared to the control saline group. The antisense
inhibitor of growth hormone receptor produced a statistically
15 significant ($p < 0.01$) and specific reduction of growth hormone
receptor levels to 59% of the control (mismatch) group in the
 $\frac{1}{2}$ dilution experiment.

The specific reduction of growth hormone receptor levels
was significantly (by t-test) different from both the saline
20 control and the mismatch control at both dilutions ($p < 0.05$).

These growth hormone receptor level measurements
following antisense treatment are consistent with the 45%
reduction in serum insulin-like growth factor-I levels in our
study using 30mg/kg antisense every second day relative to
25 control (saline).

Example 20**5 Reduction of growth hormone receptor mRNA levels and serum IGF-I in animals after treatment with antisense to growth hormone receptor- additional 1 week study**

Male Balb/C(a) mice were prepared and grouped for analysis as in Example 18 above.

10 Animals (n=10/group) were designated to the following treatment groups:

Control - saline (once every 2 days)

ASO (Antisense to growth hormone receptor)- ISIS 227446 (SEQ ID NO: 104) (30 and 50mg/kg once every 2 days)

15 Unrelated negative control oligonucleotide- ISIS 260120 (TTACCGTATGGTTCCTCACT; SEQ ID NO: 268, (50mg/kg once every 2 days)

Animals were treated and serum IGF-I levels were
20 measured as in Example 18 above. Briefly, for the one-week study, mice were given a subcutaneous dose of saline every second day, and mismatch control or antisense with administration on days 0, 2, 4, 6. On day 7, the animals were anaesthetized with pentobarbital and non-fasting blood
25 samples collected exactly 5 minutes later from the retrobulbar plexus through heparinized capillary tubes under light ether anesthesia. Serum IGF-I measurement was done by radioimmunoassay at day 7.

In the one-week study, the growth hormone receptor
30 antisense inhibitor ISIS 227446 reduced serum IGF-I by 33% at the 50 mg/kg dose, relative to saline control ($p < 0.001$), and by 20% relative to the unrelated control ($p < 0.068$). The

unrelated control at the 50 mg/kg dose reduced serum IGF-I by 17% compared to saline ($p > 0.05$).

Growth hormone receptor mRNA levels in liver tissue samples from treated and untreated mice in this one-week study were assayed. The growth hormone receptor antisense inhibitor ISIS 227446 reduced growth hormone receptor mRNA levels in liver after the one-week study by 72% at the 50 mg/kg dose, relative to saline control ($p < 0.0001$). The 30 mg/kg dose of ISIS 227446 yielded a 50% decrease in growth hormone receptor mRNA ($p < 0.0001$). The unrelated control oligonucleotide ISIS 260120, at 50 mg/kg, reduced growth hormone receptor mRNA levels by approximately 15% ($p > 0.05$).

15 Example 21

Reduction of growth hormone receptor mRNA levels and serum IGF-I in animals after treatment with antisense to growth hormone receptor- 2 week study

20 A two-week study was done in similar fashion to the one-week study in Example 18, this time using ISIS 227446 at doses of 3, 5, 10, 20 and 30 mg/kg. The mismatch control was given at the same doses. Mice were treated with antisense compound or saline every other day for 14 days.

25 Table 5 shows the serum IGF-I levels in mice treated for 14 days. P-values were determined by t-test.

Table 5
Two week mouse study- serum IGF-I levels after treatment with antisense inhibitor of growth hormone receptor

Dose of ISIS 227446 (mg/kg)	Day 14 serum IGF-I ng/ml	% decrease relative to 3 mg/kg ISIS 227446	p-value
30	126	41	0.0002
20	122	43	0.0002

10	130	39	0.0002
5	194	9	0.3261
3	214	0	-

The reduction in serum IGF-I at 14 days was dependent on dose with 39-43% decrease in levels achieved at >10mg/kg compared to 3 mg/kg. The 3 mg/kg dose of ISIS 227446 had no effect on serum IGF-I levels and was equivalent to saline (untreated) control (shown in separate experiment).

Mismatch controls gave lesser reductions in serum IGF-I levels. These results are shown in Table 6. The effect at 30 mg/kg observed with the mismatch oligonucleotide at 2 weeks was not observed with an unrelated negative control oligonucleotide (ISIS 260120; SEQ ID NO: 268).

Table 6

Two week mouse study- serum IGF-I levels after treatment with mismatch control ISIS 261303

Dose of ISIS 261303 (mg/kg)	Day 14 serum IGF-I ng/ml	% decrease relative to 3 mg/kg ISIS 261303	p-value
30	130	29	0.0094
20	164	11	0.2496
10	174	5	0.6160
5	186	0	0.9359
3	184	0	-

20

Growth hormone receptor mRNA levels in liver tissue samples from treated and untreated mice in this two-week study were assayed. The growth hormone receptor antisense inhibitor ISIS 227446 reduced growth hormone receptor mRNA levels in liver after the two-week study by 50% at the 20 mg/kg dose relative to saline control ($p < 0.001$). The 30

mg/kg dose of ISIS 227446 yielded a 53% decrease in growth hormone receptor mRNA ($p < 0.0001$). The mismatch control oligonucleotide ISIS 261303 (SEQ ID NO: 267), at 30 mg/kg, reduced growth hormone receptor mRNA levels by approximately 5 3%.

Example 22

Effect of antisense inhibition of growth hormone receptor on retinopathy

10 Retinopathy of prematurity is a neovascularization disorder that can lead to blindness in very low birth weight infants. The retinopathy (abnormal blood vessel formation) is initiated by relatively high oxygen levels such as are found in infant incubators, for example. A mouse model of
15 retinopathy (abnormal blood vessel formation in the retina) is used to study the effects of drugs on the extent of neovascularization.

Seven-day-old mice are placed in an infant incubator with their nursing mother in 75% oxygen from postnatal day 7
20 to day 12 to produce oxygen-induced retinopathy as described in the literature. Smith et al., 1994, *Invest Ophthalmol Vis Sci* 35,101-111; Robinson et al., *Proc Natl Acad Sci U S A.*, 1996, May 14;93, 4851-6. Oxygen concentration is measured at least daily while the animals are in oxygen. On postnatal day
25 12, the animals are returned to room air. Animals are sacrificed on postnatal day 17 when maximal neovascularization is observed.

Mice are dosed with antisense oligonucleotide at postnatal days 12, 13, 14, 15, and 16 or days 7, 8, 9, 11,
30 13, 15 and 17. Oligonucleotide is administered intraperitoneally at concentrations of 5, 10, 20 and 30 mg/kg. The mismatch control ISIS 261303 and/or the unrelated negative antisense control ISIS 260120 are also given.

Example 23**Additional models**

5 Studies using antisense inhibitors of growth hormone
receptor are also done in the following pathology animal
models and in humans as would be understood by those skilled
in the art: diabetic nephropathy type I and type II models,
cancer models, arthritis models and chemotherapy induced
10 diarrhea models.

What is claimed is:

5

1. A compound of from 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound specifically hybridizes with said nucleic acid molecule encoding growth hormone receptor
10 (SEQ ID NO: 4 or SEQ ID NO: 18) and inhibits the expression of growth hormone receptor.

2. A compound according to claim 1 which is from 12 to 50 nucleobases in length.

3. A compound according to claim 1 which is from 15
15 to 30 nucleobases in length.

4. A compound according to claim 1 comprising an oligonucleotide.

5. A compound according to claim 4 in which the oligonucleotide is an antisense oligonucleotide.

6. A compound according to claim 4 in which the
20 oligonucleotide is a DNA oligonucleotide.

7. A compound according to claim 4 in which the oligonucleotide is a RNA oligonucleotide.

8. A compound according to claim 4 in which the
25 oligonucleotide is a chimeric oligonucleotide.

9. A compound according to claim 7 which is a short interfering RNA (siRNA) molecule.

10. A compound according to claim 1 having at least 70% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18)
30

11. A compound according to claim 1 having at least 80% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

12. A compound according to claim 1 having at least 90% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

13. A compound according to claim 1 having at least
5 95% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

14. A compound according to claim 1 which comprises at least an 8-nucleobase portion of SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38,
10 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93 or 94.

15. A compound according to claim 14 in which the
15 oligonucleotide is selected from SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86,
20 87, 88, 89, 91, 92, 93 and 94.

16. A compound according to claim 15 in which the oligonucleotide is selected from SEQ ID NOs: 30, 44 and 57.

17. A compound according to claim 1 in which the compound specifically hybridises with a region, encoding
25 growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18), which region, segment or site comprises a translation initiation codon, a termination codon, a coding region, a 5' untranslated region, a 3' untranslated region, an intron:exon junction or an exon:intron junction.

18. A compound according to claim 17 in which the
30 region, segment or site of the nucleic acid molecule comprises at least an 8-nucleobase portion of a sequence selected from SEQ ID NOs: 161-232.

19. A compound according to claim 1 which inhibits the expression of growth hormone receptor by at least 45%.

20. A compound according to claim 1 having at least one modified internucleoside linkage, sugar moiety, or
5 nucleobase.

21. A compound according to claim 20 having at least one 2'-O-methoxyethyl sugar moiety.

22. A compound according to claim 20 having at least one phosphorothioate internucleoside linkage.

10 23. A compound according to claim 20 having at least one 5-methylcytosine.

24. A method of inhibiting the expression of growth hormone receptor in cells or tissues comprising contacting said cells or tissues with a compound according to claim 1.

15 25. A method of screening for a modulator of growth hormone receptor, the method comprising the steps of:

a) contacting a preferred target segment of a nucleic acid molecule encoding growth hormone receptor with one or more candidate modulators of growth hormone receptor, and

20 b) identifying one or more modulators of growth hormone receptor expression which modulate the expression of growth hormone receptor.

26. The method of claim 25 wherein the modulator of growth hormone receptor expression comprises an
25 oligonucleotide, an antisense oligonucleotide, a DNA oligonucleotide, an RNA oligonucleotide, an RNA oligonucleotide having at least a portion of said RNA oligonucleotide capable of hybridizing with RNA to form an oligonucleotide-RNA duplex, or a chimeric oligonucleotide.

30 27. The method of claim 25 further comprising "benchmarking" the candidate modulator of growth hormone receptor relative to a known inhibitor of growth hormone receptor signaling, activity or expression or the growth

hormone/insulin-like growth factor axis.

28. The method of claim 27 wherein the known inhibitor of growth hormone receptor signaling, activity or expression is a dopamine agonist, a somatostatin analog or growth hormone receptor antagonist.

29. The method of claim 28 wherein the known inhibitor of growth hormone receptor signaling, activity or expression is Trovert, octreotide, Sandostatin, bromocriptine mesylate or cabergoline or a compound of claim 1.

30. A diagnostic method for identifying a disease state comprising identifying the presence of growth hormone receptor in a sample using at least one of the primers comprising SEQ ID NOs 5 or 6, or the probe comprising SEQ ID NO 7.

31. A kit or assay device comprising the compound of claim 1.

32. A method of treating an animal having a disease or condition associated with growth hormone receptor signaling or the growth hormone/insulin-like growth factor axis comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide capable of modulating growth hormone receptor or insulin-like growth factor levels or expression.

33. A method according to claim 32 in which the oligonucleotide is a compound according to claim 1.

34. A method according to claim 32 in which the disease or condition is acromegaly, gigantism, cancer, diabetes, diabetic nephropathy, diabetic retinopathy, aberrant neovascularization, aberrant angiogenesis, macular degeneration, rheumatoid arthritis or shortened lifespan.

35. A method according to claim 32 in which the animal is a human.

36. A method of inhibiting the expression of insulin-

like growth factor-1 in cells or tissues comprising contacting said cells or tissues with a compound according to claim 1 so that expression of growth hormone receptor and insulin-like growth factor-1 are inhibited.

5 37. A method of screening for a modulator of growth hormone receptor signaling, the method comprising the steps of:

 a) contacting a preferred target segment of a nucleic acid molecule encoding growth hormone receptor with one or
10 more candidate modulators of growth hormone receptor, and

 b) identifying one or more modulators of growth hormone receptor expression which modulate growth hormone receptor signaling.

 38. The method of claim 37 wherein the modulator of
15 growth hormone receptor expression comprises an oligonucleotide, an antisense oligonucleotide, a DNA oligonucleotide, an RNA oligonucleotide, an RNA oligonucleotide having at least a portion of said RNA oligonucleotide capable of hybridizing with RNA to form an
20 oligonucleotide-RNA duplex, or a chimeric oligonucleotide.

 39. The method of claim 37 wherein the modulator of growth hormone receptor expression modulates insulin-like growth factor-1 expression.

 40. The method of claim 37 further comprising
25 "benchmarking" the candidate modulator of growth hormone receptor relative to a known inhibitor of growth hormone receptor signaling, activity or expression or the growth hormone/insulin-like growth factor axis.

 41. The method of claim 40 wherein the known inhibitor
30 of growth hormone receptor signaling, activity or expression is a dopamine agonist, a somatostatin analog or growth hormone receptor antagonist.

 42. The method of claim 41 wherein the known inhibitor

of growth hormone receptor signaling, activity or expression is Trovert, octreotide, Sandostatin, bromocriptine mesylate or cabergoline or a compound of claim 1.

43. Use of a compound targeted to a nucleic acid molecule encoding growth hormone receptor in the manufacture of a medicament for the treatment of a disease or condition associated with growth hormone receptor signaling.

44. The use according to claim 43 wherein the compound targeted to a nucleic acid molecule encoding growth hormone receptor is an antisense oligonucleotide targeted to a nucleic acid molecule encoding growth hormone.

45. The use according to claim 43 wherein the disease or condition is acromegaly, gigantism, cancer, diabetes, diabetic nephropathy, diabetic retinopathy, aberrant neovascularization, aberrant angiogenesis, macular degeneration, rheumatoid arthritis or shortened lifespan.

SEQUENCE LISTING

<110> George Tachas

Kenneth W. Dobie

Ravi Jain

Christopher Ian Belyea

Mark Andrew Heffernan

<120> MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN LIKE
GROWTH FACTOR EXPRESSION

<130> BIOL0002US

<150> 60/451,455

<151> 2003-02-28

<160> 268

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctccctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

gtgcgcgcgga gcccgaaatc 20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 3

atgcattctg cccccaagga 20

<210> 4

<211> 4414

<212> DNA

<213> H. sapiens

<220>

<220>

<221> CDS

<222> (44)...(1960)

<400> 4

ccgcgctctc tgatcagagg cgaagctcgg aggtcctaca ggt atg gat ctc tgg 55

Met Asp Leu Trp

1

cag ctg ctg ttg acc ttg gca ctg gca gga tca agt gat gct ttt tct 103

Gln Leu Leu Leu Thr Leu Ala Leu Ala Gly Ser Ser Asp Ala Phe Ser

5 10 15 20

gga agt gag gcc aca gca gct atc ctt agc aga gca ccc tgg agt ctg 151

Ala Asp Ile Gln Lys Gly Trp Met Val Leu Glu Tyr Glu Leu Gln Tyr
185 190 195

aaa gaa gta aat gaa act aaa tgg aaa atg atg gac cct ata ttg aca 679
Lys Glu Val Asn Glu Thr Lys Trp Lys Met Met Asp Pro Ile Leu Thr
200 205 210

aca tca gtt cca gtg tac tca ttg aaa gtg gat aag gaa tat gaa gtg 727
Thr Ser Val Pro Val Tyr Ser Leu Lys Val Asp Lys Glu Tyr Glu Val
215 220 225

cgt gtg aga tcc aaa caa cga aac tct gga aat tat ggc gag ttc agt 775
Arg Val Arg Ser Lys Gln Arg Asn Ser Gly Asn Tyr Gly Glu Phe Ser
230 235 240

gag gtg ctc tat gta aca ctt cct cag atg agc caa ttt aca tgt gaa 823
Glu Val Leu Tyr Val Thr Leu Pro Gln Met Ser Gln Phe Thr Cys Glu
245 250 255 260

gaa gat ttc tac ttt cca tgg ctc tta att att atc ttt gga ata ttt 871
Glu Asp Phe Tyr Phe Pro Trp Leu Leu Ile Ile Ile Phe Gly Ile Phe
265 270 275

ggg cta aca gtg atg cta ttt gta ttc tta ttt tct aaa cag caa agg 919
Gly Leu Thr Val Met Leu Phe Val Phe Leu Phe Ser Lys Gln Gln Arg
280 285 290

att aaa atg ctg att ctg ccc cca gtt cca gtt cca aag att aaa gga 967
Ile Lys Met Leu Ile Leu Pro Pro Val Pro Val Pro Lys Ile Lys Gly
295 300 305

atc gat cca gat ctc ctc aag gaa gga aaa tta gag gag gtg aac aca 1015
Ile Asp Pro Asp Leu Leu Lys Glu Gly Lys Leu Glu Glu Val Asn Thr
310 315 320

atc tta gcc att cat gat agc tat aaa ccc gaa ttc cac agt gat gac 1063
Ile Leu Ala Ile His Asp Ser Tyr Lys Pro Glu Phe His Ser Asp Asp
325 330 335 340

tct tgg gtt gaa ttt att gag cta gat att gat gag cca gat gaa aag 1111

Ser Trp Val Glu Phe Ile Glu Leu Asp Ile Asp Glu Pro Asp Glu Lys
 345 350 355
 act gag gaa tca gac aca gac aga ctt cta agc agt gac cat gag aaa 1159
 Thr Glu Glu Ser Asp Thr Asp Arg Leu Leu Ser Ser Asp His Glu Lys
 360 365 370
 tca cat agt aac cta ggg gtg aag gat ggc gac tct gga cgt acc agc 1207
 Ser His Ser Asn Leu Gly Val Lys Asp Gly Asp Ser Gly Arg Thr Ser
 375 380 385
 tgt tgt gaa cct gac att ctg gag act gat ttc aat gcc aat gac ata 1255
 Cys Cys Glu Pro Asp Ile Leu Glu Thr Asp Phe Asn Ala Asn Asp Ile
 390 395 400
 cat gag ggt acc tca gag gtt gct cag cca cag agg tta aaa ggg gaa 1303
 His Glu Gly Thr Ser Glu Val Ala Gln Pro Gln Arg Leu Lys Gly Glu
 405 410 415 420
 gca gat ctc tta tgc ctt gac cag aag aat caa aat aac tca cct tat 1351
 Ala Asp Leu Leu Cys Leu Asp Gln Lys Asn Gln Asn Asn Ser Pro Tyr
 425 430 435
 cat gat gct tgc cct gct act cag cag ccc agt gtt atc caa gca gag 1399
 His Asp Ala Cys Pro Ala Thr Gln Gln Pro Ser Val Ile Gln Ala Glu
 440 445 450
 aaa aac aaa cca caa cca ctt cct act gaa gga gct gag tca act cac 1447
 Lys Asn Lys Pro Gln Pro Leu Pro Thr Glu Gly Ala Glu Ser Thr His
 455 460 465
 caa gct gcc cat att cag cta agc aat cca agt tca ctg tca aac atc 1495
 Gln Ala Ala His Ile Gln Leu Ser Asn Pro Ser Ser Leu Ser Asn Ile
 470 475 480
 gac ttt tat gcc cag gtg agc gac att aca cca gca ggt agt gtg gtc 1543
 Asp Phe Tyr Ala Gln Val Ser Asp Ile Thr Pro Ala Gly Ser Val Val
 485 490 495 500
 ctt tcc ccg ggc caa aag aat aag gca ggg atg tcc caa tgt gac atg 1591

Leu Ser Pro Gly Gln Lys Asn Lys Ala Gly Met Ser Gln Cys Asp Met
 505 510 515
 cac ccg gaa atg gtc tca ctc tgc caa gaa aac ttc ctt atg gac aat 1639
 His Pro Glu Met Val Ser Leu Cys Gln Glu Asn Phe Leu Met Asp Asn
 520 525 530
 gcc tac ttc tgt gag gca gat gcc aaa aag tgc atc cct gtg gct cct 1687
 Ala Tyr Phe Cys Glu Ala Asp Ala Lys Lys Cys Ile Pro Val Ala Pro
 535 540 545
 cac atc aag gtt gaa tca cac ata cag cca agc tta aac caa gag gac 1735
 His Ile Lys Val Glu Ser His Ile Gln Pro Ser Leu Asn Gln Glu Asp
 550 555 560
 att tac atc acc aca gaa agc ctt acc act gct gct ggg agg cct ggg 1783
 Ile Tyr Ile Thr Thr Glu Ser Leu Thr Thr Ala Ala Gly Arg Pro Gly
 565 570 575 580
 aca gga gaa cat gtt cca ggt tct gag atg cct gtc cca gac tat acc 1831
 Thr Gly Glu His Val Pro Gly Ser Glu Met Pro Val Pro Asp Tyr Thr
 585 590 595
 tcc att cat ata gta cag tcc cca cag ggc ctc ata ctc aat gcg act 1879
 Ser Ile His Ile Val Gln Ser Pro Gln Gly Leu Ile Leu Asn Ala Thr
 600 605 610
 gcc ttg ccc ttg cct gac aaa gag ttt ctc tca tca tgt ggc tat gtg 1927
 Ala Leu Pro Leu Pro Asp Lys Glu Phe Leu Ser Ser Cys Gly Tyr Val
 615 620 625
 agc aca gac caa ctg aac aaa atc atg cct tag cctttctttg gtttccaag 1980
 Ser Thr Asp Gln Leu Asn Lys Ile Met Pro
 630 635
 agctacgtat ttaatagcaa agaattgact ggggcaataa cgtttaagcc aaaacaatgt 2040
 ttaaaccttt tttgggggag tgacaggatg gggatggat tctaaaatgc cttttcccaa 2100
 aatggtgaaa tatgatgtta aaaaaataag aagaatgctt aatcagatag atattcctat 2160

tgtgcaatgt aaatatttta aagaattgtg tcagactggt tagtagcagt gattgtctta 2220
atattgtggg tgtaattttt tgatactaag cattgaatgg ctatgttttt aatgtatagt 2280
aatcacgct ttttgaaaaa gcgaaaaaat caggtggcct ttgcggttca ggaaaattga 2340
atgcaaacca tagcacaggc taatTTTTTg ttgTTTctta aataagaaac tTTTTattt 2400
aaaaaactaa aaactagagg tgagaaattt aaactataag caagaaggca aaaatagttt 2460
ggatatgtaa aacatttact ttgacataaa gttgataaag atTTTTtaat aatttagact 2520
tcaagcatgg ctattttata ttacactaca cactgtgtac tgcagttggt atgaccctc 2580
taaggagtgt agcaactaca gtctaaagct ggtttaatgt tttggccaat gcacctaaag 2640
aaaaacaac tcgTTTTtta caagccctt ttatacctcc ccagactcct tcaacaattc 2700
taaaatgatt gtagtaatct gcattattgg aatataattg ttttatctga atTTTTaaac 2760
aagtatttgt taatttagaa aactttaaag cgtttgcaca gatcaactta ccaggcacca 2820
aaagaagtaa aagcaaaaaa gaaaacctt cttcaccaaa tcttggttga tgcaaaaaa 2880
aaatacatgc taagagaagt agaaatcata gctggttcac actgaccaag atacttaagt 2940
gctgcaattg cacgaggagt gagTTTTtta gtgcgtgcag atggtgagag ataagatcta 3000
tagcctctgc agcggaatct gttcacacc aacttggtt tgctacataa ttatccagga 3060
aggaataag gtacaagaag cattttgtaa gttgaagcaa atcgaatgaa attaactggg 3120
taatgaaaca aagagttcaa gaaataagtt tttgTTTcac agcctataac cagacacata 3180
ctcatttttc atgataatga acagaacata gacagaagaa acaaggTTTT cagtccccac 3240
agataactga aaattattta aaccgctaaa agaaactttc tttctcacta aatcttttat 3300
aggatttatt taaaatagca aaagaagaag tttcatcatt ttttacttcc tctctgagt 3360

gactggcctc aaagcaagca ttcagaagaa aaagaagcaa cctcagtaat ttagaaatca 3420
ttttgcaatc ccttaatatc ctaaacaatca ttcatttttg ttgtttgtgt tgtttgtgag 3480
acagagtctc gctctgtcgc caggctagag tgcgggtggcg cgatcttgac tcaactgcaat 3540
ctccacctcc cacaggttca ggcgattccc gtgcctcagc ctctgagta gctgggacta 3600
caggcacgca ccaccatgcc aggctaattt ttttgtattt tagcagagac ggggtttcac 3660
catgttggcc aggatggtct cgagtctcct gacctcgtga tccacccgac tgggctccc 3720
aaagtgctgg gattacaggt gtaagccacc gtgcccagcc ctaaacaatca ttcttgagag 3780
cattgggata tctcctgaaa aggtttatga aaaagaagaa tctcatctca gtgaagaata 3840
cttctcattt tttaaaaaag cttaaaactt tgaagttagc ttttaactta atagtatttc 3900
ccatttatcg cagacctttt ttaggaagca agcttaatgg ctgataattt taaattctct 3960
ctcttgacgg aaggactatg aaaagctaga attgagtgtt taaagttcaa catgttattt 4020
gtaatagatg tttgatagat tttctgctac tttgctgcta tggttttctc caagagctac 4080
ataatttagt ttcataataa gtatcatcag tgtagaacct aattcaattc aaagctgtgt 4140
gtttggaaga ctatcttact atttcacaac agcctgacaa catttctata gccaaaaata 4200
gctaaatacc tcaatcagtc tcagaatgtc attttggtagc tttggtggcc acataagcca 4260
ttattcacta gtagactag ttgtgtctgg cagtttatat ttaactctct ttatgtctgt 4320
ggattttttc cttcaaagtt taataaattt attttcttgg attcctgata atgtgcttct 4380
gttatcaaac accaacataa aatgatcta aacc 4414

<210> 5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

gatgtcccaa tgtgacatgc a

21

<210> 6

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6

aagtaggcat tgtccataag gaagtt

26

<210> 7

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7

ccggaaatgg tctcactctg ccaaga

26

<210> 8

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaaggtgaag gtcggagtc

19

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 9

gaagatggtg atgggatttc

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 10

caagcttccc gttctcagcc

20

<210> 11

<211> 4174

<212> DNA

<213> M. musculus

<220>

<221> unsure

<222> 2636

<223> unknown

<221> unsure

<222> 2666

<223> unknown

<221> unsure

<222> 2759

<223> unknown

<221> unsure

<222> 2789

<223> unknown

<221> unsure

<222> 3326

<223> unknown

<221> unsure

<222> 3352

<223> unknown

<221> unsure

<222> 3503

<223> unknown

<221> unsure

<222> 3666

<223> unknown

<221> unsure

<222> 3668

<223> unknown

<223>

<220>

<221> CDS

<222> (240)...(2192)

<400> 11

tgacaaccca cgagctgcca agcagggcgca gccatgggaa gaggaggcgg tctagggagc	60
ggcggcactg gcagaggcgg ctgctacagc ggcgggtggtg gcgacggctg ttactgaacc	120
ccggcagccg cggggatccc gggctgggtc cacgcggcct gaggcctcgg ctccagcagc	180
ccccaaagcgg acacgaaccc gcgttctgtc tcccgaggcg aaactccgag gtctcaggt	239
atg gat ctt tgt cag gtc ttc tta acc ttg gca ctg gca gtc acc agc	287
Met Asp Leu Cys Gln Val Phe Leu Thr Leu Ala Leu Ala Val Thr Ser	
1 5 10 15	
agc aca ttt tct gga agt gag gct aca cca gct act ctt ggc aaa gct	335
Ser Thr Phe Ser Gly Ser Glu Ala Thr Pro Ala Thr Leu Gly Lys Ala	
20 25 30	
tcc cca gtt ctg caa aga atc aat cca agc ctg ggg aca agt tct tct	383
Ser Pro Val Leu Gln Arg Ile Asn Pro Ser Leu Gly Thr Ser Ser Ser	
35 40 45	
gga aag cct cga ttc acc aag tgt cgt tcc cct gaa ctg gag aca ttt	431
Gly Lys Pro Arg Phe Thr Lys Cys Arg Ser Pro Glu Leu Glu Thr Phe	
50 55 60	
tca tgc tac tgg aca gaa gga gat aat cct gat tta aag acc cca gga	479
Ser Cys Tyr Trp Thr Glu Gly Asp Asn Pro Asp Leu Lys Thr Pro Gly	
65 70 75 80	
tct att cag ctg tac tat gct aaa agg gaa agc caa cga caa gct gca	527

Ser Ile Gln Leu Tyr Tyr Ala Lys Arg Glu Ser Gln Arg Gln Ala Ala
85 90 95

aga att gct cat gaa tgg acc cag gaa tgg aaa gaa tgc cct gat tat 575
Arg Ile Ala His Glu Trp Thr Gln Glu Trp Lys Glu Cys Pro Asp Tyr
100 105 110

gtc tct gct gga aaa aac agc tgt tac ttc aac tca tca tat acc tcc 623
Val Ser Ala Gly Lys Asn Ser Cys Tyr Phe Asn Ser Ser Tyr Thr Ser
115 120 125

att tgg ata ccc tac tgc atc aag cta act aca aat ggt gat ttg ctg 671
Ile Trp Ile Pro Tyr Cys Ile Lys Leu Thr Thr Asn Gly Asp Leu Leu
130 135 140

gac caa aaa tgt ttc act gtt gac gaa ata gtg caa cct gat cca ccc 719
Asp Gln Lys Cys Phe Thr Val Asp Glu Ile Val Gln Pro Asp Pro Pro
145 150 155 160

att ggc ctc aac tgg act tta cta aac att agt ttg acc ggg att cgt 767
Ile Gly Leu Asn Trp Thr Leu Leu Asn Ile Ser Leu Thr Gly Ile Arg
165 170 175

gga gac atc caa gtg agt tgg caa cca cca ccc aat gca gat gtt ctg 815
Gly Asp Ile Gln Val Ser Trp Gln Pro Pro Pro Asn Ala Asp Val Leu
180 185 190

aag gga tgg ata att ctg gag tat gaa att cag tac aaa gaa gta aat 863
Lys Gly Trp Ile Ile Leu Glu Tyr Glu Ile Gln Tyr Lys Glu Val Asn
195 200 205

gaa tca aaa tgg aaa gtg atg ggc cct ata tgg tta aca tac tgt cca 911
Glu Ser Lys Trp Lys Val Met Gly Pro Ile Trp Leu Thr Tyr Cys Pro
210 215 220

gtg tac tca ttg aga atg gat aaa gaa cat gaa gtg cgg gtg aga tcc 959
Val Tyr Ser Leu Arg Met Asp Lys Glu His Glu Val Arg Val Arg Ser
225 230 235 240

aga caa cgg agc ttt gaa aag tac agc gag ttc agc gaa gtc ctc cgt 1007

Arg Gln Arg Ser Phe Glu Lys Tyr Ser Glu Phe Ser Glu Val Leu Arg	
245	250 255
gta ata ttt cct cag acg aac ata ttg gaa gca tgt gaa gaa gat atc	1055
Val Ile Phe Pro Gln Thr Asn Ile Leu Glu Ala Cys Glu Glu Asp Ile	
260	265 270
cag ttt cca tgg ttc tta att att atc ttt gga ata ttt gga gta gca	1103
Gln Phe Pro Trp Phe Leu Ile Ile Ile Phe Gly Ile Phe Gly Val Ala	
275	280 285
gtg atg cta ttt gta gtt ata ttt tca aag cag caa agg att aag atg	1151
Val Met Leu Phe Val Val Ile Phe Ser Lys Gln Gln Arg Ile Lys Met	
290	295 300
ctg att tta ccc cca gtc cca gtt cca aag att aaa ggg att gat cca	1199
Leu Ile Leu Pro Pro Val Pro Val Pro Lys Ile Lys Gly Ile Asp Pro	
305	310 315 320
gat ctt ctc aag gga ggg aag ttg gag gag gtg aac acc atc tta ggc	1247
Asp Leu Leu Lys Gly Gly Lys Leu Glu Glu Val Asn Thr Ile Leu Gly	
325	330 335
att cat gat aac tac aaa ccc gac ttc tac aat gat gat tcc tgg gtc	1295
Ile His Asp Asn Tyr Lys Pro Asp Phe Tyr Asn Asp Asp Ser Trp Val	
340	345 350
gag ttc att gag cta gat att gat gaa gca gat gtg gat gag aag act	1343
Glu Phe Ile Glu Leu Asp Ile Asp Glu Ala Asp Val Asp Glu Lys Thr	
355	360 365
gaa ggg tct gac aca gac aga ctt cta agc aat gat cat gag aaa tca	1391
Glu Gly Ser Asp Thr Asp Arg Leu Leu Ser Asn Asp His Glu Lys Ser	
370	375 380
gct ggt atc ctt gga gca aag gat gat gat tct ggg cgt acc agc tgt	1439
Ala Gly Ile Leu Gly Ala Lys Asp Asp Asp Ser Gly Arg Thr Ser Cys	
385	390 395 400
tac gac cct gac att ttg gat act gat ttc cat acc agt gac atg tgt	1487

Tyr Asp Pro Asp Ile Leu Asp Thr Asp Phe His Thr Ser Asp Met Cys
 405 410 415
 gat ggt acc ttg aag ttt gct cag tca cag aag tta aat atg gaa gct 1535
 Asp Gly Thr Leu Lys Phe Ala Gln Ser Gln Lys Leu Asn Met Glu Ala
 420 425 430
 gat ctc ttg tgc ctt gat cag aag aat ctg aag aac ttg cct tat gat 1583
 Asp Leu Leu Cys Leu Asp Gln Lys Asn Leu Lys Asn Leu Pro Tyr Asp
 435 440 445
 gct tcc ctt ggc tct ctg cat ccc tcc att acc cag aca gta gaa gaa 1631
 Ala Ser Leu Gly Ser Leu His Pro Ser Ile Thr Gln Thr Val Glu Glu
 450 455 460
 aac aag cca cag cca ctt ttg agc agc gaa act gag gca acc cac caa 1679
 Asn Lys Pro Gln Pro Leu Leu Ser Ser Glu Thr Glu Ala Thr His Gln
 465 470 475 480
 ctc gcc tct aca ccg atg agt aat ccc aca tca ctg gca aac att gac 1727
 Leu Ala Ser Thr Pro Met Ser Asn Pro Thr Ser Leu Ala Asn Ile Asp
 485 490 495
 ttt tat gcc caa gta agc gac att aca cca gca ggt ggt gat gtc ctt 1775
 Phe Tyr Ala Gln Val Ser Asp Ile Thr Pro Ala Gly Gly Asp Val Leu
 500 505 510
 tcc cca ggc caa aag att aag gca ggg ata gcc caa ggc aat acc cag 1823
 Ser Pro Gly Gln Lys Ile Lys Ala Gly Ile Ala Gln Gly Asn Thr Gln
 515 520 525
 cgg gag gtg gcc acg ccc tgc caa gaa aat tac agc atg aac agt gcc 1871
 Arg Glu Val Ala Thr Pro Cys Gln Glu Asn Tyr Ser Met Asn Ser Ala
 530 535 540
 tac ttt tgt gag tca gat gcc aaa aaa tgc atc gct gtg gcc cgt cgc 1919
 Tyr Phe Cys Glu Ser Asp Ala Lys Lys Cys Ile Ala Val Ala Arg Arg
 545 550 555 560
 atg gaa gcc acg tct tgt ata aaa cca agc ttt aac caa gag gac att 1967

Met Glu Ala Thr Ser Cys Ile Lys Pro Ser Phe Asn Gln Glu Asp Ile
 565 570 575

tac atc acc aca gaa agc ctt acc act act gcc cag atg tct gag aca 2015
 Tyr Ile Thr Thr Glu Ser Leu Thr Thr Thr Ala Gln Met Ser Glu Thr
 580 585 590

gca gat att gct cca gat gct gag atg tct gtc cca gac tac acc acg 2063
 Ala Asp Ile Ala Pro Asp Ala Glu Met Ser Val Pro Asp Tyr Thr Thr
 595 600 605

gtt cac acc gtg cag tct cca agg ggc ctt ata ctc aac gca act gct 2111
 Val His Thr Val Gln Ser Pro Arg Gly Leu Ile Leu Asn Ala Thr Ala
 610 615 620

ttg cct ttg cct gac aaa aag aat ttt ccc tcc tcg tgt ggt tat gtg 2159
 Leu Pro Leu Pro Asp Lys Lys Asn Phe Pro Ser Ser Cys Gly Tyr Val
 625 630 635 640

agc aca gac caa ctg aac aaa atc atg cag tag cctttcctat ctttaaatgg 2212
 Ser Thr Asp Gln Leu Asn Lys Ile Met Gln
 645 650

caagggaaag gctgggcaca aacgcttaaa ccaaaaactat gttttaaatc tgtggtggga 2272

gagcatgaga gtggatatgg attctaaaat actttttctg gaaatgtcaa aatatcaata 2332

agtggaaaat caagaattcg taatcagata aatgctocca ttgtgaatta taaatatttt 2392

aatgaattgt cttaagact gtatagtggc agtgattgtc tgtactgtgg gtcttaattt 2452

tgtgatacta agcattaaat agctacgttt tttatgtatg tagatcatgc ttttgaaaa 2512

agcaaaacaa tcaggtggct tttgcagttc aggaaattga atgcagatta tagcacaggc 2572

tgattttttt tttctttttt aaataactgg gaactaaaac tctaggtgag aaggtaaaac 2632

tagnttggat atgcaaaaaca tttatatttga catnaaattg ataaagatat ttttaataat 2692

ttacacttta agcatgagkm ctttataata tgctacacac atattgtagt tcagaacaat 2752

ccatctnagg atgtagcagc tacagtgtaa agagggnttc atgttttggc caatgaacgt 2812
aaagaaaacc aaacaagtta gatttttaca aagccctttt ataacttcca aaacttotta 2872
actctaaaaa tgtctaataa cctgcattat tagaaaaaaa catttttaat ttgtaaacga 2932
atattttttt aattttgaaa actttatttt tttttaatgt tgaatcaacg tatcatacac 2992
caaacagtaa acagaaatta taataatgga agaagtgcct tcttcgacaa atttccattc 3052
aagccacaca gctacatgta agagaagtag aagtgatgtg gtgtgattgg ctaggatgca 3112
gaagagcttc aggaatacaa gaagtgagag cccaaggatt gggaggaggg ggctctcaca 3172
tctccacagt gcagtctgtc aaaccagct tggtttttat agtattctaa gaattattgt 3232
gtacaaggaa aagtctcaca tgtatgaaat ccagtatcca gatggggtaa agttagcaga 3292
taataggata ggaaattaa gacctagatc tagnactagt ggactttttt cacagacagn 3352
acacaaattt ttaattcagg gagaaggagc agaataaatg acttcccact cacaaagcac 3412
aactcagaag taattaaaca ggtaacagaa accttgccat caaacctttg ataagatgta 3472
ttttaagtag taagcagtat ttcaatgctt nttacttacc ctcccaggac aaccgatctc 3532
aaataaggga gataaggtag ataaaaatca ctttttgatt ctgtaataac ataaacatag 3592
ttctttgggt tagcaccccc ccaaaaaaaaa atttatggga gaaagaggac tctcagctga 3652
ctgaagaata catntnattt aaatattttt tagatgcctg aaacttttaa attaccttta 3712
agttttaatg gattaccatt ttgccaagac ctttgtgggg aaacaagctt aatgttttagt 3772
gattttgaaa tctctttcat gcaggagaga cagtgaaaat ctagccttgg gtgtttaagg 3832
ttcgccttgt tactttgtaa tagattttta taagtttttc tgctactttg ctgctatggc 3892
ttctccaatg gctacatgat ttagttcata tgaagtatca tcaacttaga atctattcag 3952

cttaaagatg tgtgttttga tgaactatct taccatttca ccataggctg accacgtttc 4012
tatagccaaa aatagctaaa tacctcaatc agttccagaa tgtcattttt tggtaactttg 4072
ctggccacac aagccgttat tcaccgttta actagttgtg ttctgcagtc tatatttaac 4132
tttctttatg tctgtggatt tttcccttca aagttcaata aa 4174

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 12

ttgacgaaat agtgcaacct gatc 24

<210> 13

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 13

cgaatcccgg tcaaactaat g 21

<210> 14

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 14

cattggcctc aactggactt tactaa

26

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 15

ggcaaattca acggcacagt

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 16

gggtctcgct cctggaagat

20

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 17

aaggccgaga atgggaagct tgtcatc

27

<210> 18

<211> 34099

<212> DNA

<213> H. sapiens

<400> 18

tgataaccag ctcagaacac acacatatta gttgttctcc ctttccttcc caccctcccc 60

attccctgac tgctagatcc agaagtcac ttcagatga actacctata tccaaatcct 120

aatctctagc tctggtttct taaacaggtc ctatgaaatg cttgaaataa aaggcaaaat 180

ggtttgtgtc tagaatcaaa ggctgacaat ggcaagcaac aggcactaaa actatgacct 240

aggaaaaatg cttttctgga agacatcggc attacctcct agacacggaa tacactggct 300

tcatcccagt agtttcttca cacactttag atacgtgtct cattaggatc acatatgact 360

cacctgattt catgccttgc cttttctttt tattctgcag attcttctaa ggagcctaaa 420

ttaccaagt gccgttcacc tgagcgagag actttttcat gccactggac agatgagggt 480

catcatggta caaagaacct aggaccata cagctgttct ataccagaag gtgccacat 540

catgcctttc tgattttctc ctccatggat gtacctacta aagtacactg agtcagatgt 600

actgtgggaa tggaagtgat ttgttgatg ttatgcaatc aatgaatatt cattcactca 660

tttattgaaa aaaatattaa tcaagcccat cctatgtgct gagtactatt ttaggcctg 720

gagatatagc agtgattaca aaagacaaaa tccttggctc catggagatt tcctccaat 780

gcagggagac aggcaataaa aattgaatta aatttcagct agtaatatag gttattaaga 840
aaaataaagc cagaaagcag catatcagca gtgtgtggga gtttgtgtat gtgcatgaga 900
atgtgtgaga gtgtgtcaaa gtgtgagtga gagcatgtat ggatacacgt gggcatgtgc 960
atgtggatga gagtgtgtgt aaaaggcttg aatgatgctg aaatgctggg tcctaggagg 1020
cctctctatt gtggtgtcct agaccagaga cataagtga acgggacagg ccacgtgagt 1080
atctggggga aaggctatgc aggcagagga aattgcaagt acaaagtccc tgaggcagtc 1140
ttggcatatt tgagggatga aaaaggccag cactgaaggc acaagattga aagtgaggag 1200
agtgatatgg gaagggatca gagagttact tagggactga ccatgccaaa cctcataggc 1260
aagggaagg ctttgaatth tactttatth gtggtggaaa gctataggth tttttgaaaa 1320
gatatatgct ttaaaagatg tagctttgth tctaaccaga taatacactc cttctcttaa 1380
atatattcag taaaagactg tagtacttht tcattthttac cagtgaccct ctaaaataac 1440
agaggaaggg tgaacaaaag acctctcaat ataggtacca tccaagttgt ttatthcttc 1500
cccttcacct ggcattatth tcattthttgt ttactctcac tgtgtatatt thtcccttht 1560
ttacatthta ggcttaaca cttcattatc tctgtthtth cacccaacct ccagagaagg 1620
cctaagcaa gatgcagggth tagtgaggac cthttatcct tggctcaagg thttcgthtag 1680
tcagaggatg acattgtcta tccaaccgaa gagctggaat agggaaggaa gatgcagcca 1740
gcagthaagg gtatgagctc agggctaaca aacctgcact tcagtgtagt tctgcactth 1800
ctcaccaagg aatactaggg aaattagcca gthtgtgtac aactcagcct cctcattthc 1860
agaaaggaga taatggactth gcctcatgac thcttgtgag gatcatatga gataacctat 1920
gaaaaatact tggcagagta cthgacacat aataagtact cactaaatgg thagctgthtag 1980

tcttcttatac ggtagtatag tgataatfff aaaataatta tgatatagaa atccagttcc 2040
tggactataa aatgactata aattgtataa gaccatttat accagtaaat tgttataatt 2100
attttaatta ttggtataag agcattttaa tgcagagctg ctgcttaatt tgcagataaa 2160
aaaatacttg gagttagcaa ccaagcagac cttccccacc tttcagtata agagaggtct 2220
cttggatgaa gtgaagtgaa gatgaaatgt ttgggcacca agtatactat atttttcctt 2280
aaggctgaca ccacagagag gttggggcca gtaaacagag ttgatttcta taaatacatt 2340
cagacatgaa gttagtatgt ttgatgacac ttttgaaatg tgtggaatca ttaagttatt 2400
tgtacaggca caattagcca aactgtaaag aaaagtagca gaataacctc ttaagctggg 2460
cccactttat gaaaataatt ttttgctacc tcaatattta ccaaatttga tgagcaaaaa 2520
gagaaatcca aaggaatgaa gccttgataa atatatatcc cttgccctca tcaatcaggg 2580
tcacataact ctgtccacag gcatcctatg cacactccag tcatttcagc atctctgggt 2640
caaatccagg atctacacta ccaaggatgc tgctgaaagt gtgactgggt aaagggaaac 2700
gttcagacat attcagaaag atgtcctaga ttttgccctg gtagtgtttg gaatcccagg 2760
agggtaagta cagcttcatg attaagtgcc aaccctaaact tacaaaatta gatatttgtg 2820
ttttttctat aaaatataac tattttgaat atcttagcca aactactatg agcccacagc 2880
ccagtttatac caagaaggat aaaactgagg gattaggagt atcaggactg gactggactg 2940
attagtgtac agttatattt gattttctcat tgcccacttc acagagaaga caatacaaat 3000
gcactttctg actccttatca ctgtttctta gaactcagtt gccaggcaac tcctgaaact 3060
atagaaacat gcttctcacc cctgacacat aaataaaaact ctgagatgat tttatccaaa 3120
gtcagagtca gtgggcagtg cagttgtttc agtttgctgg cctggcctca gtatctaaag 3180

cacaacagaa cgtgaacatg tcaggctgtc aacaggacag ttcaggcaca gccctacagg 3240
cagttgtgtg ttttgcttgg ctctgctcct tgccagggtg ctggcagaaa aggcagcctc 3300
cacatgttag agcagcagat tcaaaacagt gtctgccatc ctgtgatgac gatagtgcc 3360
aattcagcct ctgagcttgc aggggactca ggatgaatgc acattacagg catggtaaaa 3420
agaggctctg ggaagcatgt tcgagctgct ctgctctcag ctccttgcac gtaaagtctg 3480
tgtttttaaa ggaagtgggc atgtgaacac tcagtcctta aggctgtatc cccacctct 3540
tccataccca ttcaaccca cttcaaaaat taccctggtc ttaagagaaa tttcattttc 3600
tatacaaggt tgtgtggaaa atcagtaggg agaaaggca ttattacttt catttttctt 3660
taacaaaagt attaaattta aagccaaaaa cgtgcgcttt ctgtcatgaa aacagctgcc 3720
cttaaaaaca taaatgatgt tttattttta ttacttttat ctagttgggt gtcttttagat 3780
gaaaaacatt tcttctgctc tttattctta ttttaaatga tagtctcttt ctatggttct 3840
cacccttcc atttcacaag atagtctggg agcaaaccta aagcacttaa cttttgggag 3900
taagagcaga ggggagcttc catacattga ttttggtcat ctgtagagac attcaaccca 3960
gagaaggcaa gtgacacagt atctgtttta tgagctaatt tgggttcttg tctacattta 4020
atagtttaaa atataagtta taaatattta tttaaaatga aattcaacat tggttcatga 4080
agaaagaggt tggaagtagt gttttgaact agctgtttct gatccatcat gcttaaaata 4140
aatgctctgt ttgtcctgtg gagttcatgg atttgggata atctaaacag ggttttttta 4200
acagtcctca tggggaacaa ggtactgaca tgcactgttg agaaattctg tgaatcatga 4260
aagagcta atcttttagaaa tccagacctg ttaagcacta atctacatct ttggaatatc 4320
ttaatacttt gagttttcta acttttatac tgcacttat gctaagtaca tttgatatcc 4380

cttctattat gtgaaagcct cttttctgg gcaattttct tacaactact ctctttaatg 4440
cactcttact taatttgaaa gtaaatatca aattaagcat actatagttc aatgaaccac 4500
ccacctattc ctaatttttt taacatttct cttctgactc tacatacaca catacttaca 4560
cacacacaca caaacacacc ttatcttttc ttctgccttt tgcccattta ctttttgcac 4620
cagagatgaa tctctcattc aagcatatgc aacttttttt ttttttgaga tggagtcttg 4680
ctttggcacc caggctggag tgcagtggct cgatcttggc ttactgcaaa ctttgcctcc 4740
tgcgttcaag caattctcct gcctcagcct acctaccgaa tagctgggat tacagaagca 4800
tgccatcatg cccagctaat ttttgtatth ttagtacaga tggggtttta ccatgttagc 4860
caggctggtc tcaatctcct aacctatgat ccgctgcct cagcctccga aagtgcctgg 4920
attacaggca tgaaccaccg taccagcca gcatatgcaa cttttaagag tctcaaccaa 4980
agcagcaatt cactgtctca gaccctggag tctctgccat ttaaattcca atttccttcc 5040
aacagctgag gagcagctgt ctcaaggacc ctctgatact acacaagttt tctcctagtg 5100
ccaagcagac cagcctgaga aacagctata agaaggaaat aggcgtcttc tcccagcttg 5160
gcatcctttc cttccaggcc ctgccttccc tacaacctgc attgtcttca ttgtccactg 5220
ctgcccagca cccatcccac agagggatgg tcccaaacct ccacagtctg gcctgtgagc 5280
cacaggcgcc tctgcctgca cagggccatt cctacctcat cttccacaac cacagattac 5340
atggttttat gtccctttga cttatatatt gtcttctcaa ttaataggct agtgaataac 5400
atggagatga tgaactacct cacccaagta gcaattctaa ttaagaaaa ttttctgtc 5460
attccattgc cttttacttc cattaccaca ctcatgccca tacttcctta cctcaatccc 5520
tttgacctct ctgtttatth ccttcttgc cgtattgcca tctattaaac ttttaccat 5580

ccttcaagaa tgctaaaaac atacctccac cttgaagcct tccatgaaga gccagagcaa 5640
tcattccctc ttctgaactt ttaaggacc tagagagcac tactaatgag cacttaccca 5700
cattgctttg taatatgggt ttttactctt tccttctgag gcaggaggaa ttccttagac 5760
atctatgaat cccatagtgt ctgtcattat gttttagaca taaccaattc tcattaaatg 5820
tcaatagaat gaatataaga ggcccaaaaa actactcaga tgggaatttg agtcttattt 5880
tagcctgaaa ttaggggacc acatcttact tatctttata tctgcacagc gttgggtgctg 5940
gatataatgc atcactctgc ctggagcaca catcaacttg tctcctcagt ttctttcacc 6000
ataggctggt gaaacagcca ggtctaaacc ttcactgttc tctgggaatc tctagtttgg 6060
gggtgattct ctgtactggt ttaatgaaca tttttaaaat gtcctaagt ctcagaacct 6120
tcactatac aactggcata ataaagtacc taccatagga atcgatttat gagcaggcat 6180
agcatattca ttcaataaac ggaagtttta ccataggcag aagtaccaa cggcctcgta 6240
gcagtgtca gacactgatg atactgtcca ctgatgtgat atgtctcgga aatgatgtta 6300
ctaaaatacc tcttcacaaa atattgtct tccaatttat tgaatcagac tatcaagcac 6360
cttacttggga cttaagctac aacatgattt ttggaacaat taatcttttt ttaacccttc 6420
atthtaggaa cactcaagaa tggactcaag aatggaaaga atgccctgat tatgthtctg 6480
ctggggaaaa cagctgttac ttaattcat cgtttacctc catctggata ccttattgta 6540
tcaagctaac tagcaatggt ggtacagtgg atgaaaagtg tttctctggt gatgaaatag 6600
gtaaatacaca ggtttttggt tcatttgaca tagthtttaga ctaaataaat ggggaagcct 6660
gcaaggtcca agtataatca agtaggaaga cthtgtaaca gtgthtctata gatacatgga 6720
gatctgthtt acaggagatg ggatcagctg gtgaacaaga ggaaaagggc agggggaact 6780

taagttgact ttaacataaa gtagcctggc agtaaatggt gtgaagaaga gaataggaac 6840
cttgtggagt cttttccttt aggatatcctt tgaagctgcg ttgtgttttt atgttccact 6900
gcaaaggggtg aacttaatat attccttagga tttcttactt cctaattatt tgataggatc 6960
cttatattca aattcactga aatacgttgg cctttgacct ctaccattgc tgtaatcaaa 7020
gcctacattt tctttatcac aaagcataat cattctggaa ttttacattt acaaaacagc 7080
cacagttact ttaaagacat gtttattaga tctcagaaca aatactggag acaatcagct 7140
cagtgaacta agtgaaagat ccaaacagag gatcctttgc ccatcatatg gacacaaggt 7200
ggaaacaaaa caaataaaac aaacaattgt aattagaata gtcattgttta taccttaata 7260
gtataaatag caaaatagaa agaatcaaag aaggactttg agtagctgaa attagtgcct 7320
caaaatctat ccacaaaagc tcatttggtg cttataggaa tttctcgttg cttctcccaa 7380
atgtattggt ctttttatgt ggttttctag gcataagctg actggaagac ataggagtat 7440
gtggctagaa cttacagata gaaacaaata aaatctaata ggctgacttt aagggagaag 7500
attaagagaa ctgtatcaag cagtaaagat aacccaattg ctttgcaaag acaatttagt 7560
atgtgtccta acatcagtggt gtatagctgt tgagttgaaa ctaaattggga tagcagaatg 7620
ggatagtagc aagaacactg ggttaaaacc catgttctag cctgttctc tgccaatagc 7680
cagtcctact catttacctg gctgacatgc ctgtcatgtg tcacgcactg ttctgggtgg 7740
ggtggttata gaataagtac aatacagtca aagaggggaag tcaggcatgt tcacaaataa 7800
ttgcagtgca gcgtgatagg tgtagcctg gaaatacgtg gaatgcagag ctgcaaaggt 7860
ggtgccaaa ggcgtgaatg actgacaggc ctgagggatg aggaagggct gcacagagat 7920
ggtgacagtt tagttacctc tgaactggaa ttggactctc cctattttta aaaaagtgat 7980

gacccacagt ggtcaaaagc atgagtgagt attgtcaggt accacagtgg acttgccttt 8040
cagtaactac taagttccaa cagtaactta gtagttactt agtaattaca acagtaactt 8100
agtagtccca acatgttcag ggactcagga gcagttagga agccctocta gtcagctgga 8160
gaaatcatca gtagttgttt gtgccccaaa aaggaatttg gactttaact gtcacgaggt 8220
acctttgagg atgtttaaat agggaaatta cttgaggata ctaatagtta acagtcacaa 8280
aagtcttacc atgtgtcagg tataaaaacc atcttttgca atcacacttt acagataatg 8340
aaaccgaggc acagagcagt taaaggacta gttcaagtca aacagctagt agatagagct 8400
gggatttgaa cctccagcct ccatgctctt actcttgagg ctttgtagta ccacttgtct 8460
ctttattaat gtcagagaa attaatcttg ttgcaatgtg aaacgtagat tggagtggga 8520
cggactagag gtagaagagg ttaaaagact gagatgatca aggtaaaaga ttatgacagg 8580
tagctacaac tagcacaata gttgtggggc aaggtgctga gagtgaaaga gaacaaagaa 8640
ctaagtgaac cctggtagat cttgagaaag ttgtcaatca ttataagcct cagcttcctc 8700
ataaaatag tatgtatggt actacctcac agggctattc tttggatttg aagtactata 8760
ttagttagac atttgtcatt cattcaattc attcagcaaa tatttattat gctcttctct 8820
caggccagtc aatgttctcc atgctgggga tagaaactgt cttccctggt gggatttaat 8880
ccaacgagg atggaaagcg acaatgctat ggagaaatat aggaaaggag aataggagtg 8940
ttggagaggt tgcagtgttg agttttcagg attggcatcc ctgaggcagt ggcatttgaa 9000
taaagaagga ttggagagga taattatgtg tgtgtctcag ggaagggcat ttcagcaagg 9060
gggcacgcca gaagaaagat ctcaaagtag gagcatgctt ttcctcactc aatgaacagc 9120
aggccggcgg tggagtgggc acagagtgag cgaggagact ggtatgagac caaatcgcac 9180

agacaagaca gtcaaactca cccaaccatt gccaaagact ttggctttca cttggagtga 9240
ggtaggcagc ctttggaggg ttttagatga tgagcgatgt gatctaacgt aagtgttagg 9300
ataatcactg tgcagttcg cttgaggatt gcatggagaa tagactggag ggggacaaaag 9360
accaaagggg tacagtgggg agacaaatga agcaagaaga atgaaaaagg ataatggcca 9420
ggaccagggtt attagtggtg caggcgggtg gacatggttg gattctgtta tatcttgaaa 9480
gtacagctga cggaatgtgg attagtgagg aaaagatgag ccaaggacaa gttcattggtt 9540
tttatcctga gcaactagag gaattgagtc ctcgttaaca gagatggaaa agaggaaagg 9600
agagcagggtt ttggagagga agagcaaggg tttgtttggg gatataataa gtttcagata 9660
ttttttaaat atctcacagg agttgtcaat atagcatgta gatttatgta tagagataaa 9720
ggagagggtca ttattatgcc tgtaatggta tctcacagga ggtcattggtt atgcctgtaa 9780
tgggtgtacc aaatcttttc caaaaggacc ttgtctcata tcctctatctt ttcaaatgca 9840
gcataagtaa tgagttatag aaaatcttcc attaaaaaca attttatagt ttggtcactt 9900
taaacgggta agctttgatt atcaggattc ctgaatctcc acaaatcca gaagggtgag 9960
gaattattgc cattatatcg gcatatgtag tttggccatt ttgcatatcc ttccaattta 10020
atthttcaaaa tgtagtcatg attcatcaaa ttttgactct cctgtttttt aaaaaggtgg 10080
tgtcgacccc acagagggca acagcatgct cctccacat aaggcctggt ttcactgtgg 10140
gtgcacacaa gagcttcctt ctttggccaa cagatttgac agccagtaag agctcctcac 10200
tgtgtatata tgtaaagttta tctccagtca acgctagggg tgcacactct gcaacactct 10260
aggtggcctt ctgtatatat ggcagaaaaa gaaagtaa atttactctgt atctgcaagt 10320
gattttcaaa accctcagta atgagatcca actagcaaaa atttaccagg aactctctag 10380

aatataaatt tagacatagt tcctagcttt ggaatccata tttttcttca tcagcctctg 10440
agaaattgtg gtctttgagg tcctactaag cagaatgcaa caaatTTTCG tggaaactgta 10500
gagtatatca atagaacctg aggaaaacaa tgtttcaagt tgttcatgtg acagtcaaaa 10560
agacagaaaa cactgaattg tcaccatttg tgagactagc ataatgcttt cttccttctt 10620
atgtcagaag aaaatatcac atgtggctag gaagatcaca aagctagggg gcattagcag 10680
agtgtgcagg aagattgtat gagaagattg aagaagagta aaaaaggata atggctagga 10740
ccaggttata gtgggtgcagg cggtgagata tggttggatt ctggttatatc ttgaaagtac 10800
agctgacgga atctgacgga atatggatta gtgaggcaaa gatgagtctt tcaggggaaca 10860
acacagaaat gaggtaaaca gggctctctgc cccagggcca tacatagttg caagaaaaaa 10920
ggtttctcta cccctagttc cgaagcagcc ccatgtctaa attctgtaag tctttctgac 10980
tctctgtttt ttcagtttca agtgaaaata aattcctttg ccaaaatcct gatgcattta 11040
tgatatcaga gcaaaaagaa atatacaaca tggcagatct tgtaaatagt gatcagatgt 11100
tttactcaa aaggaatTTT tgtaagggct tatttagaag ttaaaaacaa gtcatccttg 11160
agttaaaaaa aaaagttact ctcttataaa gtgaaagtta taataagaaa aatattggaa 11220
gaaataagag catgaatgat caaaaatgta gaaagtaatt tggctctctg agaagaatgc 11280
cttcattaa tattaaattg tgtctgtctg tgtactaatg ctctgttgaa ttgcacagtg 11340
caaccagatc caccattgc cctcaactgg actttactga acgtcagttt aactgggatt 11400
catgcagata tccaagtgag atgggaagca ccacgcaatg cagatattca gaaaggatgg 11460
atggttctgg agtatgaact tcaatacaaa gaagtaaagta aaactaaatg gaaaatggta 11520
agatgttgct acaccttaca ctttgacttt tctttctatt tcaacaaact ctctctcatt 11580

tatcattaga ctttcctttg acctaatacc acatgttcat gctgtatgct ccataatttc 11640
ttaattgaga aaacattatt taaccggtaa aatattgtct tgaaattctg taagacagga 11700
gatgcttatg tatatatgga ggctgtgga aggaaaggaa aactatttct ccattcattc 11760
ttgctgtcca gtttaacttt agagcaaaat tatagactgg ccacttagct gtctttgggg 11820
atgtggataa aaatgggaaa gtttgtgatc cagtcaacag tgactatggc caaatatttt 11880
cccatgattt cagttgctgc tactcaaagg actcccacta aaacaaattc atacgtgtct 11940
ataggaaaac agagggaggg aatttgtctc ttagaggttt cagaaggatg ttttgttaca 12000
tacctcagag aagaatcaag ctgagattct tatgtaggca attagagagc atggtaccag 12060
ttgacctctg aatccctctc ttccttacca agcatatgga actcagcatt ttgataaatt 12120
tcacatggca cataacaaga ggaaaaacag gagtatcatg ctgctcccaa tataactaat 12180
tctaaatctg tctaaccaca gccacagcca cagccacagc caagccaagc agtttctggc 12240
cactcatcag gtgatgcccc gcagcctggc acagatcact cccagaattt tgagacacca 12300
ggacattcag tgagccactg aaaaagatgc caattttgtc attagaggaa agttaagttt 12360
ggaggaaatt tgagtagtta caatactggg ctttgaggct ctattttctg aatcatttta 12420
atthagatat ctgttctgta acttggta aataaaatgc ctgattggat gctaagtcaa 12480
acaagactgt ctaaatacaa gctacaatca aacattattt aacaacaggt actgaaataa 12540
ctactatgca gaaggcactg tgctaaatgc ctgaggtggc ggttctcaa gtgggagcca 12600
cagacccttg agggccctg agacccttc agggagtca gtactatttt cacaatacac 12660
taaaatatta ttttattaac tatgttgaat ttttaactta tggcacaaaa gcaatgctgg 12720
aaacactgct ggcaccttag catgaagcaa ggagtagga tcaaatttta ctaatagtca 12780

tgcactccca atgaagaagg aagaaaaagc cagtttcacg tttgaagttc ttgatgaagc 12840
tgtaaaaatt gttaatttta ctaaacctcg acctttgagt acatagctta ttaatattct 12900
gtgtgacata tgggaattac acattaagca tgtctgctgc gtactgaggt attgtatttg 12960
tcttgaagaa aagcgcttaa atgactgagt tgccagctga actagttgct tttattgctt 13020
ggagcaccat ttttacttgg aagagccatt gataaactgg cagatgggta ttcataattg 13080
aattggcaaa catttgcac aaaagaatga ggcaagcttg tcgcttcaag aaaaacaact 13140
gacagtattt tttgcaatgg aaaaaatttg acttttcaaa gcaattcatt ttgccttttt 13200
cgaaaatttg tgtctccaac cgtgagcttg atagtgtttt aatatttgaa gacttttctt 13260
gaagagattg atggtgatat taatgaaagt gactttttaa ttatattgtg taataaaatg 13320
tatgaacatt tagaaaaatc tacaactcag ttaaccaata ttttccaaat tactaataca 13380
tgatgtaatc aaatcatgca tggggaaatg atccattcaa agtactagat agaatcgtga 13440
atttttttaa tgatcaaaaa tttttttgta tatttattgt gtacaacata tttttttgaa 13500
atatggatac attgtagaat ggttctatca cactaagtaa catatgcatt accacacata 13560
cctttttttg tgtgttgaga aacttaaaa tctactcaga gattttcaaa atacaataca 13620
taagcattaa ctatagtcac cattttgcac aatagatttc ttaaactcat tctactaac 13680
tgaaaatttt aattctttca tcaatatctc cttaactctg caccctgccc acaaccctg 13740
ataaccacca ttcaactctc tgcttctgag ttcaactttt ttagattctg catataagtg 13800
agattatgtg gtatttgttt ttctgtctct ggatcatttt tcttaataata atacctcca 13860
ggttcatcca cattgtcaca agtgacagga tacccttctt tttttaaggc tgatagcatt 13920
ccattgtata tacctaccac attttcttta tccacttacc cattaatgga acataggtcg 13980

attctatttc ttggctgta taagtaatga acatgggagc ccagatattc tggctcaaca 14040
tactgatttc attttccttg gatataact tagtagtgga ataataaat ggatcacatg 14100
gtagttctat ttttaactct ttgaggaagc ttcataattat tttccataga gggataacta 14160
atttactc ccaccaatag tgtgcaaggg ttcccttttg tccacattct caccaact 14220
tgttatctct tcttttttg aaaatagcca tctaactc tttgtgcact ctatgccttc 14280
tgtgagctga tagctcattg tggtttaaat ttacatttcc ctgatgatta aagatgcaa 14340
gcatttttca tataoctgtt ggccatttct atatcttctt tttaaaaatt tatattcag 14400
tcctttgccc attttttaaat tgggttattt tcttgttatt gaattgtttt agttccttat 14460
atatttcaga tagtaacttc ttatcagatg tatgcaaata ttgtctcca ttccatagag 14520
tgtcttttta ctctgttgat tgtttccttg gcagtgcaga agcttttttag tttcatgtaa 14580
tcccgtttat ctattccac tttgttgcc tgttccaat ggagtcatat ccaaaaaatc 14640
attgccc aaa ccaatgtcat ggagcttttt cctatatttt cttccagtag ttgtacagtt 14700
tcaggtttta catttaagtc tttaatcgat tttgagttta tttttgtata tgaggtaaaa 14760
taagggtata atttcattct tctgcatatg gatgtccaat tttccaaca acatttaaag 14820
acagagtcct ttccttactg tgtattotta gcacctttgt gataaatcaa tttactgtaa 14880
atgtgtggat ttatttccga acactttatt cttttacatt ggtttatgtc atttttatgc 14940
cagtaccatg ctgttttgat gactatagct ttgtattatg ttttgaggtt ggtagagtga 15000
tgatttcac cttgttcttc ttgttcaaga ttgctttggc tattcatagt ctattgcagt 15060
tgcatacaaaa ttttagaatt gctttttcta tttctgtgaa aatgacatt ggaattttga 15120
taaggattgc attgaatctg tagattgctt taggtagcag ggacattcga acaatattaa 15180

ttcttctaataat ccatgaacat gggctatctg ttcatttatt tgtggtgtct tcatgtttta 15240
cagttttcag tgttcagatc tttcaccttt ttgtttaaat ttatttctag gtcttttatt 15300
ttatttttat ttttatagat attgtgaaag ggatttcttt atttctttct cagattgttc 15360
cttattagtg tatagaaatg ttactgattt ttgtatgttg actttgtatc ctgcagcttt 15420
actgaatttg tttatctggt ctagcaattt tttggtgaag tctttagggt tttctatata 15480
taaaatcatg tcatctgtaa gcaaggacaa ttttaactttt tccttctcaa ttttgatgc 15540
cttttatttc tctcttttgc ttaattgctc tgactaggat tttgaatcga gtagaataga 15600
gtagaggagt tacattgaat aaaaatggca agagtaggca tctttgtctt gttcctcatc 15660
ttagaagaaa agctttccac atttcactgt ttattatgat gtgagtttgt tatatatggc 15720
ctttattgtg ttgaaataca ttccttctat atctaattgt taagggtttt tatcatgaaa 15780
ggatattgaa ttttgacaag tgcttcttct gtatctgttg agatggttcc atggttttcg 15840
tctcggttct gttaaagtga tgtattatgt ttatgtattt gtgtgtgatg aaccatcctt 15900
gcatccctgg aataaatcct acttgatcat ggagaatggt ccttttagtg tgcttttgag 15960
ttagtttcct agtattttgt ttaagatttt tacatctgta tttatcagag atattagccc 16020
ataattttct tttctttag tgctccttca tggtttgggt ataagggtaa tgctagcatc 16080
aagaaatagt ttggtagat ccccttttct tccacttttt ggaaaagttt gagaaggatt 16140
ggtgttccgg tgaagcttcc agtgaaactg tcaggtcctg gacttctctt tgatgacaga 16200
ctttttatta ctgattcaat ctcttactt attattgggt tattagattt tctatttctt 16260
caagaaagtc ttagtagggt gttgtgtgta ggaatttatt catttctcat gcatataatt 16320
tttcagaatg gtctcttatg aacatttgta tttctatggt attggttgta atgtctcctc 16380

cttcatttct gattttggtt ttaatttggg ctttctcttt ttttattatt tagtctagct 16440
aaagattggt tgattttggt tatcttttca aaaaaacttg tttcattaat cttttctact 16500
gttttaatgt gctaactgaa aagcacatta aaaggatcat tctccatgat caagtaggat 16560
ttatcccagg gatgcaagga tggttcatca cacgcaaata cataaacata atacatcaca 16620
ttactagaac caaaaacaaa attatggaac catctcaata ttttctattc tctatttcat 16680
ttatttctgt tctgatcttt attatttctt tccttctatg aactttatgc ttagtttatt 16740
ctttttctgg tttcttcagg taaaatggtt ggttattcat ttgagatctt tgttttctga 16800
tggaggcatt tattgccatg aacttccatt gctcttagaa cgacttttac tgcattcctt 16860
aaggtttgc atgttggttc catttttgtc tcaagatatt tttgatttta ttttttactt 16920
tttaactatt tttttagggt cagagataca tgtgcacggt tgttatatag gtaaattgca 16980
tgtcacaggg gtttaccata cagattattt catcaccagg taataagcat agtaccaga 17040
aggtagtttt ttgatcttca ccttccttcc accctctacc ctccagtagg ccccagtatc 17100
tgtggtttca gtcttcgtgt ccatgtgttc tcaatgttta gctcctacta ataagtgaga 17160
atatgtggta tttgttttcc tgttcatgca ttagtgtgct tagcataatg gcctccagct 17220
ccatccatgt gactgcagag gacatgatct tgttcctttt tacgcctgag cagtattoca 17280
tgggtgtacat ataccacatt tcctttatcc agtgtacat tttctttatt ccatgtcttt 17340
gctattgtga atagtgctat gatgaacaca cgcatgcatg tgtctttatg gtaaaatggt 17400
ttatattcct tcaggtatat acccaataac gggactgctg ggtcaaata caattctctt 17460
ttaagttctt tgagaagttg ctaaactgct tgccacaatg gctgaactaa tttgaattat 17520
taccagcagg atataagtgt tcccttttct ttgcaacctc accagcatct gttatttttt 17580

gactttttga taatagcctt tctgactgct gtgatgtagt atctcattat ggttttgata 17640
tgcctttctc tctaattatt agtaatgttg agcatttttt cttacacttg ttggctcatg 17700
tttggtttct tttgaaaagt gtctgtttat gccttttgc cattttttta tgggactggt 17760
tgtttttggc ttgttgattt aaagtccctt atagattctg gatattagac atttgtcaga 17820
tgtatagttt gcaaatattt tcagccattc tgtagattat ctgttttttc agttgtttct 17880
tttgctgtgc agaagctcct tggtttaatt agatcccatt tgtcaatttt tgtttttgg 17940
gcaattgttt ttggcatcct tgatcatgaaa cctttgctaa ggcctatgtc cagaatggta 18000
tttcctaggt tttcttctag ggtttttata gtttgggggt ttgcatttaa acctttaatc 18060
catcttgagt tgatagtcgt acatgttgaa aggaaggggt ccagtttcaa tcttctgcat 18120
ataactagcc agttaccag caccatttat taaacagtgt tttcctcatt tcctgttttt 18180
gtcaactttg tcaaatatta gttggttgca ggtatgaggc tttattttgg ggttctctgt 18240
tctgttccat tgatctatgt gtcttctttt ttaaccagta ccatactgtt ttgattcctg 18300
tagccttgta gtataatttg aagtcaggta atgtgatgcc cctgggttta ttcttttttag 18360
ttaggattgc tttgactatt tgggctgttt tttgcttcca tatgaatttt acaattgttt 18420
tttctaaatc tgtgaaaaat tacattgata atttgatagg cattgcattg aatgtgtaga 18480
ttggcttggg cagtatggtc atcttaacga tattgattct tctaaccat aagcatggaa 18540
tgttttttcca tttgcgttat ctgtcatttt ctttcatcag tgttttatag ttctacttat 18600
aaagatattt cacctccttt gttaaagtga ttcctagggt tctgtgtgtg tgtgccccta 18660
taataggcta tgtaacctg ataacaattt aactttcttg cataaaaaac tctacattt 18720
tactccacat accgcccc caaacacatt ttaaattttt gatgtcacac ttacatcttt 18780

ttatattgca tatttcttaa caaattattg tacctagat tatttttaaat aattttatct 18840
ttaaaccctc attctaaaat aaaagtgatt tgcataattac catgaaaata ttagacaggt 18900
aatgtgatgc ccctggggtt attcatttta gttaggattg ctttgccaat tgggctgttt 18960
tttgcttcca tatgaatttt acaattgttt tttctaattc tctgaaaaat tacattgata 19020
atgtgatagg tattgcactg aatgtgtaga ttggcttggg cagtatggtc atcttaacaa 19080
tattgattct tctaaccat aagcatggaa tgtttttcca tttgcgttat ctgtcatttt 19140
ctttcatcag tgttttatag ttctacttat aaagatattt cacctccttt gttaaagtga 19200
ttcctagggt tctgtgtgtg tgtgtggcta taataggcta ttttaacctg ataacaattt 19260
aagtttcttg cataaaaaac tctacacttt tactccacat actccacaca cacacacgtt 19320
ttaaattttc gatgtcacac ttacatcttt ttatattgca tatttcttaa caaattattg 19380
tacctagat tatttttaaat aattttgtct ttaaaccctc attctaaaaa gtgatttgca 19440
tattaccctg aaaatattag actactttaa attggactgt gtacttactt ttactagtga 19500
gttttatact ttcatatggt tttatgttac tcattagcct ctttttcttt cagctaaaga 19560
cctcccttta gcagttcttg taagataggt ctgttggtga ggaatggta atttaaata 19620
aacaagtac aaaaagttca tcagtagagt ttcaggtttc atttttccac taacctgtaa 19680
gaatttatca tttgagtttt agtctattgt taaacagaaa tgttcacaat tatgtgaaaa 19740
gtttattaaa atattcctca ttttcctcat tatttatctg tgtgaggcca ggttttattc 19800
atttacgaaa atagcacatt ctaatagatt taattcagaa gcagttataa aaatacagtc 19860
atcttccttt aagtctgaca ttaaataaat ttgcaaaaat gtaaaacagt atcactcttc 19920
tcactctctt ttttggtgtt tgggaaagta caataatttt tatgaaaata tattatttaa 19980

caaaatcaat ttattatntt cagttaaaaa ataaggatntt taaaatnttntt tcattnttcaat 20040
ttctaataact gtaaatagtg ataggtataa cccaactaaa ccaaactcct taagattctc 20100
aaatnttntaa gagtgtaaag gagtccctgaa ataaaaaagt taaacaacct agaaaaaac 20160
aaagatataa atcagcatgt tagcattcat caattcagtt accatcattt catccctaaa 20220
agccatggca tatagttacg tctcactgag ccaccactntt gaaactccca ccctgtgcca 20280
ggtacttggtg agcatgtaac tttgttaatc aactgttcag ggctatatcc caacatggct 20340
ttgttgcaact tttcgtggca cctctgctaa atctcgttag gtagaccaa ggggtcagtt 20400
aactnttntct ttatacctntt tattcatgat atnttataagt ttggtaattt acaaaggtct 20460
tggacaaaga ccaggggctt atatataata atnttattntt ctcttgaaga aacaaacaat 20520
ataattgggtt atgaagcaca ggcgtcataa gcagaaaaca ggnttatagg taaaggggga 20580
agacctagtg tgtgtcgtt gcatcaggaa ttcattgttac catttgcaa tatgaatttg 20640
cttagcagtg tgctnttntt tctccccccc acaggatcct gctctgtccc caggctagag 20700
tacagtggcc caatctcggc tcaactgcaac ctccacctcc agagttcaag tgattctcgt 20760
gcctcagact cctgagttagc taggattaca ggcgcaagcc accacaccca gctaatacag 20820
ctaattnttg tattntttagt agagacaggg tttcatcatg ttggccagac tggctctgaa 20880
ctcctgacct caggtcatct gccaacctcg gcctcccaaa gtgctgggat tataggcatg 20940
agccactgtg cctggctgcc cttntttagta aatacattntt gcatgacct gtggttgntt 21000
acagctatntt atctagcaaa ccaataactt acagctnttntt aaaggcttaa tgaatagcat 21060
ggaattatntc atgatatctg tgccatatct tgaggaccca ctgtatacct gatattgcac 21120
tggactnttg aaatgaaaa taatgagtga tcttggggaa tttacaatgt aacatagaaa 21180

gggtgtgtatc actaaatttg cacaatgaaa cataattaat aatagaagaa gtatattatc 21240
tggcagaata gagtggggaa aagtaccagc aaagacttag aataccagct ctcctcaata 21300
cttgactta gacttggatg agaaacagtt ccccgcacag gcagatgaca gggttaggta 21360
tgataggagc cacgtaagta ggagccactc gaaatctgag tttgggtggtg ctgggtgtgga 21420
gggttgaggg aatatgaaga gaggaccaca acttgaatca ctgagggccc ttttttgatc 21480
ctattagtga aatctttaaa gaaattgtat tggtgacaat aacagagaaa taagggcttt 21540
gaggatgaaa acataggctt taaaaaaaaa cttagaaaaa aaataataaa gtaagttcag 21600
tattcagtgt cctgccttaa agaaagcatt ttaggcatgc aaatatccca tatattcaga 21660
ggcttctata aaaaatacaa acaaaccctg tcatatacac atgaggcaaa aaaagatact 21720
ttgtgagtag aaactattga ggtaaaagaa aaacttgttt tagaagctga aggcccagct 21780
gctgacttaa taaaacaaat tatgagaatt ttgtttatgc gaaaatccat gctgttgaaa 21840
acgcgagtg ttaaagtfff ctataaacag gaacaaggtg ttctaccaa aaaagtatg 21900
aaaagcacat tgaatacctg ctttgagtat ttgacttggg ggaaactacc atcactagtt 21960
gagtatacct ctttgatagc aatatgtggt aaaagtctaa cagtctcact ctaccctcc 22020
ccgagaaggt aaaggaatat cctgacctta agggttgtga gacctagatg tttcttacca 22080
aagaactccg gtgacttttc tttgcagatt taaatagca aactatftta tgggtggcttt 22140
aagccttcca gagcaagcag attaggtatg tagttccttt taataaaagt atttggaggt 22200
tcaataaagg caattatgat ttttctagga ctttttcaa ttctgtgatt atgtgaatga 22260
ctaccggaa tttccatcaa aactgatat acaacttget atggctacaa tttatfttg 22320
tgtgaaaaca tgtttgcttt tctgttotta tgtctccctt catacaaaag tataatatcc 22380

cagatatgta ggcatatagt tctgccattc agagtaattc taatatactt taatcttatt 22440
aactatctgg aagactaatg cacagttata gctgcatttc tttaagcaag tctatcatat 22500
ctttggggtt ataccaaact aaatttgtga actattatcc atttacaaaa tgattattta 22560
catcaatctt cctttaaata acaaatgctc acaatgcatt ttaaaatatt acctacttta 22620
taaaaatcca ttctgaataa aaatgggaga atacctgtag tgttcattgc attgagttgt 22680
tgactctttg gccaatatgc gtttatattt tgtcttgaaa gatggaccct atattgacaa 22740
catcagttcc agtgactca ttgaaagtgg ataaggaata tgaagtgcgt gtgagatcca 22800
aacaacgaaa ctctggaaat tatggcgagt tcagtgaggt gctctatgta acacttcctc 22860
agatgagcca atttacatgt gaagaaggta aaagaaataa aagattaaaa tagtagctaa 22920
cctggctttt gtcaatataa cagttgattc acccctgcac tggtagtgtg ttgtccaaat 22980
caaaatatat taacatcaga tatcaggatg agagaccttg agctcactat ctgtaacaga 23040
tattgttcat tgcaaaagca gaaggaagat ttagtttcca aatttttcat tcaggagaag 23100
tccggggggc agtggaagt ttagagacag gaatttgggtg gcaatctcca gatggtagaa 23160
ttcagatgat tcttttcttt atatattttt atatttctga aattttctat agtaagtttg 23220
ttttgaattt ataatcagga aaaaaagctg tactgatggg tagggaagaa agtatgtatc 23280
tatatggatg gatagatatg tggcatctaa gaggaaaccc aatattgagt cagcataggt 23340
agtcaacagc agatgcatac ggttttagaa agcggagggtg tggcttttac ctagaggaat 23400
gcctaataag tagtgtggca gtcatactta aaggagacgt ggaacatttg aaaaccctat 23460
gtaggagaat cacaacaatg attaaagttt ttaaaaatgg gacctatgaa tttagaataa 23520
aagaattaa acttttagat acagaaataa agaaaactga ttaataatga gcagaaagta 23580

tagagtatta ttattctcaa atgggaaatg gctctattcc atcttcattg aaaacagaag 23640
tttacagggc tatatgtttg ttaatgaaac aaccacaagc tacatagaaa ataaatttat 23700
atctctgtat ttactataca ggtagaatct catgatacta aatagcatta ggatgaaaat 23760
ttctatagca ccattttctc tatactctag ttaactgaat tcttgtttcc aaactatctg 23820
atattatgca attctggcct taaaagtaca atagctatac acccttaagc ttagtgtagt 23880
ggcatttaat tcacttaaca tatatatata tttttttttt tttttttttt tttttttttt 23940
tttttgagac ggagtctcgc tctgtcgcgc aggctggagt gcagtggcgg gatctcggct 24000
cactgcaagc tccgcctccc gggttcacgc cattctcctg cctcagcctc ccaagtagct 24060
gggactacag gcgcccgccca ctacgcccgg ctaatttttt gtatttttag tagagacggg 24120
gtttcacctg ttttagccagg atgggtctcga tctcctgacc tcgtgatccg cccgcctcgg 24180
cctcccaaag tgctgggatt acaggcaaca tatatttttt aaactgcctt ttccttctgt 24240
tactaacaaa aaagaagctc taactttatg ttattttcct gaatatgtca ttgatatgaa 24300
attatagaca ctacaagaca aaaaatgatt ttttctcccc caccaattct ttaaaatgct 24360
tataatatct ccctagggga ttttaataac tttttaaata agaaaagact atttcagcat 24420
aaagacctac attttaaatg gcaatgttaa ggtaaatttc atctgtcatt tttataaaaa 24480
agtgggttagc ctctgcctct gtggttaagaa tactgggtac caactgcaaa gtagctggca 24540
ggactcaat cttaaggaat gaaatagaag ttttacaac aggttcccc aagtctcata 24600
caaagtatac taaaacctga agatgggagc ctcagtagtg atctttctgt caattttatg 24660
tatataatat acatgagata tatttattat attttaataa ttttaattat tgatataaat 24720
acgtattttt atagctgtaa aatatatggt atttgtgtct aagaagtttc tgtcatgatt 24780

tatcaataaa aactctgcct tcatcttttt gataaatctt caatctggaa actaagaaaa 24840
tcaccacact taaaaaaaaa tagaaaagaa accgagtggg cattatntag gtagtgtggt 24900
aataagcaac acttttttac tgaagctgaa acctttatga tactccctgg acacatagta 24960
tgcttaaagc agattgtttg ttttcataaa acacacattg attttgaact atatgctggt 25020
tctttatfff gaagtfffft tttaatgtga ggagatttga aaagtggaca gagatgttca 25080
taaaacagaa aaaaactaag tcgttgcatt ctgtttcagt ggttatcaag agaaatcact 25140
gactttatta gatgaatata aattatgaat tttttgtgaa aagggaaagg gaaatgtaaa 25200
ctgtgcttca actattcgta attctgaaaa cgaaatattc ttgtgtgttt cagatttcta 25260
ctttccatgg ctcttaatta ttatctttgg aatatttggg ctaacagtga tgctatttgt 25320
attcttattt tctaaacagc aaaggtaggt gtggagtagt attctttggt attttgtacc 25380
agttgtttag atttccatat gtgtttctat ttgttatttg atattttctt tgtcaaatta 25440
tgagtggaaa ttttagtaa cctagtagac ttttatctcc agttatata taccattca 25500
tataaaactc aatttgttgt atttatctta gacaatttag aggttttagat totatctgga 25560
gacttgtaca ggacattaag aggcttaggc tggtgactat gcataccttg tgatatgtac 25620
ctctttatcc aagagctagc tctttccctc aagtcctcaa caagttgacc cattcattcc 25680
aggacttcaa agtatcactg agcctttggc tgagtctgat acagtcctta tatacagaca 25740
atfttttttt ttccttgaga cgggtgtotta ctctgttgcc caggctggag tgcaatggcg 25800
caatcttggc tcaactgcaac cgccgcccc caggttcaag caattctcct gcctcagcct 25860
ccagagtagc tgggattaca ggcattgccc accaagccca gctaattttg tattttttaga 25920
tacagtttca ccatgttggg cagactgggc tcgaactcct gacctcaggt gatctgcccc 25980

cctcagcctc ccaaagcgct gggattacag gcgtgagcta ccgcgcctgg cccatttaa 26040
ggatatttta aagtcccaat ggtaatcctt gttgcttctc ctagaattaa ggtgactaac 26100
actcccaggt tgcctagaac tctcctgggt tttagcaatg caagtccggt gtgccaggaa 26160
atccctcagt tccaggtaac caagacagtt gatcccccta cctagaattg aaaatacgtt 26220
ctccagctga agccaagagg catctataaa tcaaaatgag atctatgtta atatatttta 26280
aaagatttta ctttgttttg taaggtagta tagcacttgt aaacttcaaa acagaatttt 26340
gtaggaaga agaattattg ggacgctaga tttctatagt gtcaagcatg ctaaaagtct 26400
aactgaatgc agaaagggtt attttcagta gagcttcatg tccaatttta taatataaac 26460
caattggaaa gtaaaattca ttctgaattc cattttgcac ctaactttct ggcaacattc 26520
ctgttttcca aaaaagcagc tatcataaat cacaacacaa ttttctattg tttcaggaaa 26580
ataaataaat atatttttag aattttaatt tgtgtattta agtaatgcca acaacaaaaa 26640
agccaaatta ttctgttgat taatttcagt ttattaatct atatatttgg tgggaaaatt 26700
tatacataac ttcagtagat aaactcacga ggtatgtaaa gtaattagct cttagtatta 26760
gctgtgaatt tctagccatt gtgaaggcca agtcaatttg ttatgttgtt tagttatatt 26820
agttaacaat attaggaaga aaaaattatc ctctcaaaaa ataggatttc caagaaaaca 26880
tattacttct aatacagtc tttttataaa taatgaaatg cttaactata atgttttagtc 26940
aaaatcacca aattctacaa ttgatttgaa atctttattg ttctccaaa tttcctgcac 27000
taaattgaat tttctgtagg aaagaattaa ctttattttt atttgcccat taaaaacgct 27060
tatcattgtc taaatttgca tgttctactg aaagtgggaa atagtagcaa atatttgtca 27120
gcaagtatgg acagaacatg tagttccaac aattaaattg atactgcaaa gaacgagatt 27180

tttcctagaa ctgtagggct gtaaagtggc gtcaggtcct acatgccttt gaaatcttct 27240
gagtccacaa ttcattatcc aaccacttc accctgcttt aatccagtta attgagtcaa 27300
ctctagcaaa atttataatt ttatttgtat ctgatacaaa accacaaaca tagtttcaag 27360
tcaggctatt attatactgg ttcctaccac acaaccctcc cagcctttga gctgttacca 27420
attgaggaaa gaaataactg aatcagccta aaatagaatt tccaaaccag tagcgaaatt 27480
cagcctacag attcataatt tgttatttta ttttaattag ttttgatttc agagtgaaga 27540
ttttcctaca aagtgtttgt aaaatagaga attttcacac aaaaatccag atttgggat 27600
tatcttttaa aaaatgaaag atgtagtgaa actaaacaag gcagcatatg ctgcagcaga 27660
caaccagcta tcctatttgg gattggctca cattctttaa tttgccacca tcctcattcc 27720
tcctaatac tttgcaactg gcttgcttta ttctctgca tgacctgctt gggcctctta 27780
gatttatgct ctgccactgt ggcataaggt cactacaacc actagaaaac cactagcgca 27840
tgctgaatg catcatccta tttaaaaagg aaaagcacac gtcacaaagt caaacatcag 27900
ccatttgaa acctttgctt cctgtaatta gaattatgtt ccatcttttt atgtttttgg 27960
gaatttgaaa taccaatttc gagatgcaga atcaaaaaaa aaaaacaaaa cagcgaaaca 28020
gcagcatgac acaaagaacc tgggttttga tttggagtca ggttctctgg gtttgagccc 28080
caactgtgcc aactatgaat gcatgatttg aacatgttgc ttaattttcc aagtttttgc 28140
acagatatat catctgcctc cctgggagtc ataaggatta agtgaaatgt ttagtgcagg 28200
ggtcacaaac ttatttcata gagttagagt acatttttag gcttttcaag ccatacagtc 28260
tctatcacag ctactcaact ctgccactgt agcacgaaag tggccataaa caaatggaa 28320
atgaatgaag atgcttgtgt tctcataaaa ttttatctac acaaactgt gacaggccag 28380

atttggccca cagaccttaa tttagtgaac catagtttag tgcaaagtat atcccacagt 28440
gtctgattta tcagaagcac taaaaaatga tagtagttat tattaataat ttgtattact 28500
tatttctata tctgtaattc atcagtaaca atatgcttta acatttgccc cactgagtag 28560
tagaggctac ttaatgcaat ttataaaatg gatttttgct tattacttgg attaggtaaa 28620
atagcaagtg gaaatactga gaaaatgtac tccttatgga atggactgga ctgaccattc 28680
acactgagtg gaatagtaac tgatatccaa aaatctgggt accacctctt catgacagtg 28740
tcattctctga atagtcagga gttttttaa aaattaaatg aattgtttgg aataatctct 28800
gagccttttt ccagtgctat aatttgattt taaaaataa actccaggcc agatacaatg 28860
gcttatagca tataaatcca gcactttggg aggatggggc gggagtattg ccctgaggcc 28920
aggagtcca gacagctcgg gcaatgacta gagcaagact ccattacaaa aaatgaaaca 28980
acaaaaatta gcacaccctg tagtcctagc tacttaggag gctgaggcaa gaatatcgct 29040
tggcccagga gtttgaggct gcagtgaatt atgattgcac cactggactc cagtgtgggc 29100
aatgaagtaa gaccctgtct caaaaagttt taaaaaaaaat taaaaacacc ataaattcca 29160
attacactat taattgtaca aaatagatac atgatttatt catttttatg accaaaaaat 29220
aatttaaaga tttggaacaa aaaatgtaaa tgcacccctag aattgtatat ataaacccat 29280
actgattagt tagagatagt taaaatttaa tctgtcccat ctgaaatgaa ccctgtagta 29340
aaaccctggt taataagatc atcttagata atttcataat taatatgaac tatatggcta 29400
acctaccaa gtctaccctt tttcaagggt gtaagtaatc ttggctccat gtggattgac 29460
tcttttttct ttctttcctg tacaaattac tgatgagatg tacactagaa ttgccttata 29520
gctgaaatgg aaatcagctt tagatgaaat taaatttctt tctttcaaat actaaatctg 29580

gctgaaaata aaaagcatta agaaaaaac aattgtggga aaaccacatt ttcttttaat 29640
agacttcaga tgaggctttt tgggtttttt agttgttctt ttttttcctt ctacagtttt 29700
tctttctcat ttactgtcta atattttctt ctgtttctca cactccaatt atataaagta 29760
ccagaatatt tggaaaaagt aatagtattg ccaatatttt atttctatct tttgctataa 29820
ttgagaatat gtagctttta agatgtcaaa accaaaattt tatatgtttt caaggattaa 29880
aatgctgatt ctgccccag ttccagttcc aaagattaa ggaatcgatc cagatctcct 29940
caaggtaact aataatttta tctaaattgt agctagtact aattaacacc tgaagactcc 30000
tgtcatatgt tgaaggtttt ctgtaagcta tatatatcac attcaatttt cttgtatctc 30060
ttctoctaga gaaaattttt ttaaatttc tatttcttaa aaataagaaa acgtcatatg 30120
tatttaaaaa gttacacact aatttatggt tttttatat gttttgttac tgttgttctt 30180
attgtaacca taattaatct ctgaacatta tttgctaatt catttaatta ttatgagttt 30240
cttttcatag atcttcattt tctttctatt ttctaggaag gaaaattaga ggaggtgaac 30300
acaatcttag ccattcatga tagctataaa cccgaattcc acagtgatga ctcttgggtt 30360
gaatttattg agctagatat tgatgagcca gatgaaaaga ctgaggaatc agacacagac 30420
agacttctaa gcagtgacca tgagaaatca catagtaacc taggggtgaa ggatggcgac 30480
tctggacgta ccagctggtg tgaacctgac attctggaga ctgatttcaa tgccaatgac 30540
atacatgagg gtacctcaga ggttgctcag ccacagaggt taaaagggga agcagatctc 30600
ttatgccttg accagaagaa tcaaaataac tcaccttctc atgatgcttg ccctgctact 30660
cagcagccca gtgttatcca agcagagaaa aacaaccac aaccaattcc tactgaagga 30720
gctgagtcaa ctcaccaagc tgcccatatt cagctaagca atccaagttc actgtcaaac 30780

atcgactttt atgcccaggt gagcgacatt acaccagcag gtagtgtggc cctttccccg 30840
ggccaaaaga ataaggcagg gatgtcccaa tgtgacatgc acccggaat ggtctcactc 30900
tgccaagaaa acttccttat ggacaatgcc tactttctgtg aggcagatgc caaaaagtgc 30960
atccctgtgg ctctcacat caaggttgaa tcacacatac agccaagctt aaaccaagag 31020
gacatttaca tcaccacaga aagccttacc actgctgctg ggaggcctgg gacaggagaa 31080
catgttccag gttctgagat gcctgtccca gactatacct ccattcatat agtacagtcc 31140
ccacagggcc tcatactcaa tgcgactgcc ttgcccttgc ctgacaaaga gtttctctca 31200
tcatgtggct atgtgagcac agaccaactg aacaaaatca tgccttagcc tttctttggc 31260
ttcccaagag ctacgtatth aatagcaaag aattgactgg ggcaataacg ttttaagccaa 31320
aacaatgtht aaacctthtt tgggggagtg acaggatggg gtatggattc taaaatgcct 31380
tttcccaaaa tgttgaata tgatgttaa aaaataagaa gaatgcttaa tcagatagat 31440
attcctattg tgcaatgtaa atattthtaa gaattgtgtc agactgttht gtagcagtga 31500
ttgtcttaat attgtgggtg ttaattthtg atactaagca ttgaatggct atgtththta 31560
tgtatagtaa atcacgctth ttgaaaaagc gaaaaaatca ggtggcttht gcggttcagg 31620
aaaattgaaat gcaaaccata gcacaggcta atththtgth gthtctthaa taagaaactt 31680
ththththta aaactthaaa actagagggtg agaaathth actataagca agaaggcaaa 31740
aatagththg atatgthaaa cththththt gacataaagt tgataaagat atthththaa 31800
atthagactt caagcatggc ththththt tacactacac actgtgtact gcagththgta 31860
tgaccctct aaggagtgtg gcaactacag tctaaagctg ththaatgth ttggccaatg 31920
caccthaaga aaacaaact cgtthththt aaagcctth tathctccc cagactcctt 31980

caacaattct aaaatgattg tagtaatctg cattattgga atataattgt tttatctgaa 32040
tttttaaaca agtatttggt aatttagaaa actttaaagc gtttgcacag atcaacttac 32100
caggcaccaa aagaagtaaa agcaaaaaag aaaacctttc ttcaccaa atctgggtgat 32160
gccaaaaaaa aatacatgct aagagaagta gaaatcatag ctggttcaca ctgaccaaga 32220
tacttaagtg ctgcaattgc acgaggagt agtttttag tgcgtgcaga tggtgagaga 32280
taagatctat agcctctgca gcggaatctg ttcacacca acttggtttt gctacataat 32340
tatccaggaa ggggaataagg tacaagaagc attttgtaag ttgaagcaaa tcgaatgaaa 32400
ttaactgggt aatgaaacaa agagttcaag aaataagttt ttgtttcaca gcctataacc 32460
agacacatac tcatttttca tgataatgaa cagaacatag acagaagaaa caaggttttc 32520
agtccccaca gataactgaa aattatthaa accgctaaaa gaaactttct ttctactaa 32580
atcttttata ggatttattt aaaatagcaa aagaagaagt ttcattttt tttacttct 32640
ctctgagtgg actggcctca aagcaagcat tcagaagaaa aagaagcaac ctgagtaatt 32700
tagaaatcat tttgcaatcc cttaatatcc taaacatcat tcatttttgt tgttgttgtt 32760
gttgagacag agtctcgctc tgtcgccagg ctgagtgca gtggcgcgat cttgactcac 32820
tgcaatctcc acctcccaca gggtcaggcg attcccgtgc ctcagcctcc tgagtagotg 32880
ggactacagg cacgcaccac catgccaggc taattttttt gtatttttagc agagacgggg 32940
ttcaccatg ttggccagga tggctctgat ctctgacct cgtgatccac ccgactcggc 33000
ctcccaaagt gctgggatta caggtgtaag ccaccatgcc cagccctaaa catcattctt 33060
gagagcattg ggatatctcc tgaaaagggt tatgaaaaag aagaatctca tctcagttaa 33120
gaatacttct cattttttaa aaaagcttaa aactttgaag ttagctttaa cttaaatagt 33180

atttccatt tatcgagac ctttttagg aagcaagctt aatggctgat aattttaaat 33240
tctctctctt gcaggaagga ctatgaaaag ctagaattga gtgtttaaag ttcaacatgt 33300
tatttgtaat agatgtttga tagatcttct gctactttgc tgctatggtt ttctccaaga 33360
gctacataat ttagtttcat ataaagtatc atcagtgtag aacctaatc aattcaaagc 33420
tgtgtgtttg gaagactatc ttactatctt acaacagcct gacaacattt ctatagccaa 33480
aaatagctaa atacctcaat cagtctcaga atgtcatttt ggtactttgg tggccacata 33540
agccattatt cactagtatg actagttgtg tctggcagtt tatatttaac tctctttatg 33600
tctgtggatt ttttccttca aagtttaata aatttatttt cttggattcc tgatagtgtg 33660
cttctgttat caaacaccaa cataaaaatg atctaaacca ctctgtatac tgtgaattat 33720
cattgtaagg agagcttagc accactggat caaatacatc agcattgggt atggagattt 33780
ttatgtgctg agatatagag agggaaacat atcccccttc ccttattttt tgagaagaca 33840
aaagcccaac tcagaaatat cccactggct tggccctccc cttaggctgt gactcccat 33900
aggcaaaggt tcatagagct gtgtatttga tgcacatgg aaaataaatg acatgggtgt 33960
tggatgaggg agagtgatat gtgagcatta tctttacatt tccagcttga gcatgttgtc 34020
tggaaggaag gaaagcagct cttcctctgc cattcaccca ttggcctaag tcagtttatt 34080
ggactagctg cttgttatc 34099

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19

tcagggcatt ctttccattc

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

cataatcagg gcattctttc

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21

cctttaatct ttggaactgg

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

tcatcaatat ctagctcaat

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

cttagaagtc tgtctgtgtc

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

cctgctggtg taatgtogct

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

atgtaaatgt cctcttggtt

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

tggtgatgta aatgctctt

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27

ttctgtggtg atgtaaatgt

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28

aggcttttctg tggatgatgta

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29

tggtaaggct ttctgtggtg

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30

agttggtctg tgctcacata

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31

tgttcagttg gtctgtgctc

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32

gcatgatttt gttcagttgg

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

tataaaaaggg ctttgtaaaa

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

catagcagca aagtagcaga

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

gctatTTTTg gctatagaaa

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36

gattgaggta tttagctatt

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37

gatccatacc tgtaggacct

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38

ccagagatcc atacctgtag

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

tgctaaggat agctgctgtg

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

ttgtctttag gcttgatta

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

ttagaagaat ttgtctttag

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42

gtgaatttag gctccttaga

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

gctgtatggg tcctaggttc

20

<210> 44

Patent No. 11 2004 078922 WO 2004 078922

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

taacagctgt tttccccagc

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45

tttcatccac tgtaccacca

20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

ttgcactatt tcatcaacag

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

gggtggatct ggttgcaacta

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48

attgcgtggt gcttcccatc

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49

tagggtccat cattttccat

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50

caatgagtac actggaactg

20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51

aactcgccat aatttccaga

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52

agcccaaata ttccaaagat

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53

tcagcatttt aatcctttgc

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

attttccttc cttgaggaga

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

agattgtggt cacctcctct

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

aaccgaagag tcactactgt

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

ctggctcatc aatatctagc

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

tgtgtotgat tcctcagtct

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59

tatgtcattg gcattgaaat

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60

aaggcataag agatctgctt

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61

actcagctcc ttcagtagga

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62

ggacatccct gccttattct

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

ggcattgtcc ataaggaagt

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

actttttggc atctgcctca

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

gatgcacttt ttggcatctg

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

cagtcgcatt gagtatgagg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

ctctttgtca ggcaagggca

20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68

gtgctcacat agccacatga

20

<210> 69

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69

aagaaaggct aaggcatgat

20

<210> 70

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70

aaatacgtag ctcttgggaa

20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71

caatcactgc tactaaacag

20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72

aaacatagcc attcaatgct

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

gtgctatggg ttgcattcaa

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

gttttacata tccaaactat

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

catcaaccaa gatttggtga

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

gaggctatag atcttatctc

20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77

tagtgagaaa gaaagtttct

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

aatgctctca agaatgatgt

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79

acactcaatt ctagcttttc

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80

catctattac aaataacatg

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81

ctcttggaga aaaccatagc

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

tctacactga tgatacttta

20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83

cacagctttg aattgaatta

20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84

agtcttccaa acacacagct

20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85

aggctgttgt gaaatagtaa

20

<210> 86

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86

atagaaatgt tgtcaggctg

20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87

ccaaaatgac attctgagac

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88

ataatggctt atgtggccac

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89

agttatgtga ccctgattga

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90

ttgagtgttc ctaaaatgaa

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91

atggaggctg gaggttcaaa

20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92

tagggtccat ctttcaagac

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93

tctccagata gaatctaaac

20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94

tcctaatatt ctggtacttt

20

<210> 95

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95

tattagttac cttgaggaga

20

<210> 96

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 96

attttccttc ctagaaaata

20

<210> 97

<211> 1170

<212> DNA

<213> M. musculus

<220>

<400> 97

gagcaaggac tgtggaagct gctgctgctg tctgaagcga gctcctgggtt ggggtgtgatg 60

gcctgaggga ctccggaggg tgggttgtga agcacgcgac ccccgagcgc ctctgccttt 120

gcgcagtctg tgcaggctgc agctgcaagc tgggaagcaga ggagctggag tcagagtac 180

cgacgccaga gcctccatga actggggtct caggatgga tctttgtcag gtcttcttaa 240

ccttggcact ggcagtcacc agcagcacat tttctggaag tgaggctaca ccagctactc 300

ttggcaaagc ttcccagtt ctgcaaagaa tcaatccaag cctggggaca agttcttctg 360

gaaagcctcg attcaccaag tgtcgttccc ctgaactgga gacatthtca tgctactgga 420

cagaaggaga taatcctgat ttaaagaccc caggatctat tcagctgtac tatgctaaaa 480

gggaaagcca acgacaagct gcaagaattg ctcatgaatg gaccaggaa tggaaagaat 540

gccctgatta tgtctctgct ggaaaaaaca gctgttactt caactcatca tatacctcca 600

tttgataacc ctactgcac aagctaacta caaatggtga tttgctggac caaaaatggt 660

tcaactgttga cgaaatagtg caacctgac caccattgg cctcaactgg actttactaa 720

acattagttt gaccgggatt cgtggagaca tccaagtgag ttggcaacca ccacccaatg 780
cagatgttct gaagggatgg ataattctgg agtatgaaat tcagtacaaa gaagtaaattg 840
aatcaaaaatg gaaagtgatg ggcctatat ggtaacata ctgtccagtg tactcattga 900
gaatggataa agaacatgaa gtgcgggtga gatccagaca acggagcttt gaaaagtaca 960
gcgagttcag cgaagtcctc cgtgtaatat ttcctcagac gaacatattg gaagcatgtg 1020
aagaaggaac caagtccaat tctcagcacc cacatcaaga gattgacaac cacctgtatc 1080
accagcttca gaggatccgc catccctagc cttgtgggca cctgcattca tatgcacata 1140
catgcatacg cataattcaa aataataaaaa 1170

<210> 98

<211> 3976

<212> DNA

<213> M. musculus

<220>

<221> unsure

<222> 2438

<223> unknown

<221> unsure

<222> 2468

<223> unknown

<221> unsure

<222> 2561

<223> unknown

<221> unsure

<222> 2591

<223> unknown

<221> unsure
 <222> 3128
 <223> unknown

<221> unsure
 <222> 3154
 <223> unknown

<221> unsure
 <222> 3305
 <223> unknown

<221> unsure
 <222> 3468
 <223> unknown

<221> unsure
 <222> 3470
 <223> unknown

<223>

<400> 98
 atagaactgc agagtcttga gagctgcgcg gggctctcagg tatggatctt tgtcaggtct 60
 tcttaacctt ggcactggca gtcaccagca gcacatthtc tggaagtgag gctacaccag 120
 ctactcttgg caaagcttcc ccagttctgc aaagaatcaa tccaagcctg gggacaagtt 180
 cttctggaaa gcctcgattc accaagtgtc gttcccctga actggagaca ttttcatgct 240
 actggacaga aggagataat cctgatttaa agaccccagg atctattcag ctgtactatg 300
 ctaaaagggga aagccaacga caagctgcaa gaattgctca tgaatggacc caggaatgga 360
 aagaatgccc tgattatgtc tctgctggaa aaaacagctg ttacttcaac tcatcatata 420

cctccatttg gataccctac tgcacccaagc taactacaaa tggatgatttg ctggacccaaa 480
aatgtttcac tgttgacgaa atagtgcacac ctgatccacc cattggcctc aactggactt 540
tactaaacat tagtttgacc gggattcgtg gagacatcca agtgagttgg caaccaccac 600
ccaatgcaga tgttctgaag ggatggataa ttctggagta tgaaattcag tacaagaag 660
taaatgaatc aaaatggaaa gtgatgggcc ctatatggtt aacatactgt ccagtgtact 720
cattgagaat ggataaagaa catgaagtgc gggatgagatc cagacaacgg agctttgaaa 780
agtacagcga gttcagcga gtcctcctgt taatatttcc tcagacgaac atattggaag 840
catgtgaaga agatatccag tttccatggt tcttaattat tatctttgga atatttgag 900
tagcagtgat gctatttgta gttatatttt caaagcagca aaggattaag atgctgattt 960
taccaccagt cccagtcca aagattaaag ggattgatcc agatcttctc aagggagga 1020
agttggagga ggtgaacacc atcttaggca ttcacgataa ctacaaacc gacttctaca 1080
atgatgattc ctgggtcgag ttcattgagc tagatattga tgaagcagat gtggatgaga 1140
agactgaagg gtctgacaca gacagacttc taagcaatga tcatgagaaa tcagctggta 1200
tccttgagc aaaggatgat gattctgggc gtaccagctg ttacgaccct gacattttgg 1260
atactgattt ccataccagt gacatgtgtg atggtacctt gaagtttgct cagtcacaga 1320
agttaaatat ggaagctgat ctcttggtgc ttgatcagaa gaatctgaag aacttgctt 1380
atgatgcttc ccttggtct ctgcatcct ccattacca gacagtagaa gaaaacaagc 1440
cacagccact tttgagcagc gaaactgagg caaccacca actcgcctct acaccgatga 1500
gtaatcccac atcactggca aacattgact tttatgccca agtaagcgac attacaccag 1560
caggtggtga tgtcctttcc ccaggccaaa agattaaggc agggatagcc caaggcaata 1620

cccagcggga ggtggccacg cctgccaag aaaattacag catgaacagt gcctactttt 1680
gtgagtcaga tgccaaaaaa tgcacgcgctg tggcccgtcg catggaagcc acgtcttgta 1740
taaaaccaag cttaacca gaggacattt acatcaccac agaaagcctt accactactg 1800
cccagatgtc tgagacagca gatattgctc cagatgctga gatgtctgtc ccagactaca 1860
ccacggttca caccgtgcag tctccaaggg gccttatact caacgcaact gctttgcctt 1920
tgcctgacaa aaagaatfff cctcctcgt gtggttatgt gagcacagac caactgaaca 1980
aaatcatgca gtagcctttc ctatctttaa atggcaaggg aaaggctggg cacaaacgct 2040
taaaccaaaa ctatgtttta aatctgtgtt gggagagcat gagagtggat atggattcta 2100
aaatactfff tctggaaatg tcaaaatc aataagtgga aaatcaagaa ttogtaatca 2160
gataaatgct ccattgtga attataaata ttttaatgaa ttgtctttaa gactgtatag 2220
tggcagtgat tgtctgtact gtgggtctta attttgtgat actaagcatt aaatagctac 2280
gttttttatg tatgtagatc atgcttttgg aaaaagcaaa acaatcaggt ggcttttgca 2340
gttcaggaaa ttgaatgcag attatagcac aggctgattt ttttttctt ttttaataa 2400
ctgggaacta aaactctagg tgagaaggta aaactagnnt ggatatgcaa aacatttatt 2460
ttgacatnaa attgataaag atatttttaa taatttacac ttttaagcatg agkmccttat 2520
aatatgctac acacatattg tagttcagaa caatccatct naggatgtag cagctacagt 2580
gtaaagaggg nttcatgttt tggccaatga acgtaaagaa aaccaaaca gttagatttt 2640
taciaagccc ttttataact tccaaaactt cttaactcta aaaatgtcta ataacctgca 2700
ttattagaaa aaaacatttt aaatttgtaa acgaatattt ttttaatttt gaaaacttta 2760
ttttttttta atgttgaatc aacgtatcat acaccaaaca gtaaacagaa attataataa 2820

tggaagaagt gctttcttcg acaaatttcc attcaagcca cacagctaca tgtaagagaa 2880
gtagaagtga tgtggtgtga ttggctagga tgcagaagag cttcaggaat acaagaagtg 2940
agagcccaag gattgggagg agggggctct cacatctcca cagtgcagtc tgtcaaacc 3000
agcttggttt ttatagtatt ctaagaatta ttgtgtacaa ggaaaagtct cacatgtatg 3060
aatccagta tccagatggg gtaaagttag cagataatag gataggaaat taaagaccta 3120
gatctagnac tagtggactt ttttcacaga cagnacacaa atttttaatt cagggagaag 3180
ggacagaata aatgacttcc cactcacaaa gcacaactca gaagtaatta aacaggtaac 3240
agaaaccttg ccatcaaacc ttgataaga tgtattttaa gtagtaagca gtatttcaat 3300
gcttnttact taccctcca ggacaaccga tctcaaataa gggagataag gtagataaaa 3360
atcacttttt gattctgtaa taacataaac atagtctttt gggtagcac cccccaaaa 3420
aaaaatttat gggagaaaga ggactctcag ctgactgaag aatacatntn atttaaatat 3480
tttttagatg cctgaaactt taaaattacc ttttaagtttt aatggattac cattttgcca 3540
agacctttgt ggggaaacaa gcttaatggt tagtgatfff gaaatctctt tcatgcagga 3600
gagacagtga aatctagcc ttgggtgttt aaggttogcc ttgttacttt gtaatagatt 3660
ttaataagtt tttctgctac tttgctgcta tggtttctcc aatggctaca tgatttagtt 3720
catatgaagt atcatcaact tagaatctat tcagcttaa gatgtgtggt ttgatgaact 3780
atcttaccat ttcacatag gctgaccag tttctatagc caaaaatagc taaatacctc 3840
aatcagttcc agaatgtcat tttttggtac tttgctggcc acacaagccg ttattcaccg 3900
tttaactagt tgtgttctgc agtctatatt taactttctt tatgtctgtg gatttttccc 3960
ttcaaagttc aataaa 3976

<210> 99

<211> 4014

<212> DNA

<213> M. musculus

<220>

<221> unsure

<222> 2476

<223> unknown

<221> unsure

<222> 2506

<223> unknown

<221> unsure

<222> 2599

<223> unknown

<221> unsure

<222> 2629

<223> unknown

<221> unsure

<222> 3166

<223> unknown

<221> unsure

<222> 3192

<223> unknown

<221> unsure

<222> 3343

<223> unknown

<221> unsure

<222> 3506

<223> unknown

<221> unsure

<222> 3508

<223> unknown

<223>

<400> 99

acgtctggag agagagaggg agagagctgg ctgcaagcag tggttgtaac atgggactat 60

ccgcttgtgg gtctcaggta tggatctttg tcaggtcttc ttaaccttgg cactggcagt 120

caccagcagc acatcttctg gaagtgaggc tacaccagct actcttggca aagcttcccc 180

agttctgcaa agaatcaatc caagcctggg gacaagttct tctggaaagc ctcgattcac 240

caagtgtcgt tcccctgaac tggagacatt ttcattgctac tggacagaag gagataatcc 300

tgatttaaag accccaggat ctattcagct gtactatgct aaaagggaaa gccaacgaca 360

agctgcaaga attgctcatg aatggaccca ggaatggaaa gaatgccctg attatgtctc 420

tgctggaaaa aacagctggt acttcaactc atcatatacc tccatttggg taccctactg 480

catcaagcta actacaaatg gtgatttgct ggaccaaaaa tgtttcactg ttgacgaaat 540

agtgcaacct gatccacca ttggcctcaa ctggacttta ctaaacatta gtttgaccgg 600

gattcgtgga gacatccaag tgagttggca accaccacc aatgcagatg ttctgaaggg 660

atggataatt ctggagtatg aaattcagta caaagaagta aatgaatcaa aatggaaagt 720

gatgggccct atatgggtaa catactgtcc agtgtactca ttgagaatgg ataaagaaca 780

tgaagtgcgg gtgagatcca gacaacggag ctttgaaaag tacagcgagt tcagcgaagt 840

cctccgtgta atatttctc agacgaacat attggaagca tgtgaagaag atatccagtt 900

tccatggctc ttaattatta tctttggaat atttgagta gcagtgatgc tattttagt 960

tatattttca aagcagcaaa ggattaagat gctgatttta cccccagtcc cagttccaaa 1020
gattaaaggg attgatccag atcttctcaa gggaggggaag ttggaggagg tgaacaccat 1080
cttaggcatt catgataact acaaaccga cttctacaat gatgattcct gggtcgagtt 1140
cattgagcta gatattgatg aagcagatgt ggatgagaag actgaagggt ctgacacaga 1200
cagacttcta agcaatgatc atgagaaatc agctggatc cttggagcaa aggatgatga 1260
ttctgggct accagctggt acgaccctga cttttggat actgatttcc ataccagtga 1320
catgtgtgat ggtacctga agtttgctca gtcacagaag ttaaataatgg aagctgatct 1380
cttgtgcctt gatcagaaga atctgaagaa cttgccttat gatgcttccc ttggctctct 1440
gcatccctcc attacccaga cagtagaaga aaacaagcca cagccacttt tgagcagcga 1500
aactgaggca accaccaac tcgcctctac accgatgagt aatcccacat cactggcaaa 1560
cattgacttt tatgccaag taagcgacat tacaccagca ggtggtgatg tcctttcccc 1620
aggccaaaag attaaggcag ggatagccca aggcaatacc cagcgggagg tggccaogcc 1680
ctgccaagaa aattacagca tgaacagtgc ctacttttgt gagtcagatg ccaaaaaatg 1740
catcgctgtg gcccgctgca tggagccac gtcttgata aaaccaagct ttaaccaaga 1800
ggacatttac atcaccacag aaagccttac cactactgcc cagatgtctg agacagcaga 1860
tattgctcca gatgctgaga tgtctgtccc agactacacc acggttcaca ccgtgcagtc 1920
tccaaggggc cttatactca acgcaactgc tttgcctttg cctgacaaaa agaattttcc 1980
ctcctcgtgt ggttatgtga gcacagacca actgaacaaa atcatgcagt agcctttcct 2040
atctttaaat ggcaagggaa aggctgggca caaacgctta aaccaaaact atgttttaaa 2100
tctgtgttgg gagagcatga gagtggatat ggattctaaa atactttttc tggaaatgct 2160

aaaatatcaa taagtggaaa atcaagaatt cgtaatcaga taaatgctcc cattgtgaat 2220
tataaatatt ttaatgaatt gtctttaaga ctgtatagtg gcagtgattg tctgtactgt 2280
gggtcttaat tttgtgatac taagcattaa atagctacgt tttttatgta tgtagatcat 2340
gcttttggaa aaagcaaaac aatcaggtgg cttttgcagt tcaggaaatt gaatgcagat 2400
tatagcacag gctgattttt tttttctttt ttaaataact gggaactaaa actctaggtg 2460
agaaggtaaa actagnnttg atagcaaaa cattttatttt gacatnaaat tgataaagat 2520
atttttaata atttacactt taagcatgag kmctttataa tatgctacac acatattgta 2580
gttcagaaca atccatctna ggatgtagca gctacagtgt aaagagggnt tcatgttttg 2640
gtcaatgaac gtaaagaaaa ccaacaagt tagattttta caaagccctt ttataacttc 2700
caaaacttct taactctaaa aatgtctaataaacctgcatt attagaaaaaacattttta 2760
atgtgaaac gaatattttt ttaattttga aaactttatt tttttttaat gttgaaatcaa 2820
cgtatcatac accaaacagt aacagaaat tataataatg gaagaagtgc tttcttcgac 2880
aaatttccat tcaagccaca cagctacatg taagagaagt agaagtgatg tgggtgtgatt 2940
ggctaggatg cagaagagct tcaggaatac aagaagtgag agccaagga ttgggaggag 3000
ggggctctca catctccaca gtgcagtctg tcaaaccag cttggttttt atagtattct 3060
aagaattatt gtgtacaagg aaaagtctca catgtatgaa atccagtatc cagatgggggt 3120
aaagttagca gataatagga taggaaatta aagacctaga tctagnacta gtggactttt 3180
ttcacagaca gnacacaaat ttttaattca gggagaaggg acagaataaaa tgacttccca 3240
ctcaciaaagc acaactcaga agtaattaa caggtaacag aaaccttgc atcaaactt 3300
tgataagatg tattttaagt agtaagcagt atttcaatgc ttnttactta ccctcccagg 3360

acaaccgatc tcaaataagg gagataagg agataaaaat cactttttga ttctgtaata 3420
 acataaacat agttctttgg gttagcacc ccccaaaaaa aaatttatgg gagaaagagg 3480
 actctcagct gactgaagaa tacatntnat ttaaataattt tttagatgcc tgaaacttta 3540
 aaattacctt taagttttaa tggattacca ttttgccaag acctttgtgg ggaaacaagc 3600
 ttaatgttta gtgattttga aatctctttc atgcaggaga gacagtgaaa atctagcctt 3660
 ggggtgtttaa ggttcgctt gttactttgt aatagatttt aataagtttt tctgctactt 3720
 tgctgctatg gtttctcaa tggctacatg atttagttca tatgaagtat catcaactta 3780
 gaatctattc agcttaaaga tgtgtgtttt gatgaactat cttaccattt caccataggc 3840
 tgaccacggt tctatagcca aaaatagcta aatacctcaa tcagttccag aatgtcattt 3900
 tttggtactt tgctggccac acaagccgtt attcaccgtt taactagttg tgttctgcag 3960
 tctatattta actttcttta tgtctgtgga tttttccctt caaagttcaa taaa 4014

<210> 100

<211> 57489

<212> DNA

<213> M. musculus

<220>

<221> misc_feature

<222> 19, 49, 59, 71, 78, 172, 1734, 1851, 2528, 3199, 3274, 4582,
5432

<223> n = A,T,C or G

<221> misc_feature

<222> 5505 - 5604

<223> n = A,T,C or G

<221> misc_feature

<222> 9593 - 9647

<223> n = A,T,C or G

<221> misc_feature

<222> 9648 - 9692

<223> n = A,T,C or G

<221> misc_feature

<222> 14425 - 14444

<223> n = A,T,C or G

<400> 100

gactcctgct agggttgant gatgcctggg tgttcctgct aggtctaanc cacccaccnc 60

tgcatgctat nccaactnta cctaactgta ctgctgatat atccatgaaa tgtttgcgag 120

tggattgagc tgatgctatt gactgttgtg aactgaactg ctgatttcct gncaaagcag 180

atgagatttg ctccaaagag tcaattctaa ataagtccac tcccccttt tccaatagct 240

tttcttttct actacctatg gtggcgggtgg gctagaaggg aggatgaaga cattaagaac 300

catcattaa agtagacttt gaaaaaatta aatctacaaa tgacaaatca cagtataact 360

acattcttct ttctaggaac atcctgtttt ctagaactac ttattaagtt tagactttct 420

ccaatgagtg gtcttaacaa ttatttcaaa caacattttt tgatttctgg gtccgcattt 480

atacttcata tcctaactca ttggtcagtg tggccatttt gtagttccta tcattttcat 540

gatgttgttt aaagtagtat gtatatattc ataaccatat tataggtaaa cagagggaga 600

ccatgttgtc tgtaaataatt atttcaattt cttttctacc ttggatgtcc tttatttctt 660

ttctttggct tagtactcct tgtactatgt ttaataaaaa tggtaaacct agaaattctc 720

atthttgctct aaatcttaaa gagaaagctt ttgacatttc ctgagttagt ggtgtcttag 780

cctttctatt gctgtgcatg acaacaaatt tgggtgtgta agaccaccca aaaagcagc 840

cagaagtaac gttgtctaataat gtggatgct ggggacacag gtctcccctc agcattgcct 900
ctgctgtact ctccctgcac aggaaagttg cggatgaagc atgctcactg ttagctttca 960
ccaaccagg accaagacct ggggtaaagc accatcatta ctacctgctc ctacccttga 1020
tgagccagtc ttaccctaag cttttttgct taaggttgaa atagttggtg gaggcagttg 1080
ctttgccatg tagactgata atgcaaaatc tcaagggcct ctaaaacatg aaaagtctta 1140
tataggctct ggaattcttg ggttcaaacc tgagcatggt caatagcgtg tggctctgtg 1200
ctgatgccag gatattctg gaatcttctg tatgagcact agttgtggtt catatctaata 1260
attagaaaac tgttcatttg tcatggaaaa tgacaataaa ttaatgaagt atgattctct 1320
cagccacaaa gttccttacc atattatatg gaaagcaggt ttgaatagct ccgttacaag 1380
gttataattg ataactcagt tctaacctgt acaaatttca tgggtgttctc tatgctatag 1440
tggaagttct atctgtaagg tgctcagtag agactttagg cagccagatg ctgtttcact 1500
gtaatgggtc tgatatcaac caaagaaaaa gccctgatct aatttttatt cactgctttc 1560
cttggaagga atcttactgt tttctgtttt ctccaaattg aagcattcct tttctagggg 1620
ccagagaaga ttcatagcat tcctgaagct agtagaactt ccatgtcctc cagataagat 1680
agtaaattaa ctcataagac caagattgaa aaatagtaac agttgcacct cttncatgaa 1740
tctcccctgc atcttagatg gagactccaa agacatagct ttcttgagtc ctactcatg 1800
ttgggggatg cttttctgta ttcagctgcc cctgttcacc tatgtcccga naagtaatca 1860
caataaataa attagtttac catactagac ctggatacaa tcatgtcatt ggcattgccc 1920
tcatggctca tctgagacaa atacatgttt gttcacatat cctaattgtg atcaaaaatg 1980
gaatcctgtg tccggcccag ggctcaggcc tctgagcgag gtggatgtgg gaagtttggc 2040

ggatgtgggt gcacaccccc atggcaccac tgggcatgca cagggctgtg agaagccgca 2100
ggacccccctc caggggtggg aaagggtcag tctgaagtct ccacggacct gccagagttg 2160
ggctcagact ctcaggcatg cactggagt ctgtggaaga gtgcagaggc cagggacatc 2220
aggttctctg tcatggacac ctcagatgct gctggatgtc tcagaagagc tgagaacaga 2280
gtagggaccc gggctgaagg gaaaagggca tggagagggc tcaagatggg tccacagggg 2340
tgagagtcct tgtcttgctt aggcagctag ctgggttag cagaggccct ggttgagtg 2400
cagggaggcc tcctgggtgg agattagatg caaagttctt tagtagatga cctgctccgt 2460
tgctctagca cggcggatcc ctaaggtctt taaaattaga tattgtagtt tcttctctgt 2520
ttctttanct ctcattgatg tggtttggtt tataatgcca gatctttaa ggatctcact 2580
accccccccc ccatcttgcc ttatttgaga atcttctgtc cattaagac ataagagcct 2640
atctgtctgt atacttcggt gtagacaagt tctgacctg taataaatat tccttcatgt 2700
ttctctcact tcagcctttt cagtgttggg catgatgtcc tgattttctc acatagaca 2760
tccttatgag gatTTTTCAA actaagtcag tttcatcctg gtaaatcttg gtgtttcaag 2820
tcaacatacc ttacaatggt ttccagtcac cagagcacta gaatctcata gggcatttga 2880
tttatgaata ggactattag ttcttctata attctgtcct cttgtggtaa tgcaatcgag 2940
aatgaagat gtacaattgg cagagtgaag aaatttfaat attcagtaca ctttttttgg 3000
tatagtgaag cagtaacaca gtctctttta atattatttt tttatacaag tagattaatg 3060
cagctctcag cactcaacga agacatttca ttatgcagca gagattctta cagaaaacca 3120
cagctgggtca aactgcagag aataggtgac actggcctgt gtctaaacac aaatgctaca 3180
cagaagtctc cagaaagcnc ttcagaagag caaccaataa acaaacaaac aaacaaacaa 3240

acaaggaaag aactagagaa ccaggaggac ttgntaagaa acaatgtttt gtgggcgtga 3300
cagagatgat ggatgatgta ctgagacatt ccataagatc tacaaccctg tcggtggaac 3360
aacattatga actaaccagt accccggagc tcttgactct agctgcatat gtatcaaaag 3420
atgacctagt cggccatcac tggaaagaga ggcccattgg acatgcaaac tgtatatgcc 3480
ccaatacagg ggaacgccag ggccaaaaaa aaatgagaat gggtaggtag ggaagtgggg 3540
gggaagggta tgggggactt ttgggatagc attggaaatg taattgagga aaatatgtaa 3600
taaaatattt taaaaataa aaataaaaaa aatggaaaaa aaaaaaaagc ctagtagact 3660
catcacactt cccaaggcta cttcttctg tactgcagg aggtgcactg ctctctttga 3720
acttacagcc tgttcttgag gacttctaga tactgccttc tttgggggaa cccgatgggt 3780
ggagaggagg gaagtctccc gcaactacca atattttcct ctaggaggag ccccgccgcc 3840
caattgagag cgacacgcac caactcgcaa ctctcgcca gaaagcttca tcccagccct 3900
gcgactgag tagcgggggc ggcgttcagc ctccccgcag cggccccgga gctagctgcc 3960
ctcggctccc gctgccttc ccctaggcag cctggatccc cgaggcggcg ggggtccct 4020
cgcagagccg aacgccagcc gacttttccc acccctcccc tctcttctc tcccctcccc 4080
tcccctctc ccttcccagt ttcacccgc ccccttctc ctccccagc ctgacaacct 4140
acgagctgcc aagcaggcgc agccatggga agaggaggcg gtctaggag cggcggcact 4200
ggcagaggcg gctgctacag cggcgggtgt ggcgacggct gttactgaac cccggcagcc 4260
gcggggatcc cgggctgggt ccacgcggcc tgaggcctcg gctccagcag ccccaagcg 4320
gacacgaacc cgcgttctgt ctcccaggc gaaactccga ggtactggag gggagtctt 4380
attcccctca cattcgtgcc aggagacctg ggagtagacc cgggcatgcc aactgcttgt 4440

gaaaaattgg ggtcactttt atgtatttgc cccgataatt ttattttatt ttattttatt 4500
ttattttatt ttgatgagtt taggggtgggt tgtattccct tctcaaaagt tgttttctgc 4560
tgatggggtg gtgtaacceg ancctgcgtg tcctggagaa gtgtgtgtgt gtgtgtgtgt 4620
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgc gcgcgcgcgc ctgtgtgtgt gtgtgtgtgt 4680
aagttgttct tggtgctgag tgaagctgaa agttgatgtg ggcgacaagg aatggggggc 4740
agcaagcgaa ctgtcccagc ctggagcctg ctccaaccag gttgtgagat gcaaggagag 4800
gtttcttcct aagactgttt tcttggtcct aaaagtttcg cgagtgtgtt tgtcaccatc 4860
agcctgctaa cctggagcaa ggactgtgga agctgctgct gctgtctgaa gcgagctcct 4920
ggttgggtgt gatggcctga gggactccgg aggggtgggt gtgaagcacg cgacccccgc 4980
agcgtctgc ctttgccag tctgtgcagg ctgcagctgc aagctggaag cagaggagct 5040
ggagtcagag tcaccgacgc cagagcctcc atgaactggg gtgagtgaa attgtggcaa 5100
gccaaactgt cccggcgtg gacacactcg tggttatgaa atcaaccagg ctcaaagttc 5160
tgatagaact gcagagtctt gagagctgcg cgggtgagtc gggtcacgtc tggagagaga 5220
gaggagaga gctggctgca agcagtgggt gtaacatggg actatccgct tgtgggtgctg 5280
tggggaaatc tatttctggg caaggacttt atatatagca ccggggagta ctgtctgctg 5340
ggaccaggt gcaggtttcc gtggtgagct ctgatgtgtg tgcttgaaga ggtgtgcagt 5400
atgtatgtgt gctgtatggt tgcacgcgtg tngtgggagc ccattgggag gtgtgttggc 5460
ttcctgaatc aggggtgttga gtgggagaaa gaaaccatat agatnnnnnnn nnnnnnnnnn 5520
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 5580
nnnnnnnnnn nnnnnnnnnn nnnngaataca gggttttatt ttagtttctt ttgtcccacc 5640

tcccgtaatc caatgtggtg ttcaaaactcc cgtcctgacc ctccgtaatt cccattggac 5700
tctcatatgt ccagggctat cttttggact gaggtttgaa ccatccgata tatcagacac 5760
aagcataatt cttggtttgc atagagattg ttttttttta aagtatacta cttggagatc 5820
aggggaattga aaatgttgc ctctgtctgc aaggaacatg tagaacattg acacttttat 5880
agctcttcag ggattccatt ggtgctacc agagccacac ctgtagagcc atgaaacaac 5940
acttcttgct cagcgttcac tatgattagg gataacagga agagttttat cagtattgtc 6000
aagtttgcaa atgttagaaa agaagaagag aagagaagag aagagaagag aagagaagag 6060
aagagaagag aagaaaagaa aagaaaagaa aagaaaagaa aagaaaagaa aagaaaagaa 6120
aagaaaagaa aagaagagaa gagaagagaa aagaaatcag tccatggagg ccattgaaga 6180
attgggtggag tgttgataag gtgacttgta aatagggcag tattatggaa atactgggac 6240
taagcatcaa agtggttggc aatagttgtc aaatgcaaca atccttcccc aaagagttga 6300
gtactgagtt tctttaccac ccatcctgcc ttgtctctag agaagtgtgg acatagtcac 6360
cataggttat tttcccaaag aagtgtattt ccttcagata aaggcatgtg cttacagagc 6420
ccattgatca agtcctcat tcattagacc gaaagactga aggtgcagcc actcctgggc 6480
ttctaaatca ctagaaaaat ggagactggt ggctcttggg gaacatatgc ttgggtgttt 6540
cagagcacac agtcattccc agggttccct taatgtttga aaggatattc tcacctctca 6600
gcttccctct tgttacacct ccctgggatc agtacagtgt ttgtaaaaca taaattaagc 6660
tcctttggtc cttgggaaag aggtgtaaga aatgttagta tagtattata gaagatTTTT 6720
atTTTTTTTT atTTTTTatt ttttgtctta ttcaaagccc tgtgctgagc aatTTTTTTT 6780
tatctccaga tgaaactaaa agaaaataca ctaggccctg ttattagagc tgagcttgtg 6840

ggctcttttgc tgtgaggtga cccagtggct ggaagccaag gacctgaaag tctgcaactgc 6900
tcattctgtt tcctgaggaa agagctcatg ggatggagag agaattccaa cacgctgtgc 6960
atcctcatga cacatggggc acttctgaag tctgaggcaa tgctagactt actaagattt 7020
ctccacaac gttcttgtcc acacactcac gacttcacgg ggctttgaa gttatatcaa 7080
gaccgtggtc tgtggctgct tgccttgacc ttgtcccttt tctgtcttgc aggtctcagg 7140
tatggatctt tgtcaggtct tcttaacctt ggcaactggca gtcaccagca gcacattttc 7200
tggaagtgag ggtgagttct acattccttt tctccttctg tggataaag aaacaaagca 7260
gtcctgtgtt aaatctgaac aaaatcgtct aagtttttagg ttaacagcaa acaggaaacc 7320
tgtcttagct ttaaattcat aaccaggag agagccattc tggggatgtg taagtggggc 7380
aagagtcgta ggctttggca actgacattt tcctattgga aattgatgtt acgtaatgca 7440
cagggggaca tttatgatga agacaagccg ggtctccggg agagatatta aaatcacacc 7500
aaagcatcat tagcctacta atcgctcagc tcactctgaa ctaagcatag cagaatctgt 7560
ttccaaagcc tggaatgcag tccccttaat catattccct gagatgtaaa tctcaggctt 7620
ccaatgaatt tgtgcccctg ttctctgaat aatcattcat tggctgagtt ccagaggaaa 7680
aagacaccca aactaggtga ccaacgttac ccagaaatgt gagctacctt agctgtctga 7740
ctatgttccc ttatgttttt cttttatact ctcccgggtg tetcaatatt ttcagattca 7800
catgtcatag cagaaacaac aaagaataat gcaaattgggt gtgggggtgt ctgtotagaa 7860
aaaaaaaaagt gtccttacia agggctggcg gacgttttga agactgtctt gagcacgagg 7920
cagttttctt tcctggtttc attagaggat agaatagaaa caatatgttt ttgcatgct 7980
gtgcctctgg attctgttgc tgctttaagt gtagcctact cccttactca acaccaact 8040

catgttggaa aacacaatth aacagggcag ttaacacctt aagatgtccc gctgaccttg 8100
tgaccaaaaa taaatgcca gtagtgagct gctgactgtg ttaggagcaa cttggaaagg 8160
ggaacgaata gaatgcacta tttgatttct taaagcaatc ccaaaaatat ttatagaaaa 8220
gaaatcataa ttgtttgtaa ttttttggg tttttctggg gttataatgt caatattata 8280
caagtcagac gtggagggag agagagtcac gggctccact tcagccgctt ttcccatggc 8340
tgctttttag agcctgggtc tgagccagag aattacagct cagctcctct gccattccag 8400
agtcatgggtg gtttaatcgc tcctttcttc actaagggtga ctttcagtcc aaggggcaag 8460
gcttgaggag tttaaaagcc agtgaagtga aaagcacagc agaacaatca ttaaagaagt 8520
tgagaaatgc atcccaggct aacagattag agctcaaatg gttttcttta tttttctttt 8580
tttaattaga tttttctctt tatttacatt tcaaagtta tcccccttct ttgtttcccc 8640
tctgaaaatc ctctatcccc tcaccccatc aacaaccac cactcctgc ttctggcac 8700
aggcattccc ctatactggg gcatagaaat ttcacaggac caagggcctc tcctcccatt 8760
gatggccgat taggcatcc tctacatag cagctagagc catgagtctc accatgtgtt 8820
ttctttgggtt ggttgttcaa tccctgggag ctctcagggt actggttatt tcatattgtt 8880
gttcctccta tgggtgctgtt aacccttca gctccttggg tactttctct agatccttca 8940
ttggagacct tgtgctctaa tggataatga tgagcatcca cttctgttca aatggttttc 9000
aaacctagag aatttccaag ttctgttcaa cagcttaaac atttgcccag ccttcaactt 9060
catgagaaga atggtgacaa aaaagtatat ataatgttat aagccgtgtg tgtgcttgtg 9120
tgtatgtgtg catgcaagtg catgtataca catgattacc cattttctct ctgtggcaag 9180
agaagccttg atctacttct atagcagaaa tcctgaatat aataatctga gctcaactac 9240

agctctcttg gtgttcatta attcactaga ctcaatacag catatcttgc tctttgtgcc 9300
ctatggatga ctgtctgcca agtccttctc ctacccaat gtggtaacca ctggtgtctc 9360
tacaatttga ccttttattt gtaaaattac acattgatgc aacctggtt attgttcttt 9420
cctgatctga cctctttctc ttagactgat ggccactttt gctttagaga cactcacact 9480
gtggcaatgg caggagcttc aagctgaagt ctgggctatt ccatgtctat gctggtatgt 9540
tgacagctgc atgaatacag acatagagtc cottacacag tgggtgttca acnnnnnnnn 9600
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 9660
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnggacgacg gttccttgat ctgggtactt 9720
tctctaactc ctccatgggg gcccgagtcc atccaatagc tgacgtgagc atctacgtct 9780
gtggtgccag gccccagtat agcctcacia gagacagcta tatcagggtc ctttcagcaa 9840
aatctgcttt gtatgcaagg tgtcagcatt ggaggctgat tatgggatgg atcccaggta 9900
tggcagtctc taaatgggtcc atcctttcgt ctctcctcca aacttgtctc tgtaactcct 9960
ttcatgggtg tttgttccca attctaagaa agggcaaagt gtccacactt ggtcttctt 10020
cttcttgagt ttcatgtggt ttgcaaagt atcttgtatc ttgggtattc taagtttctg 10080
ggctaataatc cacttatcag tgagtacata tcatgtgagt tctttgtgat tgggttacct 10140
aactcaggat gatgccctcc aggtccattc atttgtctag gaatttcata aattcattct 10200
ttttaatagc tgagtagtac tccattgtgt aatgtacca cttttctgt atccattcct 10260
ctggtgaggg acatctgggt tctttccaga ttctggctat tataaataag gctgctatga 10320
acatagtgga acatgtgtcc ttcttaccag ttggaacatc ttctggatat atgccagga 10380
gaggatattgt gggatcctcc tccggtagta caatgtccaa ttttctgagg aaccgccagg 10440

ctgatttcca gagtggttgt acaagctcgc aatcccatca acaatggagg agtgtttctc 10500
tttctccata tcctcgccag catctgttgt cagagaagtc aggtataatt ctgataggtt 10560
tacctttata tgttacttgg catttttttc cttgcagctt ttaatattct ttcttgttat 10620
gtgcatttag tgtttgatta ttatgtgaca ggaggathtt ctttctggtc caatctattg 10680
gtgttctgtg ggcttctgta catttatggc catctctttc tttagggttag gaaagttttc 10740
ttctatgatt ttgttgaaga tgtctttggc ttttgagctg ggaagcttca ccctcttcta 10800
ttctttttat tcttaagttg gtcttttcat agtgtgcaaa attcttgtat gatttgagtt 10860
aggaactttc tacaatggca ttttctttga tcatgtattc atttcttcta tggatcctc 10920
tatgtctgaa attctctctt ccatctctgt attctattgg tgttgcatgc atctgtagtt 10980
cttgttctct ttcgtaggtt ttccatctct aggattacct ctttgtgtt ttctgtattg 11040
cttctacttc tgtttttagg tctggatcct tttattcatt accttcacct gtttgattgt 11100
atthtctgt atthtctttt tttttaattt tatttttatt agatattttc tttatataca 11160
tttgaaatgc taccctgaaa ttttctatt tccccacc cccgctccc taccacaacca 11220
ctttcccgtt tttctttaag ggatgtgttg tttctcttt aaaggcttct acctgtttga 11280
ttgtgttttc ttacatttct ttaagggact tatttatatc ctttttaaag gtctctatca 11340
tcttcatgag atgggattta aggtcacagt cttgctcttc aggagtatta gactatccac 11400
tgcttgctgt actaggagag ctgggttcta atggtgccat attgcattgg cttttactga 11460
ttatgttctt gcacttgctt tttgccatct ggttgtctct ggtgttggtt ggctgggtg 11520
tcccatgttg aagcaggctt ccagatgaa ggtggagctg tgtgtctcag gtatgagcag 11580
gcctcctggg aggcagtctg agttatgagt gtcagattgg agctgacttc ctggaaggca 11640

ggtaggagctg tgaggtgggg cacagagtgc tgatctgcat ctgcttcagg tntaggggtg 11700
gaccagaagg aagatggagc tctgacaggg tggggcacag cctacagctg ctagctgaaa 11760
ttcccatcag gtagggcagg gggattaggg tgagtgaggc agggaggggt ctcacctgtg 11820
tatgttggtt tatgtaggca gagctgtgaa gtgtgtgctg agtactgatg tgcccatatt 11880
ttcttttctt tttcttcctt gtgttttatg tgagacagag taccagtggt atggccttcc 11940
actaagacaa tattatcagt tgtctgagag aatatgggga aaacaaacat aatgtgtctg 12000
gccacactct tgaaaacaga atacttgggt gccctttggt caccaaatg ttaagtgaga 12060
atacaattgg ctaataccga ggtgagaggg aacatcctat aatacaattc aattcccatg 12120
caaactacct acagatactt tcacatcact catcttgata gctcagcccc acaaaactgc 12180
ttcctacttc agatgacaaa tgtatgtaat atactgtact tctgaaagat ttctttgcta 12240
taatttataa atagactgta ctaaagtttt gaaatgtctt tttttttca agctgggtcc 12300
catgactcat ttattagagt tgatgaattt gctacaccag ctcacagaac tcagacatta 12360
aattaatgac tttggctttt tactgagggc atcaciaagg agacagataa tgaggtatta 12420
tattaataag cctctgctac tgtaacaaat atctgaaaca atcagcttat gaagagagaa 12480
ggtttatttt gactcacagg tttggagaac tctggagttt ccagagcatg agtgggttgg 12540
tccactgctt ttgagcctat gaaatggagg aactgtagc agcagcatgt ggagaaacca 12600
cttttccttg ggacgaagaa attgctaagg gtccaggttt tgttttaaaa tctactgtccc 12660
ccacccccct accccaagt gatgggaaga cctcctaact cacctttatg tttcaaattc 12720
ctaccacctc tgagtagtgt caggctgagg atcatagctt tagcacatgg gcccttagag 12780
gaaattccat attgaaacca taacatatga agaacatgct gtagccactg tgccctctaa 12840

gcatctccag gttatcaacc aattgaaagc ttctgaactc atactatcaa ttttttgtga 12900
atgttgtatt ctctgactac atttattaaa ccaactgacca ttggtgatga gcttagccat 12960
tagaccctcc ttctcccta gaggctttga ataacactga aaaaaattcc agttctacaa 13020
ccataaatct gttttttccc atgccagctt ccatcctgag ggaggaaatc cccagccact 13080
actcaactca ttagtgtatg aaaagactca tcgctctgag tattacaaat attttaaaaa 13140
tgtatatggt aaaatacagt gggaagacta aatatagatt tagcagtgtc acacatagct 13200
tccttgctt tcatttaa atcagatatt gttgtttctg tgtagtaaca agagctggtc 13260
tatccagtcc tcttacacac tttccaccaa gaccagacaa caagtcagac tctttgtagc 13320
tagggccttt gcaaaggaac ccagctggaa ggagccttac tgagcacttt ccaactattgc 13380
ctaccttcca gacagcctgc tcccagctgt attacaatga ttgactcact tgctgcctat 13440
tcaaaaaact ccagggcctc acttgttctg ctttgccctt cccttattc tttccccatg 13500
cccaggaatg ttctcactta tagtatttcc aaaaataatt ttttaattaa atgtgggatt 13560
tgtatttttc taaagaaacc tgtgttctcc ttctatgca caagggaaac ttgagtttga 13620
actcaaagga tagatggtgg aattgttctc attgttctgt attgtgtctg ggcattgcgac 13680
ctgaggtaat gacaacccaaa aggcttccat ttgctctgac tttacaagct ctttttaagt 13740
catagataca gctttaat taaatgggggg gggttggcat ggaagcctat tatacaaaaa 13800
tgacactata acagggtcac agaagatcgt tttctacag ggatgactaa tgattttctt 13860
ctctttcttt ttcaagctaca ccagctactc ttggcaaagc ttccccagtt ctgcaaagaa 13920
tcaatccaag cctggggaca agtaagaatt tctgtcattc tactaacttg cactgatggg 13980
ttccatagtg tactataatt caaactactc tcctttctct ttctctcttt gggatactgg 14040

taacaggaaa agtgacagcg tttgaatfff ataagcaaaa agtatttttc aggatttatg 14100
tttcaatffc tgtatagagg tcatggftha tttttctggt ttgtttatgc ttgcaggtha 14160
agagaaggct ttattatgcc ttgttttaca aacttgffff taacattatt gttgttgata 14220
tttggtagta tttatataat gcttgcaatg gcaaaaaatg gaatftattt cccgaaccaa 14280
attacatat atacctcaca attctgcctt catataagca gcctatfttt tacatgtcat 14340
cgaacaccgc cccccccccc cccgtctttg ctaatcttcc cctatctaca taccaaactc 14400
aaccttcagc tcacagaaaa aggtnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 14460
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 14520
nnnncatca gggccacaag caggaaactg tccaatctca caatcaaagt aaatgccaca 14580
gttgtcaaat gtggacatac ttgctatatt cacacagggg acttggaata tataatttac 14640
acatgcagta ttaaaataaa taattcagat tcagcacaaa gtttactffc ttgctataa 14700
atfttaggca agtatgggag tgtatgaatc tftaaaaaaa aaaacaaaat ggagctaaga 14760
aagtgcgat aacataactt atftacaagt ctccaaatft tcttgaaaat atcacatgag 14820
aagtaagcaa atagaattca ccagctftta gagcatttac caaactccag tgaatatcaa 14880
tacctgcata aaagftaact cacactgaac tftgtgtaac caacatcact ftctaattcc 14940
aagctcctac agaacatccc atagagctct taatacccaa tggctftftct agcccaatgt 15000
ftcaaagtec ftccatagtc ftccctaaaa catggtcagg ttgtcacaga aatatgccac 15060
tatgctggta actatftgfc ttggtcaggt ftctatftct gcacaaacgt catgaccaag 15120
aatcaagtag gggagaaaag ggtftattca gtctacactt ccacattgct atftattacc 15180
aaaggaagtc aggactggaa ctcaagcagg tcaggaagca ggagctgatg cagaaacat 15240

ggaaagatgt tatttactgg cttccttacc ctggcttgct cagcctgctt tcttttagaa 15300
cccaagacta ccagaccaga gatggtacca cccacaatga gctatgcctt cccctcttga 15360
tcactaattg agaaaatgcc ttacagctgg atctcatgga ggcatttcct caagggaggt 15420
tactttctct atgataactc cagtttgtgt aacgttaaca cacaaaatca gccagtacag 15480
tcaacctctg gcctacacaa atacacacag atatacacac cctcatgtac acacacacac 15540
acacacacac atccaagaag aaatgcaaat gactaccaat ggtcttccaa gatcttttga 15600
gtacaagcag tgtaaatgct aaaatttctt cagaacgtgg aacatcttca gttccaacac 15660
tcatttgtag aagtgggaat taatctgggg tgcaaagggt gaactcttgt gaattgcaac 15720
attcttttct gggatgctat agtagatgct aaacaatgcc actgttaggc ttaagcattc 15780
ctgcttagga cttttctcct ctctgcctat tatcagattt ctagtcttag gcatgttttt 15840
catctttcaa atgaactact tgccctcata tcctttccac tagctctggg tcttaaacia 15900
gccctacaga ataatgcagg aaataaagtc acaacttttt ggcttcaaaa ttgatgactg 15960
acagtagaaa ggaatagctg ctgagaagggt aagcccggaa aagtgccttt ccagatgtta 16020
gtatcacctc ccagagagac tggctttatc ttcatagttt acatacttca gcagttatgt 16080
tccgtgggaa tggcacatgt ccttcctcac tccatgtatg ccttttcttc ttgttctgca 16140
ggttcttctg gaaagcctcg attcaccaag tgtcgttccc ctgaactgga gacattttca 16200
tgctactgga cagaaggaga taatcctgat ttaaagaccc caggatctat tcagctgtac 16260
tatgctaaaa ggtgaaggct tcacgccctt ctgactttgt cctccactga tttctcagtc 16320
ggatggtgtg gagagattcc cattgagtga aagcacgtgg gcgtgcctgt gggcatacgt 16380
gagtgtgtgc agaggcttga gtaatatttg aactgaggag gtctcaggga ccttttctaat 16440

gtagtgtggtt aaaatgggga aaagaagtga aaaaaactgt gtgagtatat gatggagagg 16500
ctttggaggc aaagaaaatc acagatgcaa tgtccgtgtc agcatgtttg agaatcacia 16560
gagcctgtat aggtgacatg agactgaaac ttgggaaagt gacatgtgaa ggagttagag 16620
ggctaccag atactgtaac aatgagcttg tagtcccggg aagaccactg aatcttactt 16680
tgtgctttaa aaaaactgtg ttttaagagc ctccaatact tggcttctct ataagaatta 16740
attaattaca ctaagtgagg gaacttgctc ttttgTTTT atocatgtcg tctggaatga 16800
cacttgatga ggaagacaaa catctggaaa cgtggctcacc accagtcctt aagtttcatt 16860
ccctggccaa gtctctcttt cctctcctcc cgctgttact atgcagtacc agcataattt 16920
atgggatagt ctgtgatatt ttaatacacc tatatgatgt gtgattctca aaccaggaca 16980
attggtgtat ctatcacttg aagcatttat cattgtgtgt gtgtgtgtgt gtgtgtgtgt 17040
gtgtgtgtgt ttgccagggc caccaaaaat cttctctact agatattttt aaatacatga 17100
ttaatcgttg tcaactataa ttaccctact gtgctataca acaaacatca ccatttttaa 17160
tgtagagtt aaatactttc ttgtctttct ttctccatg aacctccagg gaaagccaac 17220
gacaagctgc aaggttagtg aagacccttt gtottagact ttcattccaag ggcttgagaa 17280
tgacatgttc cactccgtag atgatagga agggaaagga aggaagatgt gggagggcag 17340
ttagtccgag ctagcctcct gcagtatgtc ctggcttcag tccttgctca ccaaggaaca 17400
gccagcaaat tagttaaacc aagtctctc cattctagta gtataatagg cttagttcac 17460
agcttcttag gtggaagaat tcctgatata gttcattctg cataattaat caatcatcaa 17520
tcaattaatc aataagcaag attttcttag tatataataa taatttaaaa caataatgat 17580
atagaacca gattcctaaa ctataaaaag taattcctta ttgcttatgc ttattaatag 17640

actataagaa ctttctaatag cctacctgag tgtttaatth acagacaaca aaaactthaa 17700
gtgaacaaca aagactgact ctacccatct tctagttatg aaaggcacca cagacatacc 17760
cctgcctaag gcacacagag atgaggtagt ttggaaccaa acgcactact tatttaactt 17820
gaggttgata ctataaagag gtatgggcca gtaaagtaga ggcaggcaga cagacagaca 17880
gacagacaga tactcagatg tgagctaaag tgtttgggaa cacttttgaa aatgtatgaa 17940
ttgattctgt tatttctaata atgaaaagag agagaaactc actagatgtc atctttacac 18000
cttgcttcgg tagctcagac agcttagcac catcaaaaca aatgagaagt tttcataca 18060
ggcaccactg accaaactga tctaagtagc agtgggataa catcttgaat cagttctaata 18120
ccaggaaaat gatttttcta cctcctgtc agtcacccaa cctagctgtg agccaaagaa 18180
tgaatccaga gacactgagc cctcacagcc atccttgttt ctcactttct tcagtcagag 18240
ccacagtatc tgtctgcagg tctcctctc acatcccaat ctcccagca tcctagtct 18300
gcactcacc tggaactaa caagaaatct gctgcaagta tgaccggggg aaaagaatat 18360
ctccgacata tgcaaaagaa catcctgtt tagctctagt ggaacctaga atctcaggag 18420
aaaaatatcc ccatctcct aaataccatg aacacaaaca aactcatgat gaagtgcaa 18480
acaaaaccc caaatcagga ttttggttc tctctacaaa aaaaaaaaaa aaaaaaaaaa 18540
accaaccata aatactttga atattctagc caaacccaca aaagtcctca gccctgtttg 18600
tctgagaatt gaatgtaaaa tcaaggggta gtctatcaga atggatctgt actgatgcat 18660
gggctctcag cacccaacta cacagagaca aaggcacagg gggaaacttc aactcttggt 18720
atthggctctg agagtttggt cctaggcaac tcctaaaact atagaatcat tctcccatc 18780
cctcaccac aactacag catactthaa thcaactt atagtctgtg gaggcagaaa 18840

gaaccagcag atgtggtagt gtgtctgggc tgcttttggga atccaaagca cacatgaatc 18900
taagcacggtt gggctgtcag cgggacagaa aggcacaagc ctgcatgtgt tctgcttggga 18960
cccaattcct agccaggtaa gctggcagag gagatggcct agcttaagaa agcagctgat 19020
tcaaagcagt ctctgaagcc ctgtgattga gatcctgcca aatcctgcct ctgcacttga 19080
aggcaactgg gtttgaatgc aaagcagagc tgtgccagaa agagactctg ctgagtgcgg 19140
ccgagctttg ggaaggcttc ctggagcaag ctgaaacctg gtaacatcag cctttccttt 19200
cactcctttt accatatttatt ttaactgaaa aaaatattat catcagactt catcctaaag 19260
gatttgagat tcagttcact gggatgtagg gtgacgacta atctgtctcc tttttgtag 19320
aggaggttgg ttagctatat ccttcctga agtttatgcc aggcagaggt gagatataag 19380
tatggcctgt gggttcaagg gactctaaat gacacagtag ccttggtaga aggagacagt 19440
catagtagtt aacagttgac atcacttagt tgggaattatt taatgtttgt gggcctgaaa 19500
tctggtttta ttttatttat ttatttattt atttttttgg ttctcactat tctttttttt 19560
tttaattttt ttcccacttt ttattaggta tttagctcat ttacatttct aatgctatac 19620
caaagtcccc catacccacc cactccccct ttttggcctt ggtgttcccc tgtactgggg 19680
catgacttct ctgttcctta tttttactcc atgaaaacct ttagagagaa atactgcttt 19740
cactcttcta tttttaatga aatctcttat ggtccttact cccgtcacia ggtagtctgt 19800
ggcaatcaaa gaacttcatt tgagggcaag aagaagaaaa gtagctgcct tagagcacct 19860
tacgtcttgt acggaatgca gggcagacia gtggcttcat gtttcatgag gttattcggg 19920
tttggcctga gatttactag cttaaaagat ccattttagc cagatatggt ggcattgtgtc 19980
tagtcttagc acttgggagg cagaagtaag tggatctctg agttcagcgc cagcctgggc 20040

tacaaagcag tttcagaaca cctaggacta cacagctggt ctgaaatcat gtctcaannn 20100
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 20160
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnntga tggccgtcc aactatgaat 20220
atcctcccat ccctcaccac aacactacag catactttaa ttcaacactt atagtcgtgg 20280
aggcagaaag aaccagcaga tgtggtagtg tgtctgggct gctttggaat ccaaagcaca 20340
catgaatcta agcacgtggg ctgtcagcgg gacagaaagg cacaagcctg catgtgttct 20400
gcttgacc aattcctagc caggtaagct ggcagaggag atggcctagc ttaagaaagc 20460
agctgattca aagcagtctc tgaagccctg tgattgagat cctgccaaat cctgcctctg 20520
cactgaagg caactggggt gaatgcaaag cagagctgtg ccagaaagag actctgctga 20580
gtgcgccga gcttggaag gcttcctgga gcaagctgaa acctggtaac atcagccttt 20640
cctttcactc cttttaccat ttattttaac tgaaaaaat attatcatca gacttcatcc 20700
taaaggattt gagattcagt tctactgggt gtaggggtgac gactaatctg tctccttttt 20760
gttagaggag gttggttagc tatatccttc cctgaagttt atgccaggca gaggtgagat 20820
ataagtatgg cctgtgggtt caaggactc taaatgacac agtagccttg gtagaaggag 20880
acagtcatag tagttaacag ttgacatcac ttagttggaa ttatttaatg tttgtgggcc 20940
tgaaatctgg ttttatttta tttatttatt tatttatttt tttggttctc actattcttt 21000
ttttttttaa ttttttccc actttttatt aggtatttag ctcatttaca tttctaagc 21060
tatacaaaa gtccccata cccaccact ccccttttt ggccctggtg ttcccctgta 21120
ctggggcatg acttctctgt tccttatttt tactccaatg aaaaccttta gagagaaata 21180
ctgctttcac tcttctattt ttaatgaaat ctcttatggt ccttactccc gtcacaaggt 21240

agtctgtggc aaatcaaaag aacttcattt gagggcaaag aagaagaaaa gtagctgcct 21300
tagagcacct tacgtcttgt acggaatgca gggcagacaa gtggcttcat gtttcatgag 21360
gttattcggg tttggcctga gatttactag cttaaagat ccattttagc cagatatggt 21420
ggcatgtgtc tagtcctagc acttgggagg cagaagtaag tggatctctg agttcaaggc 21480
cagcctgggc tacaagcaa gtttcagaac acctaggact acacagctgt tctgaaatca 21540
tgtctcaaaa accatgatgg ggatgggggg tcctgagatt gggagttgtg ttttcaacta 21600
gctattcctg acacacttca cattcagatt aactottata agagctatgt cctgtggaac 21660
tgatggattt agaaatccta accagggttt cacatacaag cccaggaac aggactactt 21720
gcattgtcaa atgtcagaaa acctcacaga aactgaagca caacggagct aggtggctcc 21780
ttatagtaga cgcagacctg ctgaccacta gctgccctgg atatttgac catcctaaga 21840
cttacttttt aaaactgaca cagttagtca cataaagtgc acttgatgtc ttcgctggta 21900
taggtttttg ttgttgttgt tgttgtttta ttttgttttt atctttttta ttagatattt 21960
tctttattta cattttaaat gctatcccga aagtcccta taaccctgc gccctaccc 22020
accactccc acttcttggc cctggcattc ccctgtactg gggcatataa agtttgcaag 22080
accaaagggc ctctcttccc aatgatggac tactaggcca tcttctgcta catatgcagc 22140
tagagacacg agttctgggg atactgatta gttcatattg ttgttccacc tatagggttg 22200
cagaccctt cagctccttg ggtactttct ctagctcctc cattgggggc cctgtgttcc 22260
atccaatagt taactgtgag catccacttc tgtatttgcc aggcactggc ctagcctcac 22320
acgagacagc tatatcaggg ttctttcagc aaaatcttgc tggcatgtgc aatagaatgc 22380
ccagtgtctt ggacaatttg ggtagaactt tttagttcac actcagtttg aatgtcagaa 22440

tcattcaatg actcacctgt ctctgactgt tcgctgtcac agcatgggtgc acaagcctgc 22500
acaagcatac tttatcttaa ccttagcttt tctctactta cttcccctgt gatagcggag 22560
gcttctttcc acccaagggc tcgcagcttt taagaatctc agccggaatg taagcaacag 22620
ttccctgcct ctaattctga attctctctt gtgttaatot caagtgtatt caaacagctg 22680
atgagcagct gtctcaatgg cctgattct atgtgagtcc ctagtaccaa ataactagcc 22740
tgagaaacag ctgttaagga actgtaaatg cagctgactt cagggctctc catgccttcc 22800
tttcaggccc tgccttcccc ccagcctggg ttttcattgc ccactgccgc cagcacatcc 22860
tgccagtgga aaactctcat ccgcatctag cttgccagca ccagcacctg tgccctgccca 22920
gagtcactcc tgtcactctg tgtgtctgtc tgtctgagtg tgtacatggt catatgtgtg 22980
caciaatgtg tgtgtttgta tatgttcata taagatgtac atgcttgtgc acagatgtgt 23040
gtttatatgt atgtcatgta gaaggccgag gctgggtgtca tctttcattg tttcccacct 23100
cttgatgttt aagatagagt ctctcactga acctggagcc ttgccaatt ggctagacta 23160
gctggccaag caagctggaa ggatactcct gtctacctcc ctagcactga ggttccatgc 23220
gcttctcatg cagtgtttcc atgggttctt ggcatacaatt tcaggtcatc atgtttgcac 23280
agcatgccac tgactgaagc atcttgcagg cccctacttt aaccttcttt cctaaccaca 23340
gttaccatga ctttgcattc tcttcacctg taaaccctct tctcaactga aacaggctag 23400
taaataaagc aaagagagga agaattatcc cacctgtggt tatcaatcat cacatcacta 23460
tggcaaacac atgagagaaa caacttaaag gaggaggggt tactgtaccc cccacatcat 23520
agagggctca gtccgcggtg gctgaatat gctgctatcg gcccgaggag ggcagaaaat 23580
agtgggtggca ataacatgta caactctggc tactcagttg atactgtcaa ggaaaaagag 23640

agctagtcac ggggaggggc ttggaaggag ataacactat ccaaattcac accctcagtg 23700
tcctgcttcc tccagccagc ccaccttctg tttttotacca ctcccaatag tgccatcaaa 23760
ttgtgattcc atcaatgatt aatccagtga ttgggtcact gagaaattat tgggtccacc 23820
agctgagaac gtacagcatg tacactcaat aaacagaagt ttgtatttta ggcagaagta 23880
ccatataggc tcctgacaat cttcagattc taataaact ggccatagat gggaggtttc 23940
taagaactgg tcttgctgaa gtgttacatt tttatcttat aagatacttg tgtcttagct 24000
tagtgaatct ggctgccaga taccttactt tgactaaagc atagtttcgg gaacgattaa 24060
tctttttttt tttttttttt taccctccat ttcagaattg ctcatgaatg gaccocaggaa 24120
tgaaagaat gccctgatta tgtctctgct ggaaaaaaca gctgttactt caactcatca 24180
tatactcca tttggatacc ctactgcatc aagctaacta caaatggtga tttgctggac 24240
caaaaatggt tcaactgtga cgaaataggt aagccgtggg ttgctttcat ttgacaaagc 24300
tttagactaa atattaagga agccccaatt tccaagtata atcaagtaga aagactttgt 24360
ggtttttaggt atatggagtc tgtctcacag gagtctaaaa gaatagagtc taaaaataca 24420
ggtaacttga ttccagctta aagaagcctg acaatggaac tagagaaatg cccagtgcac 24480
aagagcattg actgctctcc ggaggacca ggattgtttc ccacccccta catagtagct 24540
aacaacaatc ttgaatctag ggtatctgat accttcttgt ggctccaaac acaaacacat 24600
agtacacaga catgcatgca gacaaaacac ccatgcaaat aaaatacaca aatttttaag 24660
ttgaaaaagt agatacctgg tagtagatgc tatgaagaaa ttcatcaggg gctaagagat 24720
ggctctaaag ttaagagcac ttgctgcttt tccaggggac ctgtcatcca tgtgggtggct 24780
cacaaccacc tgtgtaactc tagtttcatg aaccttcaaa cctctgtgat atcaggata 24840

cacatgggtgc acacacataa aagcaggcca tacaatagaa tctaagccta gatttctcatg 24900
atcacaaaac aaaacaacca tggccacaaa acaaaattta ccaaacagtc ataatcaggt 24960
caaagttgtg tttatatgac ctcaaacaaa cattgatgaa tatttgctcg ggaaaacatg 25020
tcagagagcc atgtggatga tttttttgct tcccatcctg tgaacataaa gaggaactga 25080
aacaagtaac cataactagg atgtccgtgt ttacagtatg attatacaaa cagcaaaggg 25140
aaagaaagca acaaggggtt ttcagtagct gaccaggggtg ctttaagatc tatccacaag 25200
atcccatttt tcctcacgtg aactgtccct tctggcagac aagtgttatt tcttgggcag 25260
caacagcctg gaagacagtg gggaatgtgg ctgactgctg cagacagata gcaagcaaac 25320
catggaagtg tgctttccag agagagggtc gagaaaactc atgggttcta gaggctactt 25380
atattattggc ctctcccaa ctgcagagct gaagctagac aaggaagtgg tggattagtt 25440
gtaaggacac tggtttaaga gccatgcttt gtcctgcct ctatctgact ctactgagc 25500
tcttgcatac ctgcgactat actgtatgat acagtogagt agtggaaattt ggagttcaa 25560
aaaaaatctc agtacagtgt accataacac agtatgggtg gtcctggact tgaggtgttt 25620
ggatacataa aaaaacaaag tagtgaccaa atgcatgaat gacctgctat gcctgtagga 25680
ttaagaggag ccagatgaac caaactgtaa cagttcagtt aactcataaa atgtgaatga 25740
tatttaccaa gagtcacaga ccttccagaa actactcagt tctaattattg gtaaaagaaa 25800
aaaaaaaaag aaaagaaag aaaggaaagg aaaggaaagg aaaggaaaag aaaagaaaag 25860
aaaagaaaag aaaagaaaag gaaaggaaag gagaggaaag gaaagaaaag aaaaagaaa 25920
gaaaagagaa aagaaaannn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 25980
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnatt 26040

gtcaggatat caccagttca gctcacatgg atcaatagcg gtagttcaat ccactcacia 26100
acccattca gaaaccagct atggcagttc tatgcagaag aaacccccag gctctgccac 26160
tcggcccaag tcctagctgc agaagcagga agaagccacc agaaccaccac cagaagtact 26220
ttggtgcatt tttctctatg aagtcatgac aaacaatgac cagcaaagaa tggcaaggag 26280
aaccaatgcc atatagtgc gaccactgtc tgggtggacc tttccaaata gaatatgttc 26340
tctcaagcat acactetaac aaaacatcac atgccctttt tctaggctgc ttccagaaaa 26400
acatcctatg tccgttctta gcaacacatc cttccacatg tctcattcag taaaaacaca 26460
ctctcataac atagtttcca gaaaaacatc atatgacaca actgagtctc caaagaaacc 26520
agaaatttcc acttcaaaga catgtagtgt gtaggagtca ggagcagact gctatatattt 26580
tgatagaggg tctgagcctc ctctataaa tgctatgtat cacatctatt taaagtagaa 26640
atggaaattt ctataaataa acatgagtga tgaatttcag aaaattttcc atcaaaaaca 26700
tttttaaagc cccaggtata ttgagataac tgtaatcca gcaactgtgga ggctgaattg 26760
ggatcatcaa cttaaggcta cataatgaaa tccttttctca aaaatgtata tatactatac 26820
atgtgtatat agataggcag atgtggactg gagaggtggg ccagctattg agagtatttt 26880
ctactgtata actccacttt agaggatttc caataccctc ttctggcctc tgaaggcatt 26940
cattcaggtg gtatatatgt gtacatacag ataaacactc atacacatta aataaaaaac 27000
ttaaaagtat gaggaaagag atgttcatgg ggtagaaaa ggaatcataa aggaacagga 27060
gagtatctta tgggaggagg acaaaaagga gacagtggaa caggaaagca gaagtagaga 27120
ttatggtcat ggaggaaggg aactagcaaa tggaagactc taggaagtga agtaacctaa 27180
tgaaggtgca agatgaataa aaacaatgta tattaatata tacatgtgaa aatatcataa 27240

tgaatgcccc actttctatg ctcaactttaa aaagctaatt gaaatgcaca tacacattca 27300
aaactagtcc cttaaaaagt taagctttct atgggtgttt tgttcccatt tctaagaaag 27360
ggtaaagtgt ccacactttg gtggtcttcg ttcttcttga atttcatgcg tttggcaagt 27420
tgtatcttat atcttgggta tcctaagttt ctgggctatt gtccacttat cagtgagtac 27480
atattgtgcg agttcctttg tgattgggtt acttcattca ggatgatacc ctccaggctc 27540
atccatttgc ctaggaattt cataaattca ttttttaata gctgagtagt attccattgt 27600
gtaaagtac cacattttct gtatccattc ctctgttgag gggcatctgg gttctttcca 27660
gcttctggct attataaaca aggctgctat gaacatagtg gagcatgtgt tcttcttacc 27720
ggttgggaca tcttctggat atatggccag gagaggtatt tcgggatcct ctggtagtac 27780
tatgtccaat tttctgagga accgccagac tgatttccag agtggttgta caagcttgca 27840
atcccaccaa caatggagga gtgttcccct ttctccacat cctcgccaac atctgctgtc 27900
acctgagttt ttgatcttag ccattctgac tggagtgaag tggaatctca gggttgtttt 27960
gatttgcatt tccctgatga ttaaggatgt tgaacatttt tttcaggtgc ttctctgccc 28020
ttcggtatcc ctcaagtgag aattctttgt ccagctctga gccccatttt ttaatgggggt 28080
tatttgattt tctggagtcc accttcttga gttctttata tatattggat attagtcccc 28140
tatccgattg ggataggtaa agatcctttc ccaatctggt ggtggtcttt tgtottattg 28200
acgggtgtctt ttgccttgca gaagctttag agtttcatga ggtcccattg tcaattctcg 28260
atcttacagc acaagccatg ctgttctggt caggaatttt ttcccctgtg cccatatctt 28320
caaggctttt ccctactttc tcctctataa gtttcaggtc tcggttttat gtggagttcc 28380
ttaatccact tagattgacc ttagtacaag gagatagaaa tggatcaatt cgcattcttc 28440

tacatgataa cgcagttg tgccagcacc attggtgaaa atgctgtctt tttccactg 28500
gatggtttta gctcccttgt caaagatcaa gtgaccattt ggagctgtga cgaaaggatg 28560
gaccatctag tgactgcat atgcagggat ccaccccata atcagcatcc aaacgctgac 28620
accattgcat aactagcaa gatttcgctg aaaggacca gttatagctc tctcttgtga 28680
gactatgccg gggcctagca aacacagaag tggatgatca cagtcagcta ttggatgggt 28740
cacaaggccc ctaatggagg agctagagaa attacccaag gagctatagg gaactgcaac 28800
cctataggtg gaacaacaat atgaactaac cagtaccogg gagctcttgt ctttagctgc 28860
atatgtatca aaagatggcc tagtcggcca tcaactgcaa gagaggtcca ttggacttgc 28920
aaactttata tgccccagt acaggggaac gccagggcca aaaaggggga gtgggtgggt 28980
aggggattgg ggaggtgggt atgggggacc tttgggatag cattgaaaat gtaaagagg 29040
aaaataccta attaaaaaaaa aaagttaagc ttatggttat tcctcaattc ctaacaaatc 29100
caggacaaag taatactgct attgtatagg actatgaagc tcgaatatcc ttcacattta 29160
atctctaaaa tgtattcatg aatagatgta gttaatatct ttaaagagg aaaatctttc 29220
ttatctctta aatgggggta gggggagggtg tatgtaacag tggccgaaac atacccttcc 29280
attataggtc tgtgtctact ctgagtcaat gcctctctgg tgaattctag ggatccaaac 29340
tttctaagta gctatgtgca tatgttaaga aataaattaa gttttaattc tgtaccttca 29400
agtagtttca aaaggcttgg taataagccc tatctagtaa cactttgctt gagacatggc 29460
aaaatttaga tataaattgt agctttggga tctataattg actttatcat ctttcttgaa 29520
accctagtct ttatggccct cataagaata cagagatata tctaagaata tgatagagga 29580
ttactagcag aaactgagca aaatgcaatt tcgaattgct cacttgacag ctgagcagag 29640

agagtaagca ctaaattctc tgcttcctgt aacaggccat atttaaaaag tgaagtcttt 29700
ctaactctct acttctttgg tttttgattt gtgtgtgtgt gtgtgtgtgt gtgtctgtgt 29760
gtctgtcaaa atcctaaagt acaaatgcta tcagagctaa aaataaatac gtagcacaac 29820
aactcttcca atgaatttca gatttgagac taaaagggaa ttagaggaga ttttataagt 29880
atTTTTTTaa atgaaacatc attcttacat ttaaaaatgt tgctctgtta taaagtagag 29940
ttcaatcgat gtggattgtc ggaagaatta ggagtgtggt cagagtgtgg tcaaaatgaa 30000
tgaaatgatt tggctctctga aggaagcaga ctatcactat caagagtgtt tctctggagt 30060
ctaatcaatt ctccattgaa ttcacagtgc aacctgatcc acccattggc ctcaactgga 30120
ctttactaaa cattagtttg accgggattc gtggagacat ccaagtgagt tggcaaccac 30180
cacccaatgc agatgttctg aagggatgga taattctgga gtatgaaatt cagtacaaaag 30240
aagtaaataga atcaaaatgg aaagtggtaa gagtcactcc attctataca ttgacttttc 30300
ttctttctaa ttcaatactc actttcttat ttgtaataac actttctttt cacctaggac 30360
tatatttcca aattatgtgc cctataactt gttattagag gaagactgat ataatctcaa 30420
taccttaaaa gtatctaaga caacaaatgc tgatgtgaat cttccatgta gatatatgga 30480
agagtattgg gaggagaaaa ccatttcctt agttatcttt ggtgttcagt ttaacctagg 30540
aacaagggtca cagacttacc actttgctat cttagagat gtggttgaac ttaactagga 30600
tcatgatcaa ggtcaagagt aggctatggc caaatgttat cccatgactt taatgactgc 30660
tactcataag acctatatta gtatttgttc ttggttctct ccagaagaga ggcacaaaaga 30720
aggaatttaa tctatagagg tttcataaag atgttctttt acatacctca gagaaaatca 30780
agctgagagg ccacttcata agggagaaga gagcaaatg gcccgcaaac ctctcacttc 30840

cctgccaaagc acttgggaaac tcggcactga gataaattct acatggcaca caacaagaag 30900
ggaaacagga ttaccatgcc attccaaata taactaattc taaatcagtc taaccacagc 30960
cacagccctg gccaaagtcaa gcagcttctc gatagggcatg acgttgtacc cagcacccctg 31020
gcagggctca ctccccaaat tttgagacat gaggccctgt ctattcagtg tagcaccaaa 31080
aatgaagcca attttgtcat tagcagagaa tacaacttgg ggtgcctcga acagctactt 31140
cttctgttca aagttctggt ttctaaatca ttctaattta gatatctggt ttatgacttg 31200
gtacccaaaag gggcctggct ggatgttaat tcaaacaagg ctttctaaac cgagtcataa 31260
tcaaacactt attcgcccac caaatatagg aacaactact ttgcacaagg taccaagggc 31320
acctgaggta gcagttttga aaatgagaaa catgtacctc tgaggactct tgagaccatc 31380
tcaagggagc atatgaggtc aacactaatt tcacactaat aacatgtttg ttccttagtt 31440
caaaaacagt ggtaagaaaa ctactgcctc gtggcatgaa tcaagtcagc aatcccattg 31500
tttacagtta cattgtgaag ctcacattaa aggctggggc tgtttcctag gagcctctgc 31560
ttaaattctca gccttggagt gtattgctgt cccagctcct gtggcacatg gagagtacac 31620
actgtactca tctacattcc aaggtaatga aggatcaaaa cacttaaattg cttcagcaac 31680
cagaccagca gctcttttgt atgaagcaca aattttatac gaaggacaaa acacatacta 31740
gtagataatc acttatatth gaattgacaa agatttctca aggaaacatt tgttcttcca 31800
gtgaacatct gacaaggtht gcaccagga tgtaacctc caggcagaat agagthttta 31860
acaatgtata tctacaacca taatthgcct tccaacgtag taagacttac cccaaaagga 31920
tccattgtga tattagcaaa aatggtggtt ttatgttaga taataaaatc tgtgaagact 31980
tctgatgctt acatctcagt aaactagatt aaatathttt tcaaatagcc tgagagtaat 32040

tacactaatc acataatcat atattatgta aaattatcat taattatcat gttaatgatg 32100
ttttgaaata tttatatgtg gtaagatggg tcagcagagc tatgaatgga tatatTTTTc 32160
acagatgttt ttgaactgac agtttcaaat ctgctctctt gtatattcca aaatatccct 32220
TTTTTTTTct acccatttgt tcatcaaagg gcccaagttg atccatattt tggctacagt 32280
tatcatgatc aggcaaagt atctttaaca tattaatctt atttccttgg gatataaatt 32340
attaataaaa aatcactgg atcatatggg aactttagtt ttcattattg agtagcctct 32400
atactctttt cagttgttac tgtgccaatt tttatttcaa taaacaagtt agaaaagcca 32460
tcaacaatct caccctgcta tgaattcttc aagatactgg tcaggaaaca agccctga 32520
ttgtagtatg aatactacag gaattactac ctactttcta gttagtttta aagccttcca 32580
cacaagatgg aaccataacc tgacatcatt aactgggcca aaacaacatg gctggctagg 32640
ttataagccc tataggagaa atcaatagat agacatagta gttaattgcc tcccccaagt 32700
tattaacact ctactcataa attaatacac ctctgaccc tcattggaga agcttctctt 32760
ttcaacagag agtagttaat acagagaacc tcattcagtc agtatgcaga gcactcaaca 32820
ctgaatggaa tatccatata ctaccactc cccccaagat taaaaggtta ttgaggaaga 32880
aatattagaa gtgtctaaag gcctcaatgg ctatagagaa actatttact ggccacagac 32940
atgcagttac acacacagtt gctggaagtg catgagtaga aggtttacac aagatcatgg 33000
cagccaaatc ccagcatggt tctgggagag ccttaggacg ctctccctg cctgagaagc 33060
tcttgacatt gtcagagcta ctgggaagct gggagagact ggatttcttc agggatgtga 33120
gacctgagag gcattccatg ctccagcagg tggccccaca cctatgcaca taaaagcagt 33180
aaactgag tattttaaaa gagagagaga gagagaaaga gagcagagcc agaacttgtg 33240

tcctactct aagttgggga agaaaagtac tggataatta aggaaaagaa tgggaggtgg 33300
gaggtggatt tgatcaaaca tagacattta tgaatactaa atataatddd tctcatttta 33360
tattagttgg ccattaaaag ccaagtttac aattaaataa aatattttaa aaatatcttt 33420
tctgtcaatc cttttcagta tgtttctagt ttcacctgtt tctgctctga cacttgccac 33480
cccctccctt gcttcagtct ctttgagat ctgttttgac ttttactagt tcctagaggt 33540
atagtgattg gtccttgtct ggtgcagtta aaggttccct cagaaaactg aaagatagta 33600
gagaaagaca gagatgggag gggcataggt ttgacttccg gggttcccta tggattatgt 33660
acaatgtag tgaaatcttt cactaatacc gatgacagtg gctgagaaac caagtcttgc 33720
tccaagcgtg aaacccaagt ttaaaaatga ctcaataaaa aacaagaaag tgtaaaattc 33780
agagtcctag tctaaagaaa acattttaaa catacaaatc ctggatatac tcagaggctc 33840
ctgtcaggag gcacaccct atcatatgag catggcgggg aaaaaatact tgtgcataga 33900
aaccaagtgg agtgaaaaac aatttgtttc agatgttgag gtccagctcc taataaaaca 33960
aataatgggg tttatcgatg tgaaaatcta tgctgctgaa aaggatgaaga ttccactttg 34020
ttcttattaa caggaactag gagtcctact cataacatac aaaaaacata ttgagacca 34080
cgagcatgag tgtttgacac agagcagtga ttttcaatgt tcctaatgct gcacagctcc 34140
tcatgtgtgg tgacccccaa agatagaatt actttgttgc tattccatga gtgtaatggt 34200
gctactgctt tgacttgtaa tgtaaatac actgacttac tggaaaggac tgtgataatg 34260
cagacctgg gtctgcctct ctaatagcaa tatcttatag agctaactct cctacgctca 34320
cttctttgt ctggagaaag ggactatcct aagtttcaaa tctgtgaaac acagatgttc 34380
agtgtcagg gtctccagtg attttctgtc atgtgcattt tcctggggag atgtgacct 34440

ctagtccctc tagacagagt accaacaaca gatcaaccaa actgtcccac ccacttctag 34500
gttacagaac cagtgaggtg atccactgtc gaaaggagaa cacatgaggt ttacttacag 34560
gtgggctgcg agtgactcac tcgcagccca caagcaggag gatgagcaaa ggnnnnnnnn 34620
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 34680
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnatccgtgt ctgcgattga tcacactcca 34740
gcccaccaag caggcaggat gactcacaaa ggttaccttc ctggtgctgc ctacagagtt 34800
cacaggaaga tcagctgadc agacagcctc ctctcctcag caacagttct gtacttgacc 34860
ttgtggaagg cccttgtagg tttattcagg tttctgaaac ctccagcctt ctgagctata 34920
ctgacttctt aagtctgaag attcttccag aaaagtgttt ctgttctgag gacatagcta 34980
cctcacaatt ttctatggac attcttgagc aacagactac tctgaggcaa gtttaagact 35040
tccggagtaa ataaagtgtg tagctgcttt caataaaagt ctttggcagt tcaagacaac 35100
tatggatatt tgaggactgt ttcaaattct gtgattatca ataaatgact tctgcccaga 35160
tttcccaggg aatacatatg ctacagataa atgatttgct tgtggccata atttgttttg 35220
gtgtggaaat atgaggtttc ctgtcctact atatcactcc atacaaaact ataatacccc 35280
agataaatag cataccaata tacctcttac agatctgccca tgccctaattc tattacgact 35340
tactcttagt tgactattta agaccaaatg caaacatatg gotgcatttt tgatactaaa 35400
ataaatttga ggattattat ttaacaaaa ttatttacat aatttgtctc agtccatctt 35460
atttaatagc caattccttc taggtaggtt caaatattac tcactttcta gaaaccaggt 35520
tcaaagagaa aaggaaaaac actttagtaa tctgtgcatt gagttgttaa tgccctgaggc 35580
aatctgtttt ttattttggt ttgaaagatg ggcctatat ggtaacata ctgtccagtg 35640

tactcattga gaatggataa agaacatgaa gtgcgggtga gatccagaca acggagcttt 35700
gaaaagtaca gcgagttcag cgaagtcctc cgtgtaatat ttcctcagac gaacatattg 35760
gaagcatgtg aagaaggtag tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 35820
tgtgtgctgt cgtgctgtgc cgcgcgcgca tctaaatgac agctagcatg acttttggca 35880
atatatgcta acatatgcct ccacttgta gtatattgtc taggtcaata tactgtagtt 35940
tcacatatca ggggcaagac attgaagtca ctatctggag aagatgtatg caatgaaaag 36000
gaaacaaaa gaggggctgg agatatggct cagtgggtaa gagcacttcc tgttcttcta 36060
caggaaccaa gtccaattct cagcaccac atcaagagat tgacaaccac ctgtatcacc 36120
agcttcagag gatccgccat ccctagcctt gtgggcacct gcattcatat gcacatacat 36180
gcatacgcat aattcaaaat aataaaataa aattttaaaa attaacaaca gaatttgttt 36240
ccaaattatt tgatttagga aaggtatcag ggcaggtgga aactcagaga gggatatacga 36300
tggttgtccc tgaacaacag aatttctggg gagttgggtt tttttttct ttgtatgtct 36360
ctacattccc aatttttttc ttcaatgtgg gtgttttgaa tttttatcca gaagaaacaa 36420
atztatctga ggtttgaaga aggaaatgtg atactcatgg gattggagga gtacaggtgt 36480
gggttttact tagagaatgc ctagctggaa gtataggaag tcatgtgttg gtcacattct 36540
ggggacacgg gacacacttg gaactcctac acaggagaac aacagagatg atgcagggtt 36600
tctccgtgtc tgtatataaa agtagttaga ctctgcctct gtggttaagaa tattgggaaa 36660
cgacctcaag ggaactgggg ggacatttag tcctaaggaa aaagatagaa gtgtcataga 36720
caaattctcc cacagctcat aaagtacaga agtatctgaa cagcctcagc acagtgtaca 36780
caaacacaca gtattaaact ataaaaacgt gctctacatg cctaggtata gcacgggtgac 36840

tctagcctca taactttgat atatoctcaa tgtggaaact gacagatatac attatgtcctt 36900
aaagtattag atggacatcc tttacttagg ttttaacaaac aacagttttt ttgttttttt 36960
tttttttttc tgggtgctaaa gccctgggtga tattccacag acatttggac atatgagaag 37020
cttagagggtt tcaggttttt gcaatgtggtt tgaaaacttgc gcttttcatt ttgagttttt 37080
ctttttataa taattttact ttttaaatta taatataatt acattgtctc cccttcagtt 37140
ttcttccttc aacccccacc atgtaccgtc acgaccatag gatggccatc acctcacttt 37200
ctcttaaatt tttggcgtct tattctttaa ctgtttatat atatatataa aacatatatt 37260
tatatatatt aaatatgtta tatatgtata tttacacata taaaatatat gtatacacat 37320
gtgcttaaca tgtatataca tataggtaga tgtatacata tatacacgta tatatatata 37380
tgtatatata tatatatatg tgtgtgtgtg tttacatata tgtatttaaa aacagttaaa 37440
gaaaaagaga ccaaaaattt gagggaaagt gaggaagtga tcatcatcat atatatgtat 37500
atatgtgtga catatatatg cttaaatacta tatctacata tatagataga tagatataga 37560
ttaaagcagt ggacaagcat gctgtatgct taggaaagaa aaatccgaag ccatcctact 37620
gtgtttccat ggttatgaag ttgaaaacttt gccatatgaa ttcagattaa tggatatttt 37680
caagtgggga aggacagtgc cttgtaaact ttgcttgggt tattcatagt tctgtcagtg 37740
aaatattcctt tcctgtttta gatatccagt ttccatgggt cttaattatt atctttggaa 37800
tatttggagt agcagtgatg ctattttagt ttatattttc aaagcagcaa aggtagggtgt 37860
gaagcactct ctttaatatg tttttacaag ttctcatttc catgtgtact ctcgtgtgtt 37920
atgtgaaatg ttctcttgta cagcacaagt ggctatctta attaactcag aaaagtttaa 37980
tttctgggtt tacctttacc acatctgtac tcagtctggt gtctgtcgtg tttacctttt 38040

tttaaaaaat ggatgattta aatcaggaag tttaggcaca tcctgtcata ctaaggcatc 38100
atrtcacgga catttttgtc agtcttgttt ggttctatcc tagcctctct gagtctgtgg 38160
atrttaacat gattatcctt tactttatat taatatccac tcataagtga gttcatacta 38220
cgtttgtctt tctgggtgtg ggttacctca ctcaggatga tgtttttcta gttccatcca 38280
ttgcctgaa attttcatga tgcattgtt tttagcagct gagcaatata ctccattgta 38340
tgaatgtacc acattttctt tattaattct tctgtggaag gagccttcaa agtctaaaaa 38400
aaaaaatta tattgtattc tcttgagtc tagagtctac agctattcag ccaactgccat 38460
ttgaacttcc ttgtaccacc taacctctct gaaaatctac atctgtgtgc tcaacaggat 38520
cttctaaatc actttgaata acaaaatgcc atttttcctc ttggaaaaaa acttagattg 38580
cagaaaatgt tttatgcagc atgctgcggg gggcgggggg cgtgggacat tgctatcatt 38640
tggcctttgt ttgcacttaa catagtttca acaccatttg tgatcatgag ctttctagga 38700
ataccacttt caagattcca gaattcagtt ggtctttgca ctataagccc tgtgtgtcct 38760
gggaagtcc tcagttctgg gccaccaata gttggttggc ctatctaaac ttgaaatcaa 38820
gctgttcaac tgaagtcaag aggcacttag tgactcaaaa tggaatgtag gaacaaatat 38880
atggtatagg cttttagttg ttgtagtaat ccagcattca cacatctcaa aattagccat 38940
tttaataaaa atgtgcagaa gaaattcagg taatgccatc aaccttcaac tgaataaact 39000
tcattttcat cagggtttca ccatcaatat cataaataaa tgagggggaa aaaactogct 39060
gcataatfff attttgaact tagcttttta gccacattct tgtttttgca gaacatatac 39120
tacagttgaa acaacagggg tttcagttgt ttgaggaaag taaatttatc ttttagagttt 39180
taagtaagac atgagcttga ataaggccaa ccagagtcaa attaattgat tttagttoat 39240

tagtctatag agctagtgaa attgcaaatt ttatatggaa ctgtagtaaa taaaattgct 39300
ttgtacataa aactattcac cctaataccg ttcatttcat gtcacaaagg cgggaccgag 39360
tgatgatctc nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 39420
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn agtaatgagc 39480
cggaccata gcagcataga gtggatagca tagtcagaca gctggcttgg agcatcactc 39540
tgggcctgaa ggcagcccac caagggtctg tataatggag agcacagata atatcatctc 39600
cctttcctgg tgtgtaagga ttgatgaaag ttaaatgcaa gagccgatca tctgatctat 39660
aaataatcat gtggtgaggt tttagggacc atatctgtat cacaactggt ccaatgacgt 39720
atagaagcat tcagagataa tgtgttgggt ttaaggataa aacttggtta gctagtaaca 39780
gaaagatggt ttatgtaaat ttattcaaga aatgttatgg aacaacttcc atgtgctaag 39840
taatataatt ccaacaagag acaaatctgt agaataaaca ttgaaattaa ctacagtcaa 39900
aaacaattat ttcagggctg aaagcagtag ttcagcaagt gagagtgtat agcgctcttg 39960
tagaggagtc aagttcaatt cccagcacct atatggggty gctcacatct gctgtaacct 40020
tagctcgtct gccctcccta ggtacctact cattcatggg atataatcac agaaggacac 40080
ataaaataaa aataaaatga taaatcttga gggcgggttac atggaagagg ctttatttag 40140
agagggcaac tgggagtggc tataggaaag aaaggagata attcaatttc agttaaaaat 40200
attagtaata gatTTTTTaa agaaaaaata atttcaatat ttgaaagaga aatgtcaat 40260
acatcttggc attatgcata caattctacc cttattagag atgattcagg ttagtctgtc 40320
ctattttaag taatacaggc actatcatgt tggctagaag ttatcatcaa tgctttttgg 40380
ttactatgga ctgtgtagtg cttagcccag tgtagtgtt agcccaacct atttttttca 40440

agtttgaaaa taattttggg tccatTTTTat tgattgtcctt gttttctatt tgggtgttaca 40500
tgcttttaaaa gtatcttatt tgtatcttat ttataagtta catgaaagct ggcttttagac 40560
agaatttagac tcctcactgc caagtactaa aattgaccac tcatcaatag cactaaaaaa 40620
aaaaaaagag ttaaaccatg acttagctaa atgatcttaa acgaaggcct ttgggtgatg 40680
tttttctcct gaaacttttg ccacctactt cctgcttaga actctccctc tcttttgaat 40740
attctgctta tacaagatat aagaatgcct agaataagtg atagtactgg caatatttca 40800
ttctaccttt ttgagataat ttttaagatg taaaataaag atgtagaaat aacactttat 40860
ttgtttccaa ggattaagat gctgatttta cccccagtcc cagttccaaa gattaaaggg 40920
attgatccag atcttctcaa ggtaactaag tctacattgt ggatcattca attaagtagt 40980
acctaaagaa tactatctat cttctgttgg gaggggtggg ggtggttggg tggttggttg 41040
ggtttgttgg tgactttggg ttttttgggt tttggagtgt tttgattttt ttgtgtttgg 41100
ttagttgggt tggtttagtt tgaaatcaca atgcatccta tctaaagtta tataatgggt 41160
ttttgagttg cttttcatag atctccactt tctctctgcc tcctaggaag ggaagttgga 41220
ggaggtgaac accatcttag gcattcatga taactacaaa cccgacttct acaatgatga 41280
ttcctgggtc gagttcattg agctagatat tgatgaagca gatgtggatg agaagactga 41340
agggtctgac acagacagac ttctaagcaa tgatcatgag aaatcagctg gtatccttgg 41400
agcaaaggat gatgattctg ggcgtaccag ctgttacgac cctgacattt tggatactga 41460
ttccatacc agtgacatgt gtgatggtac cttgaagttt gctcagtcac agaagttaaa 41520
tatggaagct gatctcttgt gccttgatca gaagaatctg aagaacttgc cttatgatgc 41580
ttcccttggc tctctgcatc cctccattac ccagacagta gaagaaaaca agccacagcc 41640

acttttgagc agcgaactg aggcaacca ccaactcgcc tctacaccga tgagtaatcc 41700
cacatcactg gcaaacattg acttttatgc ccaagtaagc gacattacac cagcaggtgg 41760
tgtagtcctt tccccaggcc aaaagattaa ggcagggata gcccaaggca ataccagcg 41820
ggaggtggcc acgccctgcc aagaaaatta cagcatgaac agtgcctact tttgtgagtc 41880
agatgccaaa aaatgcatcg ctgtggcccc tcgcatggaa gccacgtctt gtataaaacc 41940
aagctttaac caagaggaca tttacatcac cacagaaagc cttaccacta ctgcccagat 42000
gtctgagaca gcagatattg ctccagatgc tgagatgtct gtcccagact acaccacggt 42060
tcacaccgtg cagtctcaa ggggccttat actcaacgca actgctttgc ctttgctga 42120
caaaaagaat tttcctcct cgtgtgggta tgtgagcaca gaccaactga acaaaatcat 42180
gcagtagcct ttcctatctt taatggcaag ggaaaggctg ggcacaaacg cttaaaccaa 42240
aactatgttt taaatctgtg ttgggagagc atgagagtgg atatggattc taaaatactt 42300
tttctggaaa tgtcaaaata tcataaagtg gaaaatcaag aattcgtaat cagataaatg 42360
ctcccattgt gaattataaa tattttaatg aattgtcttt aagactgtat agtggcagtg 42420
attgtctgta ctgtgggtct taattttgtg atactaagca ttaaatagct acgtttttta 42480
tgtatgtaga tcatgctttt tgaaaaagca aacaatcagg tggcttttgc agttcaggaa 42540
attgaatgca gattatagca caggctgatt tttttttct tttttaaata actgggaact 42600
aaaactctag gtgagaaggc aaaactagtt tggatagca aacatttat tttgacatga 42660
aattgataaa gatattttta ataatttaca cttaagcat gagtacttta taatatgcta 42720
cacacatatt gtagttcaga acaatccatc taaggatgta gcagctacag tgtaaagagg 42780
gtttcatggt ttgggtcaatg aacgtaaaga aaaccaaca agtttagattt ttacaaagcc 42840

cttttataac ttccaaaact tcttaactct aaaaatgtct aataacctgc attattagaa 42900
aaaaacattt taaatttgta aacgaatatt tttttaattt tgaaaacttt attttttttt 42960
aatggtgaat caacgtatca tacaccaaac agtaaacaga aattataata atggaagaag 43020
tgctttcttc gacaaaattc cattcaagcc acacagctac atgtaagaga agtagaagtg 43080
atgtggtgtg attggctagg atgcagaaga gcttcaggaa tacaagaagt gagagcccaa 43140
ggattgggag gagggggctc tcacatctcc acagtgcagt ctgtcaaacc cagcttggtt 43200
tttatagtat tctaagaatt attgtgtaca aggaaaagtc tcacatgtat gaaatccagt 43260
atccagatgg ggtaaagtta gcagataata ggataggaaa ttaaagacct agatcttttt 43320
tcacagacag acacaaattt ttaattcagg gagaaggagc agaataaatg acttcccact 43380
caciaagcac aactcagaag taattaaaca ggtaacagaa accttgccat caaacctttg 43440
ataagatgta ttttaagtag taagcagtat ttcaatgctt cttacttacc ctcccaggac 43500
aaccgatctc aaataagga gataaggtag ataaaaatca ctttttgatt ctgtaataac 43560
ataaacatag ttctttgggt tagcaccccc cccaaaaaaa atttatggga gaaagaggac 43620
tctcagctga ctgaagaata catctcattt aaatattttt tagatgcctg aaactttaaa 43680
attaccttta agttttaatg gtatttacca ttttgccaag acctttgtgg ggaaacaagc 43740
ttaatgttta gtgattttga aatctctttc atgcaggaga gacagtgaaa atctagcctt 43800
gggtgtttta ggttcgctt gttactttgt aatagatttt aataagtttt tctgctactt 43860
tgctgctatg gtttctcaa tggctacatg atttagttca tatgaagtat catcaactta 43920
gaatctattc agcttaaaga tgtgtgtttt gatgaactat cttaccattt caccataggc 43980
tgaccacgtt tctatagcca aaaatagcta aataacctca tcagttccag aatgtcattt 44040

tttgggtactt tgctggccac acaagccggt attcaccggt taactagttg tgttctgcag 44100
tctatattta actttcttta tgtctgtgga tttttccctt caaagttaa taaatttatt 44160
ttcttggatt tctgatctta tgtttctaata agccttgaag cacaattacc tagacatgta 44220
ctgagactaa ctgtaaagga cgtagatgag ttcatttaaa tgcacagtg aatagtggat 44280
cgtggatcac aaagcggcag aggagcaggg tgtgggtaag atagtctttt tcttttatgg 44340
actctgcctt ctctttagga taacactcat gtggacagag acttacagat gctttgaaca 44400
catcctaaaa gttaaagtgt gtgtccaagt tgatggggaa ttgtgggaaa tggaaagagg 44460
agcgttgtct ctaaactaca tttctagctt gagtgtgtta tctgccattg ggaagagtgg 44520
ttctccctgg gcttatgtat tgacagagtt cttcattctg atgactcgtc atcataagag 44580
actgacaatg agtctctata ctagttgctt ttctaataat tgctgaata agcaacttag 44640
ggacaagagg tttgtcatag ttcccagttt agaggggtgg aaaggcaggg cacctggagt 44700
ggcctggctt gtaacagtgg gaacttgcaa catgacttgt ccacatcttg gaggataagg 44760
aaacagaaag ctccagctag aactaaaggc aatatgact ttcagttccc acccccagct 44820
acttggttg tcagatatat ccctaaacc aaaggttcca caactcctaa tacagagcca 44880
tcagcttgac accaggtctt caaacacggg agcctctgaa agacattttt ctattcaagc 44940
catatgtaag tttcttctc ctgggaggaa ggttggttag gcaggttggtg tggctcagct 45000
cgagatggag aggcttagat tcttacttca ggtttcaagt ggtgaattac atgctctcag 45060
gcatgcatta aggcctagga ggtagaaggc tgacattgga attaccagc cactggacag 45120
ctgtttactg tttcagccag tttcccaagc tgccaagact gtagagaata cttgggtgact 45180
acattctatt taaaaaaaa caaaaaaaca cacaaaaagc tgagcagtggt ttgtgcacgc 45240

cttcaatccc agcacttggg aaacagagggc aggtggattt ctgagttcaa ggccagccta 45300
gtctacagag tgagttacag gacagccagg gctacagaga aaccctgtct acttcaagca 45360
cctgatatcg attgcctaca ggtgctagac aagaccaat cttctgaaga ggacctgtct 45420
atrtcagaag attgatgact cgtgattatg tgtatctgtc tgttcttaaa tattgtgata 45480
attcgctcta ccaagatgtg tactaacaga aaatatttac atgtttttat agaaaaaaaa 45540
gtttgacagt aaatttattc tagtaagaaa tcacatccaa gctgggtggg gtagtggcac 45600
acacctttaa tcccagcaca caggaggaag aggcagggag atctctgtga gttcaaggtc 45660
agcctgttct acaaggtgag tttcaggaca gccagaccta catctcaaca gaaaaaagaa 45720
aacgggaaag aaatcacaag cataaaagct agagatgggt tcaagctaaa ctcttgttta 45780
aaattcaagt tcttacataa tatgtcccca gttgcctttg ccaattttat atttatgagc 45840
tgggtataaa gggcaccatt taaaaataag aatttgagct ttgctaacat cactttcttt 45900
ggaaaactaa taggtatatt gtgtttacct tgttatatgg gtaaaacccc ttatgggtaa 45960
aaggattcct cccaggttaag ttcagtttga atggactgaa acgataaaat ctagagatac 46020
gctagacttt agacttgagt acgactcttt tttttttttt tttttttttt gtaaaaaaga 46080
tatttatctc tcattttggt agcatttact gaggacaatc atgacacagt tctactttac 46140
aaaactatca ggaagtaaca attgacggt catgtgaact ataattacct acttttcttc 46200
ttctacaaca tgtacctcag agacaggatg acaggccaag aagaacatga tataccacct 46260
gacattaata gcaagcacat gctttcaaaa gaatttcaca ataacaactta ttcaaaaata 46320
tcatttttga ttctttgact attttataac acctcagaaa ggattgtcta ttttacagca 46380
aagggtgac aagaatttat tgggtaaatg aattcaaaat ttaatacaca agtaagtagt 46440

ctagagttag catgtacaaa gcttcatttc tgcccatgag tcccaaagtg attcccatga 46500
ttcccaaagtt gtccctctgg cagagtcatg attgttcttt ttttaatatatt tttattacat 46560
atcttcctca attacatttc caatgctata accaaaagtc ccccatacce tccccccac 46620
ttccctacce acccattccc atttttttgg cctggcattc cctgtactg gggcatatac 46680
agtttgcatg tccaatgggc ctctctttcc agtgatggcc gactaggcca tcttttgata 46740
catatgcagc tagagacacg agttctgggg gtactgatta gttcatattg ttgttccacc 46800
tatagggttg cagaccctt cagctccttg ggtactttct ctagctcctc cattgggagc 46860
cctgtgatcc atccaatagc tgactgtgag catccactta tgtgtttgct agggcccagc 46920
atagtctcac aagagacagc tacatctgag tcctttcaat aaaatcttgc tagtgtatgc 46980
aatgggtgtca gtgtttggaa gctgattatg ggggtgatcc ctggatatgg cagtctctag 47040
atgggtccatc ctttctctc agctccaatc tttgtctctg taactccttc catgggtggt 47100
tgttcccaat tctaagaagg ggcaaagtgt ccacacttca gtcttcattc ttcttgagtt 47160
tcatgtgttt agcaaattgt atcttatatc ttgggtatcc taggttttgg gctaatatcc 47220
acttatcagt gagtacgtat tgtgtgagtt cttttgtgaa tgtgttacct cactcaggat 47280
gatgccctcc aggtccatcc atttggctag gaatttcata aattcattct ttttaatagc 47340
tgagtagtac tccgttgtgt agatgtacca cattttctgt attcattcct ctggtgaggg 47400
gcatctgggt tctttccagc ttctggctat tataaataag gctgctatga acatagtgga 47460
gcatgtgtcc ttcttaccag ttggggcttc ttctggatat atgcccagga gaggtattgc 47520
tggatcctcc ggtagtacta tgtccaattt tctgaggaac cgccagactg atttccagag 47580
tggttgtaca agcctgcaat cccaccaaca atggaggagt gttcctcttt ctccacatcc 47640

tcgccagcat ctgctgtcac ctgaatTTTT gatcttagcc attctcactg gtgtgaggtg 47700
gaatctcagg gttgTTTTga tttgcatttc cctaatagatt aaggatggtg aacattTTTT 47760
caggTgcttc tctgccattc ggtattcctc aggtgagaat tctttgttca gttctgagcc 47820
ccattTTTTa agggggttat ttgattttct gaggtccacc ttcttgagtt ctttatatat 47880
gttgatatt agtcccctat ctgatttagg ataggtaaag atcctttccc agtctggttg 47940
tggtctTTTT gtcttataga cagtgtcttt tgccttgcaag aaactttgga gtttcattag 48000
gtcccatttg tcaattctcg atcttacagc acaagccatt gctgttctgt tcaggaattt 48060
ttcccctgtg cccatatctt caaggctttt ccccactttc tcctotataa gtttcagtgt 48120
ctctggTTTT atgtgaagtt ccttgatcca cttagatttg accttagtac aaggagataa 48180
gtatggatcg attcgcattc ttctacatga taacaaccag ttgtgccagc accaattggt 48240
gaaaatgctg tctttcttcc actggatggt tttggctccc ttgtogaaga tcaagtgacc 48300
ataggTgtgt gggttcattt ctgggtcttc aattctattc cattgggtcca cttgtctgtc 48360
tctataccag taccatgcag tttttatcac aattgctctg tagtaaagct ttaggtcagg 48420
catggTgatt ccaccagagg ttcttttatc cttgagaaga gtttttgcta tcctcggttt 48480
tttgttattc cagatgaatt tgcaaattgc tccttctaata tcgTtgaaga attgagttgg 48540
aattttaatg gggattgcat tgaatctgta gattgctttt ggcaagatag ccatttttac 48600
aatgttggtc ctgccaatcc atgagcatgg gagatctttc catcttctga gatcttcttt 48660
aatttctttc ttcagggact tgaagttttt atcatacaga tctttcactt ccttcggttag 48720
agtcacgccg agatatttta tattatttgt ggctattgag aagggtggtg tttccctaata 48780
ttctttctca gcctgtttat tctttgtgta gagaaaggcc attgacttgt ttgagTtaata 48840

tttatatcca gctacttcac cgaagctggt tatcagggtt aggagtctc tgttgaatt 48900
tttagggtca cttatatata ctatcatatc atctgcaaaa agtgatattt tgacttcctc 48960
ttttccaatt tgtatcccct tgatctcctt ttgttgtoga attgctctgg ctaatacttc 49020
aagtactatg ttgaaaagg agggagaaa agggcagcct tgtctagtcc ctgattttag 49080
tgggattgct tccagcttct ctccatttac tttgatgttg gctactgggt tgctgtagat 49140
tgcttttatc atgtttagggt attggccttg aattcctgat cttccagaa cttttatcat 49200
gaatgggtgt tggatcttgt caaatgcttt ttctgcatct aacgagatga tcatgtgggt 49260
tttgtctttg agtttgttta tataatggat tacattgatg gattttcgta tattaacca 49320
tccctgcac cctggaataa aacctacttg gtcaggatgg atgattgctt taatgtgttc 49380
ttggattcgg ttagcgagaa tttattaag aatttttgca tcgatgttca taagagaaat 49440
tggctgaag ttctctatct ttgttgatc tttctgtgg ttaggtatca gagtaatagt 49500
ggcttcatag aatgagttgg gtagagtacc ttctacttct atcttgtgaa aaagtttgtg 49560
cagaactgga gttagatctt ctttgaagg ctgatagaac tctgcactaa acccatctgg 49620
tcctgggctt tttttggctg ggagactatt aataactgct tctatttctt taggggatat 49680
gggactgttt agaaggtaa cttgatcctg attcaacttt ggtacctgg atctgtccag 49740
aaatttgtcc atttctcca ggttttccag ttttgttgag tatagccttt tgtagaagga 49800
tctgatggtg ttttgattt cttcaggatc tgttgttatg tctccctttt catttctgat 49860
ttgttaatt aggattttgt ccctgtgcc tttagtgagt ctgctaagg gtttatctat 49920
cttggtgatt ttctcaaaga accaactcct cgtttggta attctttgaa tagttcttct 49980
tgtttccact tggttgattt caccctgag tttgattatt tcttgcctc tactcctctt 50040

gggtgaattt gcttcctttt tttctagagc ttttagatgt gttgtcaagc tgctagtatg 50100
tgctctctcc cgttttttct tgaaggctca taactatgag tttccctctt agaaatgctt 50160
tcattgtgtc ccaaagggtg ggtacgttgt ggcttcattt tcattaaact ctaaaaagtc 50220
tttaatttct ttctttattc ctctcttgac caaggtatca ttgagaagag tgttgttcag 50280
ttccacgtg aatgtggctt tccattatta tgttgttatt gaagatcagt cttaggccat 50340
ggtggtctga taggatacat gggacaatct caatattttt ttgtaattt tttaatgatt 50400
aattgtgaat ttcacatcat gtaccccaat tacactcatc tccccatcc cttcatatct 50460
gccttgcac cctcctaagg aaaacaaaat ataaaaataa aaacaacaaa aaggagaaaa 50520
acaccatttt aaacaaacta aagaaaagtc atctcgtctg agtgtgataa gtatactctt 50580
ctgtctgtac attttaactt gaaatgttca tggaatgagt cattggctctg gttccctctg 50640
aactccctct tatttgaatt ttattcttaa gattctctct attctaatgt ctttagtact 50700
cttagtgat taacacaggc tttaatatata tactctgaat ttttctttat ctttataaaa 50760
ttatcatgta taacattttc ctttttttct gagttgaata aaattctttc ttactggaac 50820
ttctatgaga tatatggtga agattatcaa cctgtattcc attaatggta actgctcatt 50880
cagatgtttc attgaaattg tcctcatttt gaaataggaa ataaacctat aattgcagtg 50940
tctggtacaa agaagcagat caaattctaa gcttccagtg tcacattgtc cagcagctct 51000
ggcactgggt atattttaaa gtcattttta aggtacactt tattattgga tattttcttt 51060
atttacattt caaatagtct cccctttccc tatccccccc agaaactccc tatcccatcc 51120
ccccttctcc tgtttctatg aggggtgtgcc cccacccact cactctctcc tgctaccct 51180
catattcccc tactcggggg aaacaaacct tcatgggacc aagggtgtct tctcccattg 51240

atgcctgaca aggccatcct ctgctacata tgcagttgaa gccatgggtc cttctatgtg 51300
tactccttgg ttggtggttt agaccctgga agctctgggt ggtaaatatt gttgttcttt 51360
ttatgggggtt gcaaacccca tcagctcctt cagtcocttta actaacacct ccattgggga 51420
cccagagatc agtttaatgg tcagctggga gcatccgct ctgtataggt caggctctgg 51480
cagagccata cactttttat tgggtacctt gtttgaacca agagaaatat aaaatcctaa 51540
agtattctga cctcagcata acaagatcaa ttcagctgat taaaatgtct tctattgttt 51600
ctttctgttt cctcatctct agcaactata aataacagat ccctaaaatg aaatgtgtac 51660
aaatccagag aacaaaagga gggactgtca acaatgagga gtccaacaaa gagtgacagc 51720
aagcagtttt agatagttaa caagaaatgt ctaaaagaat atccagctca acaaccctta 51780
aatttctgcc cactaaaaca atgtcagatc attatctctt taaatgtcaa taaaggagag 51840
gggtaattga gatagcaact gtaactgtga aattgagata tcctgttagt atgacatgag 51900
tagagatttg tacagatgaa tgacctgagg aaaacgtctc atcaattcta cctctttgtg 51960
cagtgatatt gcttctggaa aacaactgtt agagaagaag tagaaataca ccagaactcc 52020
atcctccacc accccagaga tgattattgt gataatcctc atgttactga aaaactggca 52080
atactcaata tcaataaacc cacaaaagtt ttaattatca gatcctaaca tgaaaaccta 52140
agtgcaaata gacacacagg cattcaaggt ttcacgtgaa gaaactgatt gttctcttcc 52200
attcatttaa atacatgaag aacaacagat gttgggttta acccgttgaa agatgagttg 52260
tggctcacag ttgaaaaatg actgtcctaa atagcaggtg gtcaatacat cgtgaaatat 52320
tagttaatat ggtcattcaa tgttatgtcc ttagttttct gtttatatgg tggcatgagt 52380
gggagatgct acatttcttc ctccagtgag aaggagaatg ctttcaggca tataatgacg 52440

atTTTTTTTT tCctgtaaga tacataactc tttgcatctc ctacctccca caccagccta 52500
tcatggatca ttaacggatt ctgtgcattc ttcttaaate ctctccccat atcctttgca 52560
agttctgcaa gtagatagga tgttttttagg tgatccagtc tgcagcatcc ctttttaate 52620
agcctttcat gttaagattt tattcttggc atattcagat aatatcaaca aagctgagct 52680
gatttcactt gaattaacaa agaacaaaag gccttttcta gaaatgaggg tgacaatata 52740
tccagtatgt attgaggaga ttctaataaa aatgaaacaa aaatcaaaat aaaaaggaaa 52800
actatTTaat ataaagcctt tctttcaatt ttctttacac attttattag aaaatacctc 52860
ctctgcctcc tcaccttctt tctctctctc ccatacatcc acaaattgga ttgctaaatt 52920
tctgtgtacc caagtgtgca tttataatga taaaaagatc aaaattgact ctggaaaaaa 52980
atgatagggt tgtaaacaga tttcttatat ttctattata atttagctca tcttcttgaa 53040
atgtgcccaa ggctacaatt ctgtttgaaa ctggagatat cagtttgac tgctcagggt 53100
gtctcagagt aactacttc atgttcaagt ggtttgtagg gagccagtac agaaacctaa 53160
aaggagctac agaccaggct cttttcttg atgtcttctt tcttgttctt ctagtotaat 53220
ttttgtgtaa tttgatgaag ccactagtag cttcagattt aaatctgcca tttggggtaa 53280
tgtggggcag aatgtcatct attttcttta ttaagccaaa gtaacattct tatctaacaa 53340
gaactttgcc tctgtgaagt ctaataattt cccctaataa aactagtccc tgaccaaaaa 53400
aaaccctact gagaagtctt aactaatcca actatatctg acttcaacac tataatggga 53460
tttatctctc cttgaaaca aatgttattc ttgaagattt attaaaatgc agatgcaaac 53520
acttaggtgc attgtctttc aatgagtatt tgggcaacat tcttttaaat tttttattag 53580
gtatTTTctt tatttacatt tcaaagtcta tcccaaaagt ccccatacc ctccccacc 53640

cactctccta cccacccact cccacttctt ggccttggtg tttccctgta ctgaggcata 53700
taaagtttgc aagaccaagg ggcctctctt cccaatgatg gctgacgagg ccatcttctg 53760
ctacatatgc agctagagac acgagctctg ggggtactgg ttagttcata ttgttgttcc 53820
accaataggg ttgcagaccc ctttagatcc ttgggtacgg tattagtcag ggttctctag 53880
agtcacagaa tttatggata gtctctatat agtaaaagaa tttattgatg acttacagtt 53940
ggcagcccaa ttcccaacaa tggttcagtc gcaggatga atggaagtcc aaggatctag 54000
cagttactca gtctcacaca gcaagcaggc gaaggagcaa gagcaagacg cccttcttcc 54060
aagcagaagg tgtagcccag attaaagggtg tgttctacca cacgcttaat tccagatgac 54120
cttgaactca gagatttaat cttctggaat ccactatgcc tcaagatctc cataccaaga 54180
tccagatcag aatcttctat ctccaagcct ccagataagg gtcactgggtg agccttccaa 54240
ttctgtattg tagttcattc caaatacagt caagttgaca accaggaata gccactacag 54300
gtactttctc tagctcctcc attgggggcc ctgagttcca tccaatagct gactgtgagc 54360
atccacttct gtgtttgcca ggcaccggca tagcctcaca agagacagct atatcacggt 54420
cctttcagca aaatcttgct ggtgatgca atgggtgacg catttgaggg tggactccag 54480
aaaatcaaat aaccccccaa aatgggggatc agagctaaac aaagaattct catcttgagt 54540
aacattttaa ggtatggtgt tacacaaatt tttgcactcc tttctcotta tcttacactg 54600
gaatctaaaa aggagagaaa gttccctttc aaggataaat taggaagatc tagaactaca 54660
tagtagatta tctaagatca cataacatcc aatccagtag gagaagagaa ggagatgagc 54720
agtctacaaa attatatgcc acttgactc atgacttgct agcttgatg tagtcttatg 54780
actacagtca gctacaaggt tctctgtgaa atggctttta ctgggtccta ttgctaattc 54840

aaattagaaa gtgtcaataa aactggcaat tagtaactta gagcatgtca tagacggcta 54900
tatcaatcct atgagtaaag tcatttaaata gtttattcaa aaggttgtca tgtaataaac 54960
tgtgattcat gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgttaaaa atatgaattg 55020
gagaggatta ggaaagcatt cttcaagtcc aatttagaat gttggctagg acttgggcat 55080
ttctagtaga gaagataaca aaaatataat ggactcaaaa ttagctgaaa tggcaacttg 55140
aagatatgat aggcaatgga ggcaaagcct cttgataaca tgtagacttc tgatatgtaa 55200
tgcaaacctct ggagacaggt atttatgggt acttgagttt tgttttagaa ttgtgtttca 55260
gaggcctcta ccatgctatc ggtttctgtc tttccaaaac atgatttgaa aaacaatcaa 55320
tcacaattct caatgctatc actgttaact attcccatga aactcctttt tgaggctatc 55380
cttaggctct tcgttctatc cttagggagt ttgaatgtat caaacatcac agaatgctga 55440
atctcactat tcaaaaaggt aagctgcatg aacaggctca ataccagca cattaattct 55500
gtcaacagga atggatcaca actgtcttcc tgtggtatta gtgtggacag gactgtcact 55560
cacatagtga aatgttcgtc tcacagtctt ctgtgtggag ttatttagtc ctaatgacaa 55620
ccatgaatgt tctaactaca tgagtagtta aaagaacat agcaaaattc cagaccgggg 55680
aagtcacctc tttcatttgt attgctcata tatgtatttc actaactact tggtcctttg 55740
taacatttct tgactcatga ccttttttta aaatctgaaa tagctcaatc ataacataat 55800
ttaaaaaaac atccaacagg caaagcatgc tgggtgcacat ctgtatttag agcatgctgg 55860
tgcacatctg tatttagagc actcagcaac tggaggctga agccagagga tgaggagttc 55920
aaggtcattc tgggctacag acaaacact ttcttgggaa attttctcag agagagagag 55980
aactaaatca aataaaaaac atattatcta agtgtatgct cctcaattaa ttattcttta 56040

attaacattg gtgcaactgaa cattggtgca ctgaaatgaa gaaagaaacc aatgtttaca 56100
gaacatacta caggatttcc agtaaaagac actgctacaa tgaatgggta aatgtatacc 56160
atagaatgaa atagactagg atttttaatg catattggta tttcagaatt tgtttttgca 56220
tttatttctt cttaaaaaa tattcaatgt tctgcaactct gaggccttgg taaacttaaa 56280
ttcagtggac ttctcttctt actcttctta gagatgtcac aggaccagat taaaattaca 56340
cagttatacc taggtgggtg tggtacaccc cttaaatctc aatatttgag acaaagacag 56400
gtggatcttt gagtttgagg ccagcctatt ctacagagtt ctagaacagc caggggctac 56460
aaagagaaac ccaatcttaa aaacacaagc aaaaaaaaaa aatccaaata ttatattcaa 56520
tttacttaga tgaaaagcat aatctgcctt gagtttaaca ttcaagtctc ttaaattgatc 56580
ttgtggcttc aggtagactc tagcccaggg gtggccttca ctacagctgg aagcctctaa 56640
aaatattctg ggcaaagagc agcagctgca ttagatgaag caatcatctg ggacaattga 56700
tacactcttc tggaaccagg tgtgtgtgag agagtgggag agaccacaag atagaggatt 56760
attaatttat ggggattttg gggagattta tatacccaca caacaacttc tagaagctac 56820
tgaccaagac gcaccaagaa ataaccagga aacgtctaca aaatttcaac cctagcttct 56880
ctaccagatt ttaactaaac gagatcttct tgcaaaggta aaataactgg agggaaaaaa 56940
aaagattctt gacatacatt ctgaaaaaaa ttataagaat atccagcctt gatttcagag 57000
gtatctatag gactatgggt tgtattcttg tgtagttacc tttgattaag tctaagttaa 57060
ttttttgatt gtctctaagt caagtcaggt ctctgcaacta ctccatgtg cttttacatt 57120
tttgaaaaat aaatttctaa ccaagctaag cttggattta tgcgctgttg ttgttccagt 57180
tgttgacttc tcctttaacg agatctctct gtatccttcc tccctcttag tcaactcttt 57240

tccaagtgtt agagaagcct ttgactgctt gctcctttta tcaactgaatt tgggcttcta 57300

aaatctatcc aacagaagaa gggtagagttt cttgagcatt actctgtgaa actgggtccac 57360

ttgaagagat taaggtttga aatgcctccc tttggctcct tagcattagt gaatcttatt 57420

gtgtgaacag cttcttgtaa tatcttgtaa gttaggttga caagttgtgt gagacatagc 57480

ttttaccag 57489

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 101

tgcttggcag ctcgtagggtt 20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 102

atggctgcgc ctgcttggca 20

<210> 103

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 103

tacctgagac ctcggagttt

20

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 104

acaaagatcc atacctgaga

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 105

gctgggtgtag cctcacttcc

20

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 106

tttgccaaga gtagctggtg

20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 107

acgacacttg gtgaatcgag

20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 108

tggttttccc ttttagcata

20

<210> 109

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 109

atgagcaatt cttgcagctt

20

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 110

agttgaagta acagctgttt

20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 111

agtagggtat ccaaattggag

20

<210> 112

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 112

gtccagttga ggccaatggg

20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 113

gaattatcca tcccttcaga

20

<210> 114

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 114

gtactgaatt tcatactcca

20

<210> 115

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 115

ctgaactcgc tgtacttttc

20

<210> 116

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 116

aactggatat cttcttcaca

20

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 117

tgctactcca aatattccaa

20

<210> 118

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 118

gctttgaaaa tataactaca

20

<210> 119

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 119

atcagcatct taatcctttg

20

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 120

tgagaagatc tggatcaatc

20

<210> 121

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 121

ttgtagttat catgaatgcc

20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 122

catcattgta gaagtcgggt

20

<210> 123

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 123

ctccaaggat accagctgat

20

<210> 124

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 124

aggcacaaga gatcagcttc

20

<210> 125

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 125

agagccaagg gaagcatcat

20

<210> 126

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 126

aagtcaatgt ttgccagtga

20

<210> 127

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 127

tgtcgcttac ttgggcataa

20

<210> 128

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 128

gtaattttct tggcagggcg

20

<210> 129

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 129

cactgttcat gctgtaattt

20

<210> 130

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 130

tttttggcat ctgactcaca

20

<210> 131

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 131

atgtcctctt ggttaaagct

20

<210> 132

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 132

cgtggtgtag tctgggacag

20

<210> 133

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 133

cgggtggaac cgtggtgtag

20

<210> 134

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 134

tcaggcaaag gcaaagcagt

20

<210> 135

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 135

taggaaaggc tactgcatga

20

<210> 136

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 136

taaaacatag ttttggttta

20

<210> 137

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 137

tcccaacaca gatttaaac

20

<210> 138

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 138

caaaagccac ctgattggtt

20

<210> 139

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 139

tcctgaactg caaaagccac

20

<210> 140

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 140

gcattcaatt tcctgaactg

20

<210> 141

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 141

taaatgtttt gcatatccaa

20

<210> 142

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 142

ttgtaaaaat ctaacttggt

20

<210> 143

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 143

tacctgagac cccagttcat

20

<210> 144

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 144

tacctgagac cccgcgagc

20

<210> 145

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 145

tacctgagac ccacaagcgg

20

<210> 146

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 146

cctccagtac ctcggagttt

20

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 147

gtccttgctc caggtagca

20

<210> 148

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 148

ttccactcac cccagttcat

20

<210> 149

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 149

gcagttctat cagaactttg

20

<210> 150

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 150

ctccagacgt gacccgactc

20

<210> 151

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 151

ccacgcaccc acaagcggat

20

<210> 152

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 152

taacctatgg tgactatgtc

20

<210> 153

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 153

tacctgagac ctgcaagaca

20

<210> 154

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 154

atgctcacgt cagctattgg

20

<210> 155

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 155

aaattcttac ttgtccccag

20

<210> 156

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 156

ttggctttcc ctggaggttc

20

<210> 157

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 157

cttcactaac cttgcagctt

20

<210> 158

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 158

cacggcttac ctatttcgtc

20

<210> 159

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 159

tcacacctac ctttgctgct

20

<210> 160

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 160

catcttaatc cttggaaca

20

<210> 161

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 161

gaatggaaag aatgccctga

20

<210> 162

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 162

gaaagaatgc cctgattatg

20

<210> 163

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 163

ccagttccaa agattaaagg

20

<210> 164

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 164

attgagctag atattgatga

20

<210> 165

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 165

gacacagaca gacttctaag

20

<210> 166

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 166

agcgacatta caccagcagg

20

<210> 167

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 167

aaccaagagg acatttacat

20

<210> 168

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 168

agaggacatt tacatcacca

20

<210> 169

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 169

acatttacat caccacagaa

20

<210> 170

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 170

tacatcacca cagaaagcct

20

<210> 171

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 171

caccacagaa agccttacca

20

<210> 172

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 172

tatgtgagca cagaccaact

20

<210> 173

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 173

gagcacagac caactgaaca

20

<210> 174

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 174

ccaactgaac aaaatcatgc

20

<210> 175

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 175

tctgctactt tgctgctatg

20

<210> 176

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 176

tttctatagc caaaaatagc

20

<210> 177

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 177

aatagctaaa tacctcaatc

20

<210> 178

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 178

aggtcctaca ggtatggatc

20

<210> 179

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 179

ctacaggtat ggatctctgg

20

<210> 180

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 180

cacagcagct atccttagca

20

<210> 181

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 181

taatccaggc ctaaagaca

20

<210> 182

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 182

tctaaggagc ctaaattcac

20

<210> 183

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 183

gaacctagga cccatacagc

20

<210> 184

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 184

gctggggaaa acagctgtta

20

<210> 185

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 185

tggtggtaca gtggatgaaa

20

<210> 186

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 186

ctgttgatga aatagtgcaa

20

<210> 187

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 187

tagtgcaacc agatccaccc

20

<210> 188

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 188

gatgggaagc accacgcaat

20

<210> 189

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 189

atggaaaatg atggacccta

20

<210> 190

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 190

cagttccagt gtactcattg

20

<210> 191

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 191

tctggaaatt atggcgagtt

20

<210> 192

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 192

atctttggaa tatttgggct

20

<210> 193

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 193

gcaaaggatt aaaatgctga

20

<210> 194

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 194

tctcctcaag gaaggaaaat

20

<210> 195

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 195

agaggaggtg aacacaatct

20

<210> 196

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 196

acagtgatga ctcttggggtt

20

<210> 197

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 197

gctagatatt gatgagccag

20

<210> 198

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 198

agactgagga atcagacaca

20

<210> 199

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 199

atttcaatgc caatgacata

20

<210> 200

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 200

aagcagatct cttatgcctt

20

<210> 201

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 201

tcctactgaa ggagctgagt

20

<210> 202

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 202

agaataaggc agggatgtcc

20

<210> 203

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 203

acttccttat ggacaatgcc

20

<210> 204

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 204

tgaggcagat gccaaaaagt

20

<210> 205

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 205

cagatgccaa aaagtgcac

20

<210> 206

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 206

cctcactc aatgcgactg

20

<210> 207

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 207

tgcccttgcc tgacaaagag

20

<210> 208

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 208

tcatgtggct atgtgagcac

20

<210> 209

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 209

atcatgcctt agcctttctt

20

<210> 210

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 210

ttccaagag ctacgtattt

20

<210> 211

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 211

ctgttttagta gcagtgattg

20

<210> 212

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 212

ttgaatgcaa accatagcac

20

<210> 213

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 213

atagtttggg tatgtaaac

20

<210> 214

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 214

tcaccaaatac ttggttgatg

20

<210> 215

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 215

gagataagat ctatagcctc

20

<210> 216

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 216

agaaactttc tttctcacta

20

<210> 217

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 217

acatcattct tgagagcatt

20

<210> 218

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 218

gaaaagctag aattgagtgt

20

<210> 219

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 219

gctatggttt tctccaagag

20

<210> 220

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 220

taaagtatca tcagtgtaga

20

<210> 221

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 221

taattcaatt caaagctgtg

20

<210> 222

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 222

agctgtgtgt ttggaagact

20

<210> 223

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 223

ttactatttc acaacagcct

20

<210> 224

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 224

cagcctgaca acatttctat

20

<210> 225

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 225

gtctcagaat gtcattttgg

20

<210> 226

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 226

gtggccacat aagccattat

20

<210> 227

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 227

tcaatcaggg tcacataact

20

<210> 228

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 228

tttgaacctc cagcctccat

20

<210> 229

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 229

gtcttgaaag atggacccta

20

<210> 230

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 230

gtttagattc tatctggaga

20

<210> 231

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 231

aaagtaccag aatatttggg

20

<210> 232

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 232

tgccaagcag ggcgagccat

20

<210> 233

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 233

aaactccgag gtctcaggta

20

<210> 234

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 234

tctcaggtat ggatctttgt

20

<210> 235

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 235

ggaagtgagg ctacaccagc

20

<210> 236

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 236

caccagctac tcttggcaaa

20

<210> 237

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 237

ctcgattcac caagtgtcgt

20

<210> 238

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 238

tatgctaaaa gggaaagcca

20

<210> 239

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 239

aaacagctgt tacttcaact

20

<210> 240

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 240

cccattggcc tcaactggac

20

<210> 241

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 241

tctgaagggg tggataattc

20

<210> 242

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 242

tggagtatga aattcagtac

20

<210> 243

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 243

gaaaagtaca gcgagttcag

20

<210> 244

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 244

ttggaatatt tggagtagca

20

<210> 245

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 245

gattgatcca gatcttctca

20

<210> 246

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 246

ggcattcatg ataactacaa

20

<210> 247

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 247

atcagctggt atccttggag

20

<210> 248

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 248

gaagctgac tcttgcct

20

<210> 249

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 249

tcactggcaa acattgactt

20

<210> 250

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 250

ttatgcccaa gtaagcgaca

20

<210> 251

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 251

aaattacagc atgaacagtg

20

<210> 252

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 252

tgtgagtcag atgccaaaaa

20

<210> 253

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 253

agctttaacc aagaggacat

20

<210> 254

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 254

tcatgcagta gcctttccta

20

<210> 255

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 255

gttttaaatc tgtgttggga

20

<210> 256

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 256

aaacaatcag gtggcttttg

20

<210> 257

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 257

cagttcagga aattgaatgc

20

<210> 258

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 258

ttggatatgc aaaacattta

20

<210> 259

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 259

aaactccgag gtactggagg

20

<210> 260

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 260

tgctaacctg gagcaaggac

20

<210> 261

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 261

atgaactggg gtgagtggaa

20

<210> 262

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 262

caaagttctg atagaactgc

20

<210> 263

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 263

gagtcggggtc acgtctggag

20

<210> 264

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 264

atccgcttgt gggtagctgg

20

<210> 265

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 265

gaacctccag ggaaagccaa

20

<210> 266

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 266

aagctgcaag gttagtgaag

20

<210> 267

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 267

agagagctac ctaactaaca

20

<210> 268

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Scrambled control oligonucleotide

<400> 268

ttaccgtatg gttcctcact

20